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Abstract
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic
pneumonia, an economically significant and chronic respiratory disease affecting swine.
M. hyopneumoniae adheres to ciliated swine respiratory epithelial cells thereby causing
ciliostasis and epithelial cell death, making the pigs susceptible to secondary infections.
The gene mhp183 encoding the archetype cilium adhesin P97 shares a two-gene operon
with mhp182, which encodes P102. Paralogues of P97 and P102 are found within the M.
hyopneumoniae genome. P97, P102 and their paralogues are displayed as
endoproteolytic cleavage fragments on the cell surface of M. hyopneumoniae, and bind
a variety of host molecules such as glycosaminoglycans, plasminogen and fibronectin.
These M. hyopneumoniae adhesins are believed to play an important role in
colonisation.
M. hyopneumoniae has been detected in organ tissues distal to the respiratory
tract. The mechanism of dissemination from the site of colonisation is unknown, though
numerous pathogenic bacteria utilise host plasmin, to aid bacterial dissemination. In this
study, we show that M. hyopneumoniae binds plasminogen in a dose-dependent and
lysine-dependent manner. M. hyopneumoniae surface-bound plasminogen is shown here
to be converted to functionally active plasmin by exogenous mammalian activators,
such as tissue-type plasminogen activator (tPA) and urokinase-type plasminogen
activator (uPA). M. hyopneumoniae coated with plasmin degrades fibrinogen,
highlighting the potential for M. hyopneumoniae surface-bound plasmin to promote
tissue destruction and facilitate tissue invasion.
The M. hyopneumoniae P97 paralogue Mhp271 contains a C-terminal lysine
residue, for which plasminogen typically has a high affinity. P97 contains two repeat
regions, R1 and R2, which play a role in the adherence of M. hyopneumoniae to host
molecules. Within Mhp271, there are two R1 repeat regions separated by an R2 repeat
region; however, the number of tandem R1 repeats is fewer than the eight previously
recognised as being required for swine cilial binding. Sequencing of these repeat
regions in a set of M. hyopneumoniae strains shows that the number of tandem repeats
in the R2 and the second R1 domains is variable. Two recombinant proteins were
constructed; one containing the first R1 domain (F1271) and the second containing the Civ

terminal portion of Mhp271, which includes the R2 domain together with the second R1
domain (F2271). In in vitro binding assays, F2271 bound heparin, fibronectin and porcine
cilia, while F1271 did not bind these molecules. Heparin reduced the adherence of F2271
to cilia (by ~ 69%), indicating that F2271 binds the heparinase sensitive
glycosaminoglycans at the surface of ciliated swine respiratory epithelia. F2271 is an
inefficient plasminogen-binder despite containing a C-terminal lysine residue. Cell
surface shaving with trypsin combined with two-dimensional liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS) revealed that Mhp271 is surfaceexposed; therefore, both the R1 and R2 repeat regions in Mhp271 may contribute to M.
hyopneumoniae adherence to host molecules.
Mhp385 is another P97 paralogue possessing a C-terminal lysine residue and R1
repeats. Antisera raised against recombinant protein fragments of Mhp385 reacted with
115 kDa, 88 kDa and 27 kDa proteins in Western blots of whole cell lysates of M.
hyopneumoniae cells, which were confirmed by LC-MS/MS as the Mhp385 preprotein
P115385 and cleavage fragments P88385 and P27385, respectively. This is the first time a
preprotein belonging to the P97 and P102 paralogue families has been identified by
mass spectrometry and indicates that Mhp385 is inefficiently cleaved. Cleavage occurs
at a novel cleavage site (761L-N-V↓A-V-S766) defined by the semi-tryptic peptide
752

IQFELEPISLNV763 denoting the C-terminus of P88385. Trypsin digest studies show

that P115385, P88385 and P27385 are surface-exposed. Heparin- and cilium-binding sites
were identified within P88385. No primary function was attributed to P27385; however,
this molecule contains four tandem R1 repeats with similarity to porcine collagen type
VI, which may be an instance of molecular mimicry. The Mhp385 recombinant protein
fragments did not bind plasminogen in surface plasmon resonance assays.
The mhp385 gene shares a two-gene operon with mhp384, which encodes the
P102 paralogue Mhp384. We show that Mhp384 is efficiently cleaved, at a site that
closely conforms to a previously identified cleavage motif of members of the P97 and
P102 paralogue families (S/T-X-F↓X-D/E), to create P60384 and P50384. P60384 and
P50384 are cell surface-associated and contain heparin- and cilium-binding sites. This
study expands the knowledge about the function(s) and endoproteolytic cleavage of
members of the P97 and P102 paralogue families, which is integral to understanding
how M. hyopneumoniae colonises swine and thereby causes chronic disease.
v
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1.

Introduction
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1.1 The Genus Mycoplasma
The name ‘Mycoplasma’ was derived from the Greek word ‘mykes’, meaning
fungus, due to the mycelial or filamentous morphology of the organisms, and the Latin
word ‘plasma’, meaning formed, to represent the plasticity or pleomorphism of the
bacteria (Razin and Jacobs, 1992). Mycoplasmas are taxonomically grouped into the
Class Mollicutes (mollis, soft; cutis, skin) due to their lack of a cell wall. Studies on 16S
and 5S ribosomal ribonucleic acid (rRNA) sequences revealed that Mollicutes evolved
regressively (by genome reduction) from Gram-positive bacteria with low guanine and
cytosine (G + C) content (Rogers et al., 1985; Woese et al., 1980). Phylogenetically
they are related to the Clostridium-Streptococcus-Lactobacillus phylum branch (Rogers
et al., 1985; Woese et al., 1980). Within the Class Mollicutes, members of the genus
Mycoplasma have the smallest genomes (ranging from 580 kb to 1380 kb) (Razin et al.,
1998), with M. genitalium being the smallest in size, although it still has double the
number of predicted genes considered necessary for survival (Maniloff, 1996;
Mushegian and Koonin, 1996). It is assumed that a number of the excess genes must be
involved in the host-bacterium interaction (Razin et al., 1998). During evolution,
Mycoplasma spp. lost many of the genes involved in amino acid biosynthesis; therefore,
they obtain exogenous essential metabolites from their host. Consequently
mycoplasmas have strict nutritional requirements and are usually obligate parasites with
strict host and tissue specificities. Host organisms include insects, plants and animals
such as reptiles, fish, arthropods and mammals. Despite having limited metabolic
options they are efficient at colonising their hosts and causing a wide range of diseases
that often take a chronic course. Examples of human diseases caused by mycoplasmas
include primary atypical pneumonia (Biscardi et al., 2004) and nongonococcal urethritis
(Horner et al., 2001). Mycoplasmas have also been linked as a cofactor in rheumatoid
arthritis

(Taylor-Robinson,

1996)

and

the

disease

caused

by

the

human

immunodeficiency virus (HIV) (Grau et al., 1995). The immune response is responsible
for many of the pathogenic manifestations to the host during mycoplasmal diseases
(Razin et al., 1998). The major habitats of humans and animals are mucosal surfaces of
the respiratory and urogenital tracts, the eyes, alimentary canal, mammary gland and
joints (Razin et al., 1998). Their fastidious nature makes mycoplasmas difficult to grow
in axenic cultures (Miles, 1992), which has hindered the study of these organisms in the
past.
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Mollicute genomes are very rich in adenine and thymine (A + T). Typically the
G + C content is between 24 - 33 mol%, apart from a few exceptions, such as M.
pneumoniae (G + C 40 mol%) (Razin et al., 1998). In addition to this, the TGA codon
encodes tryptophan in all Mollicutes, except members of the genera Acholeplasma and
Phytoplasma (Inamine et al., 1990; Osawa et al., 1992; Razin et al., 1998); this codon
functions as a translational stop signal in other bacterial species. As a result, in-frame
TGA codons must be manipulated to TGG for expression of recombinant constructs in
standard bacterial hosts (Futo et al., 1995). The M. genitalium strain G-37 genome
sequence (Fraser et al., 1995) was one of the first bacterial genome sequences published
and since then at least 23 genomes from different species of the genus Mycoplasma
have been publicly released (http://www.ncbi.nlm.nih.gov/).

1.2 Mycoplasmas that Infect Swine
There are a number of mycoplasmas that have been isolated from swine.
Common non-pathogenic mycoplasmas include Mycoplasma flocculare, Mycoplasma
sualvi and Mycoplasma hopharyngis (Thacker, 2006). M. flocculare is frequently
isolated from the respiratory tract of swine. Although it is not pathogenic it has
antigenic similarities to the pathogenic Mycoplasma hyopneumoniae, which can
complicate

their

differentiation

particularly

serologically,

even

though

M.

hyopneumoniae and M. flocculare differ genetically (Thacker, 2006). Currently there
are four species of Mycoplasma that are pathogenic to swine: Mycoplasma hyosynoviae,
Mycoplasma hyorhinis, Mycoplasma suis and M. hyopneumoniae.
Both M. hyosynoviae and M. hyorhinis are common inhabitants of healthy pigs
(Timoney et al., 1988). M. hyosynoviae colonises the pharynges, tonsils and nasal
cavities of pigs. However, during periods of stress the bacteria can migrate to the
bloodstream and to the joints and tendon sheaths where it causes arthritis, typically in
pigs between 25-100 kg being fattened for slaughter (grow-finishing pigs). Complete
recovery often occurs after a few weeks (Thacker, 2006; Timoney et al., 1988).
Disease associated with M. hyorhinis is usually the result of systemic invasion.
However, very little is known about how the mycoplasmas move from the respiratory
tract to induce systemic disease (Thacker, 2006). When M. hyorhinis becomes systemic
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the bacteria can cause polyserosistis and arthritis, which generally occurs in 3-10 week
old pigs, while infection in 3-6 month old pigs typically results in only arthritis
(Thacker, 2006). Complete recovery is possible, but very slow (Timoney et al., 1988).
M. hyorhinis is also a common contaminant of cultured human and animal cell lines
(Razin et al., 1998). This bacterium is also well known for its highly complex system of
variable lipoprotein (Vlp) expression, providing a very diverse coat of surface proteins
(Yogev et al., 1995).
M. suis is a hemotrophic Mycoplasma, which adheres to the surface of
erythrocytes (Hoelzle, 2008). The unculturability of this Mycoplasma has limited
advances in the pathobiology of this organism. Infection with M. suis can often result in
life-threatening anemia (febrile acute icteroanemia) primarily in piglets, pregnant sows
and feeder pigs under stress. Low-grade infections can be asymptomatic. Clinical signs
include mild chronic anaemia, illthrift, infertility and immune suppression (Hoelzle,
2008). The symptoms of M. suis infected pigs can be treated by tetracycline, glucose
and iron dextran; however, infected pigs remain life long carriers (Gresham et al.,
1994). This may be linked to M. suis being able to invade erythrocytes (Groebel et al.,
2009).
The focus of this thesis is on pathogenic M. hyopneumoniae, which was first
isolated from swine pneumonic lungs in 1965 (Goodwin et al., 1965; Mare and Switzer,
1965). They are small in size (from 400 nm to 1,200 nm) (Mebus and Underdahl, 1977;
Tajima and Yagihashi, 1982) and have only been found in pigs, where they colonise the
upper respiratory tract causing mycoplasmal pneumonia, a chronic respiratory disease
associated with reduced productivity for the swine industry. M. hyopneumoniae
infections are commonly described as enzootic pneumonia because they are often
associated with secondary infections, which increase the severity of the pneumonia. M.
hyopneumoniae affects up to 80% of pigs around the world (Ross, 1999) and economic
losses associated with chronic pneumonia are significant within the swine production
industry (Thacker, 2006). Based on 16S rRNA sequencing, M. hyopneumoniae is, not
surprisingly, most closely related to the mycoplasmas that inhabit the respiratory tract of
swine: M. hyorhinis and M. flocculare (Stemke et al., 1992). The next section has been
dedicated to summarising current knowledge of M. hyopneumoniae.
4

1.2.1

M. hyopneumoniae Colonisation of the Porcine Respiratory Tract
M. hyopneumoniae can be observed microscopically on the surface of the

ciliated respiratory epithelium of swine, predominately associating with the cilia and
microvilli of bronchial and bronchiolar epithelial cells (Figure 1.1A and B) (Livingston
et al., 1972; Mebus and Underdahl, 1977; Tajima and Yagihashi, 1982; Underdahl et
al., 1980). M. hyopneumoniae adherence to the ciliated epithelium is important in the
pathogenesis of the disease (Blanchard et al., 1992; DeBey and Ross, 1994). The
intimate association of M. hyopneumoniae with cilia leads to a marked inflammatory
and cell-mediated response. Microscopic lesions develop and are characterised by an
infiltration of inflammatory cells in bronchial and alveolar lumina, and peribronchiolar
and perivascular lymphoid hyperplasia (Blanchard et al., 1992; Mebus and Underdahl,
1977; Redondo et al., 2009; Tajima and Yagihashi, 1982). Alveolar collapse can occur
as a result of the pressure caused by the infiltration of macrophages, lymphocytes,
neutrophils and oedema into the lumina (Redondo et al., 2009; Tajima and Yagihashi,
1982). M. hyopneumoniae infection induces alveolar macrophages to increase the
expression of pro-inflammatory cytokines, including interleukin (IL)-1, IL-6, IL-8 and
tumour necrosis factor-alpha (TNF-α) (Thacker, 2006). The extent of pneumonic lesions
caused by M. hyopneumoniae infection is reduced in thymectomized pigs treated with
anti-thymocyte serum, suggesting that T-cells contribute to the pathogenesis of
mycoplasmal pneumonia (Tajima et al., 1984). Interestingly, in one out of three pigs
from the group of thymectomized pigs treated with anti-thymocyte serum, M.
hyopneumoniae was isolated from the spleen. M. hyopneumoniae is considered to be an
extracellular pathogen that persists by associating with the surfaces of respiratory
epithelial cells. There have, however, been reports that challenge this view, with M.
hyopneumoniae being isolated from the liver, spleen, kidneys, bronchial lymph nodes,
pericardium fluid and the brain of infected swine (Buttenschon et al., 1997; Friis, 1974;
Le Carrou et al., 2006; Marois et al., 2007).
Macroscopic (gross) lesions indicative of mycoplasma pneumonia consist of
acute (purple) to chronic (grey) areas of consolidation occurring primarily in the
cranioventral areas of the lung. Both the microscopic and macroscopic lesions are not
distinctive to M. hyopneumoniae infections. Microscopic lesions can be seen on airway
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surfaces from as early as two weeks after infection (Ross, 1999). Recovering lesions
have been observed 11 weeks after infection (Blanchard et al., 1992); however, both
microscopic and macroscopic lesions have also been recorded as persisting for up to 16
weeks post-infection (Underdahl et al., 1980).
The adherence of M. hyopneumoniae to cilia leads to ciliostasis, and loss of
cilia, epithelial cells and bronchial goblet cells (DeBey et al., 1992; DeBey and Ross,
1994) (Figure 1.1C). The damage to epithelial cells in combination with excessive
mucous production and the pressure of surrounding lymphoid tissue results in the
disruption of the function of the mucocilary apparatus of the airways, leaving the host
more susceptible to secondary bacterial infections (Blanchard et al., 1992; DeBey and
Ross, 1994). DeBey and Ross (1994) demonstrated that no epithelial cell damage occurs
when M. hyopneumoniae is separated from porcine cilial rings by a 0.1 µm pore sized
membrane; thus, cilial damage is not believed to be the result of secreted factors/toxins,
at least not prior to attachment. Cilial damage could be related to the M. hyopneumoniae
induced release of intracellular calcium from the endoplasmic reticulum of ciliated
tracheal cells after attachment to cilia (Park et al., 2002). Calcium acts as an
intracellular signal to induce loss of cilia. The mechanism and components of M.
hyopneumoniae that are involved in this release are unknown, although it is likely to be
a key factor in the onset of epithelial cell damage since non-pathogenic strains fail to
induce the release of intracellular calcium (Park et al., 2002).
Electron microscope studies have shown that a ‘fuzzy layer’ surrounds M.
hyopneumoniae cells (Tajima and Yagihashi, 1982; Zhang et al., 1995). This layer
forms a bridge between M. hyopneumoniae and cilia (Tajima and Yagihashi, 1982) and
also contains proteins that are involved in adherence of M. hyopneumoniae to cilia
(Zhang et al., 1995) (Figure 1.2). Excessive broth passage of M. hyopneumoniae cells
diminishes their ability to adhere to ciliated cells and reduces the thickness of the fuzzy
layer (Tajima and Yagihashi, 1982). Thus, the ‘fuzzy layer’ has been purported to play a
role in adhesion and pathogenesis. The actual chemical composition of this layer is
unknown, but it readily stains with ruthenium red (RR), which stains polyanionic
compounds, indicating that it at least partly consists of polyanionic polymers, probably
polysaccharides (Tajima and Yagihashi, 1982). A similar layer has also been observed
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in other mycoplasmas such as Mycoplasma synoviae, Mycoplasma meleagridis,
Mycoplasma dispar and M. pneumoniae (Tajima and Yagihashi, 1982).

Figure 1.1 Interaction of M. hyopneumoniae with swine cilia. Transmission electron
micrograph showing M. hyopneumoniae associated with cilia and microvilli on swine
tracheal ring epithelium, taken five days after inoculation of swine with M.
hyopneumoniae. M represents M. hyopneumoniae; C, cilia; and Mi, microvilli. The bar
in the bottom right hand corner represents a length of 0.83 µm. The electron micrograph
is from DeBey and Ross (1994). (B) Scanning electron micrograph of mid-trachea from
a M. hyopneumoniae infected pig ten weeks post-inoculation showing M.
hyopneumoniae cells amongst normal cilia. Magnification: x2100. The micrograph is
from Underdahl et al. (1980). (C) Scanning electron micrograph of mid-trachea from a
M. hyopneumoniae infected pig ten weeks post-inoculation showing loss of cilia and
scattered mycoplasmas. Magnification: x3000. The micrograph is from Underdahl et al.
(1980).
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Figure 1.2 Transmission electron microscope images illustrating the fuzzy layer
surrounding M. hyopneumoniae cells. (A) Section of the bronchiolar epithelium from a
pig intranasally infected with M. hyopneumoniae killed five weeks after inoculation.
The capsular layer (C) surrounding M. hyopneumoniae cells is stained with RR, and is
bridging the gap between mycoplasmas and some microvilli. Bar represents 200 nm.
The image was taken from Tajima and Yagihashi (1982). (B) M. hyopneumoniae cells
grown in cell culture medium reacted with monoclonal antibody F2G5, which detects an
important cilium adhesin of M. hyopneumoniae (P97), and goat anti-mouse IgM
conjugated with gold particles. The arrows indicate gold particles in the fuzzy layer. Bar
represents 100 nm. The image was taken from Zhang et al. (1995).

1.2.2

Clinical Signs
M. hyopneumoniae infections are clinically characterised by a non-productive

cough, reduced daily weight gain and reduced feed efficiency (Maes et al., 1996; Sibila
et al., 2009). Economic losses to the swine industry are mostly due to the reduced
weight gain and feed efficiency, increased mortality and increased costs due to
treatments (Thacker, 2006). The severity of the disease varies depending on strain,
pressure of infection due to housing conditions, environmental conditions and
secondary infections to which M. hyopneumoniae predisposes the pig (Sibila et al.,
2009). Secondary infections with opportunistic bacteria or viruses lead to the onset of
enzootic pneumonia, where a mild pneumonia becomes more severe and the duration of
the disease increases (Thacker, 2006). Opportunistic bacteria or viruses include the
porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus
(SIV), porcine circovirus type 2 (PCV2), Pasteurella multocida, Actinobacillus
pleuropneumoniae,

Arcanobacterium

pyogenes,

Bordetella

bronchiseptica

and

streptococcal species (Sibila et al., 2009; Thacker, 2006). The term ‘porcine respiratory
disease complex’ (PRDC) is now frequently used to describe co-infections between
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bacteria and viral respiratory pathogens such as those listed above. M. hyopneumoniae
is considered to be a primary agent in the development of PRDC (Thacker et al., 1999).
Due to the variability of pathogens in PRDC, diagnosis, treatment and control are very
difficult for all those involved with the industry; therefore, it is not surprising that
PRDC is a major problem to the swine industry worldwide (Brockmeier et al., 2002).
1.2.3

Diagnosis of M. hyopneumoniae Infections
The best diagnostic method to confirm M. hyopneumoniae infection is to isolate

M. hyopneumoniae from infected lungs. However, M. hyopneumoniae is fastidious,
requiring a specialised media called Friis Medium (Friis, 1974) for culture, is slow
growing and is often outcompeted by other swine mycoplasmas such as M. hyorhinis or
M. flocculare (Maes et al., 1996; Thacker, 2004). Serology is commonly used to
determine the presence of M. hyopneumoniae within a herd, with several commercial
enzyme-linked immunosorbent assays (ELISAs) available for detection of antibodies to
M. hyopneumoniae in serum (Djordjevic et al., 1994; Thacker, 2004). The serum
antibody response to M. hyopneumoniae can be variable. This may be due to its low
exposure to the immune system as a result of colonising the ciliated epithelium in the
respiratory tract; differences in time taken for animals to seroconvert; M.
hyopneumoniae’s potential to alter its surface antigens; and antibody levels generated in
response to vaccination against M. hyopneumoniae being dependent on the vaccine used
(Thacker, 2004). Vaccine induced antibody levels do not correlate with the level of
protection (Djordjevic et al., 1997; Thacker et al., 1998). Polymerase chain reaction
(PCR) in conjunction with serology increases the ability to detect the presence of M.
hyopneumoniae. Whilst PCRs are quick, relatively inexpensive and have the ability to
detect low levels of M. hyopneumoniae, they need to be specific and able to deal with
genetic differences between field isolates (Thacker, 2004). Examination of the lungs at
slaughter may help determine prevalence of the bacteria, but many gross lesions heal by
the time of market sale and other bacterial pneumonias can cause lesions that mimic
those of M. hyopneumoniae (Sibila et al., 2009).
1.2.4

Current Control and Treatment of M. hyopneumoniae Infections
M. hyopneumoniae can be easily transmitted between pigs through direct

contact, aerosol and sow-to-pig transmission, and can also be spread within litters, with
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increased animal density influencing disease prevalence (Maes et al., 1996; Ross,
1999). The likelihood of M. hyopneumoniae transmission between pigs is exacerbated
by the fact the disease is only resolved after a long period (if at all). Prevention of
mycoplasma pneumonia requires good management practices combined with
prophylactic use of antibiotics and vaccination (Maes et al., 1996); however, these are
only partially effective in reducing disease symptoms and outbreaks. Tetracyclines and
macrolides are the most frequently used antimicrobials (Maes et al., 2008). Since
mycoplasmas do not have a cell wall, β-lactam antibiotics that inhibit cell wall
synthesis, such as ampicillin, penicillin, amoxicillin and cephalosporin are ineffective
(Thacker, 2006). M. hyopneumoniae resistance to macrolides, lincosamides and
fluoroquinolones (Vicca et al., 2004) and tetracyclines (Inamoto et al., 1994) has been
reported; however, antimicrobial resistance is currently not a major problem in the
treatment of M. hyopneumoniae infections (Maes et al., 2008). There is, however,
increasing concern about the use of antimicrobials in the agricultural industry with an
increase in the number of antibiotic resistant bacteria (Gousia et al., 2011;
Khachatourians, 1998).
Vaccines that are commercially available consist of M. hyopneumoniae
bacterins. Vaccination with these vaccines, irrespective of serological status of the host,
provides only limited protection against M. hyopneumoniae infection and does not
prevent colonisation (Martelli et al., 2006; Messier et al., 1990; Thacker et al., 1998).
Commercial vaccines reduce clinical signs and lung lesions, and improve daily weight
gain and feed conversion ratio (Maes et al., 1998; Maes et al., 1999). However, they are
expensive to produce due to the rich medium required for M. hyopneumoniae to grow in
vitro, combined with the time consuming nature of the process and the costly mode of
delivery (Ross, 1999). Therefore, further investigation into other vaccine strategies is
warranted.
1.2.5

Cell Surface Adhesins and Putative Adhesins of M. hyopneumoniae
Given that mycoplasmas do not have a cell wall, their cell membrane acts as the

primary interface between the host and the environment. Cell membrane components
that mediate attachment to the host are critical to the parasitic lifestyle of mycoplasmas,
and play crucial roles in host adaption. Adherence of M. hyopneumoniae to porcine
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tracheal epithelial cells is abolished if the Mycoplasma is treated with trypsin or
periodate, indicating that surface proteins and carbohydrates are involved in the
adherence process (Zielinski and Ross, 1993). Microtitre plate cilium-binding assays led
to identification of monoclonal antibodies (mAbs) F2G5 and F1B6, which inhibit the
adherence of M. hyopneumoniae to porcine cilia by 62% and 67%, respectively (Zhang
et al., 1995). MAbs F2G5 and F1B6 have identical antigenic specificities. In
immunoelectron microscopy studies, mAb F2G5 reacted with proteins located in the
fuzzy capsule that surrounds M. hyopneumoniae cells (Zhang et al., 1995) (Figure 1.2).
Affinity chromatography of CHAPS (3-[(3-cholamidopropyl)-dimethyllammonio]-1propanesulfonate) soluble M. hyopneumoniae proteins with mAb F2G5 led to the
identification of the cilium adhesin of M. hyopneumoniae. The mAb F2G5 affinity
purified M. hyopneumoniae protein primarily contained a 97 kDa protein (P97), which
adhered to porcine cilia and dose-dependently inhibited M. hyopneumoniae cells
binding to cilia (Zhang et al., 1995). Purified recombinant P97 from E. coli also bound
to purified porcine cilia (Hsu et al., 1997).
1.2.5.1 The Cilium Adhesin (P97)
P97 is a cell surface protein expressed from an open reading frame (ORF)
coding for a 124.9 kDa protein; however, the protein undergoes post-translational
endoproteolytic cleavage at amino acid position 195 of the translated sequence (Hsu et
al., 1997; Zhang et al., 1995). The processed protein has a predicted molecular mass of
102.9 kDa based on its amino acid sequence, but migrates as a 97 kDa protein in onedimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (1D SDSPAGE) (Hsu et al., 1997). Within the C-terminus of the P97 amino acid sequence is the
presence of two proline-rich repeat regions, named R1 and R2 (Hsu et al., 1997). The
R1 region consists of tandem copies of the sequence AAKPV(E). Downstream of R1 is
the R2 region, which consists of repeats of the ten-amino acid motif GTPNQGKKAE
(Hsu et al., 1997). Both the number of R1 and R2 repeats can vary between strains of
M. hyopneumoniae (Stakenborg et al., 2006; Wilton et al., 1998). R1 is more variable
than R2 with the number of R1 repeats usually being within 2-21 compared to 2-6
copies of the R2 repeats (Stakenborg et al., 2006; Wilton et al., 1998). The number of
repeats does not appear to be change with laboratory passage (Stakenborg et al., 2006).
P97 is highly conserved between M. hyopneumoniae strains apart from variations within
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the repeat regions (Jenkins et al., 2006). Examination of truncated recombinant P97
expression products revealed that the cilium-binding site and the mAb F1B6/F2G5
epitope, which were confined to R1 region of P97 (Hsu et al., 1997; Minion et al.,
2000). Transposon insertion within the R2 region did not abrogate P97 binding to cilia,
suggesting that the R2 region was not essential in cilial binding (Hsu et al., 1997). MAb
F1B6 recognises at least 2.5 repeating R1 units (Hsu and Minion, 1998a; Minion et al.,
2000), with eight consecutive repeating R1 units required for cilium binding (Minion et
al., 2000). However, the number of repeats does not directly correlate with the
variability in cilial adherence activity between strains (Hsu and Minion, 1998a; Minion
et al., 2000; Stakenborg et al., 2006). The presence of R2 is important for P97 binding
to heparin (Jenkins et al., 2006) and has recently been shown to bind fibronectin
(Seymour, 2011). This is discussed later in section 1.4.
Western blots of whole cell lysates from M. hyopneumoniae cells with mAb
F1B6/F2G5 detect numerous proteins with masses ranging from 25-130 kDa (Zhang et
al., 1995) (Figure 1.3). Size variable antigens have been reported for several other
Mycoplasma species; however, the banding pattern on 1D SDS-PAGE gels is typically
very evenly spaced and molecular studies have confirmed that a change in the number
of tandem repeats typically gives rise to these patterns (Razin et al., 1998). By
generating a number of different antisera raised against different recombinantly
expressed regions of P97, part of the complex banding pattern was shown to be due to
multiple endoproteolytic cleavage events (Djordjevic et al., 2004). The majority of
cleavage products were shown by a combination of trypsin digestion and electron
microscope studies to be extracellular and remain associated with the cell (Figure 1.2B
and Figure 1.3) (Djordjevic et al., 2004). The unresolved issue is understanding how
these adhesin cleavage products remain associated with the cell surface even though the
hydrophobic N-terminal leader peptide has been removed during processing (Djordjevic
et al., 2004). This post-translational processing is discussed further in section 1.2.5.4.
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Figure 1.3 Western blot analysis of trypsin digested M. hyopneumoniae strain J cells
with mAb F1B6. Whole cell lysates from M. hyopneumoniae cells were exposed to
different amounts of trypsin; lanes 1-8 represent digestion with 0, 0.3, 0.5, 1, 3, 10, 50,
300 µg/mL trypsin. Indicated on the left are molecular mass standards. Image was taken
from Djordjevic et al. (2004).
1.2.5.2 P102
The gene encoding P97 shares an operon with a gene that encodes a 102 kDa
protein (P102) (Hsu and Minion, 1998b); both are transcribed as a single messenger
ribonucleic acid (mRNA) transcript and expressed in vivo (Adams et al., 2005).
Immunogold electron microscopy of M. hyopneumoniae with antiserum raised against
recombinant P102 revealed that P102 is located within the fuzzy layer surrounding the
mycoplasma cells (Djordjevic et al., 2004). Immunogold electron microscopy of
respiratory tissues from M. hyopneumoniae infected pigs with monospecific, polyclonal
mouse anti-P102 serum, also detected P102 on the surface of M. hyopneumoniae
(Adams et al., 2005). This study also showed P102 in association with cilia 0.5 µm
from the closest M. hyopneumoniae cells; thus, it was suggested that M. hyopneumoniae
secretes P102. This is the first report demonstrating the association of a M.
hyopneumoniae protein with trachea cilia, in a section of trachea tissue taken from a M.
hyopneumoniae infected pig. Recently, the ability of recombinant P102 to interact was
PK15 cells was demonstrated (Seymour et al., 2012); thus, there are various forms of
evidence indicating P102 is a cilial adhesin of M. hyopneumoniae.
1.2.5.3 P97 and P102 Paralogues
The sequencing of the M. hyopneumoniae strain 232 genome subsequently led to
the identification of P97 (Mhp183) and P102 (Mhp182) paralogues, where a paralogue
was defined as having greater than 30% identity over 70% of the protein length (Minion
et al., 2004). There are six P97 paralogues (Mhp107, Mhp271, Mhp280, Mhp385,
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Mhp493 (P216) and Mhp684) and six P102 paralogues (Mhp108 (P116), Mhp272,
Mhp274, Mhp275, Mhp384 and Mhp683) (Figure 1.4). Mhp494 (P159) also shares
some similarity with P102 but does not qualify as a paralogue using the definition of
Minion et al. (2004). Mhp274 appears to be a truncated P102 copy, and within the
amino acid sequence common to both proteins there is only one amino acid change
difference, whilst all other paralogues appear to be the result of gene fusions with nonhomologous sequences (Adams et al., 2005). Most of the genes encoding P97
paralogues share an operon with a gene encoding a P102 paralogue and vice versa,
except for Mhp280 (P95) (Adams et al., 2005).

Figure 1.4 Genes encoding P97 and P102 and their paralogues in the M.
hyopneumoniae strain 232 genome. The arrows show the direction of transcription.
Number 4 indicates the P97 and P102 two-gene operon. The black bars show the gene
for P97 and its paralogues. The grey bars show the gene for P102 and its paralogues.
Listed above each bar is the gene number and the assigned name (if any) in brackets.
The gene number is according to the strain 232 genome sequence in GenBank
(accession number AE017332.1). The gene of the P97 paralogue P95 (mhp280) is not
shown as it is not found with a P102 paralogue. This figure was adapted from Adams et
al. (2005). Sizes of the bars indicate the relative length of each gene.
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Gene specific reverse transcriptase-PCRs (RT-PCRs) of M. hyopneumoniae
taken from bronchoalveolar lavage fluid (BALF) of experimentally challenged pigs
revealed that the genes for P97, P102 and all of the paralogues, except for Mhp280,
were transcribed during infection, and all the genes except mhp107 and mhp108 were
transcribed with their operon partner, suggesting they may have related functions
(Adams et al., 2005). Whether mhp494 is transcribed was not investigated since it was
not recognised as a P102 paralogue and, therefore, not included in the study. An mRNA
transcript of its operon partner mhp493 was found. The genes mhp107 and mhp108 are
separated by 54 base pairs, which is the largest distance between genes within the P97
and P102 paralogue families (Adams et al., 2005). A greater distance exists between the
genes mhp493 encoding a P97 paralogue and mhp494 encoding a protein that shares
some similarity to P102 although it was not classified as a paralogue (Wilton et al.,
2009). There is at least 94% similarity between each paralogue and their homologues
from three sequenced M. hyopneumoniae genomes (pathogenic strains 232 and 7448,
and laboratory passaged, non-pathogenic J strain) (Ferreira and de Castro, 2007). This
observation suggests the paralogues are highly conserved and are potentially important
proteins.
1.2.5.4 Endoproteolytic Cleavage of Members of the P97 and P102 Paralogue
Families
P97, P102 and their paralogues appear to be the target of a M. hyopneumoniae
protease(s) (Bogema et al., 2011; Burnett et al., 2006; Djordjevic et al., 2004; Pinto et
al., 2007; Seymour et al., 2010; Seymour et al., 2011; Seymour et al., 2012; Wilton et
al., 2009; Zhang et al., 1995). Such proteolytic processing has not been demonstrated
for other (non P97 or P102 paralogues) M. hyopneumoniae proteins (Djordjevic et al.,
2004; Wilton et al., 2009). In addition the processed fragments do not contain any
typical attachment sequences, such as a transmembrane domain, yet they remain
associated with the cell surface (Bogema et al., 2011; Burnett et al., 2006; Djordjevic et
al., 2004; Seymour et al., 2010; Seymour et al., 2011; Seymour et al., 2012; Wilton et
al., 2009). The role of this selective processing has yet to be determined but it has been
hypothesised that it allows M. hyopneumoniae to alter its surface architecture
(Djordjevic et al., 2004; Jenkins et al., 2006).
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P97 undergoes two major endoproteolytic cleavage events: at position 195 in the
amino acid sequence to produce the 97 kDa protein and between the R1 and R2 repeat
regions (Djordjevic et al., 2004; Hsu et al., 1997). Further research is required to
explain the complex banding pattern seen in Western blots of whole cell lysates of M.
hyopneumoniae cells with anti-P97 serum and mAbs F1B6 and F2G5. Like P97, P102
also undergoes post-translational endoproteolytic cleavage resulting in N-terminal 60
kDa protein and a C-terminal 42 kDa fragment (Djordjevic et al., 2004; Seymour et al.,
2012). Thus, the processing of P102 does not appear to be as complex as for P97.
Edman sequencing identified that the N-terminal sequence of the 42 kDa protein was
AEEAKG (Djordjevic et al., 2004).
Comparison of the amino acid sequences at the endoproteolytic cleavage sites of
members of the P97 and P102 paralogue families identified some common residues at
the site of cleavage. The N-terminal cleavage site of P97 and the cleavage sites of P102,
Mhp683 and P216 undergo endoproteolytic processing within a S/T-X-F↓X-D/E motif:
a phenylalanine residue is located in position -1 of the site of cleavage, an alcohol
containing residue (S/T) is present at the -3 position, and at the + 2 position is
negatively charged (D/E) amino acid residue (Bogema et al., 2011). However, this
motif does not fit the endoproteolytic cleavage site between the R1 and R2 repeat
regions in P97.
1.2.6

Vaccines
The potential of P97 and the P97 R1 repeat region as vaccine candidates has

been investigated. Intramuscular vaccination of swine with a P97 fusion protein induced
a P97-specific serum humoral response but did not protect against M. hyopneumoniae
infection, as determined by a non-significant difference in reduction of coughing scores
and lung lesion formation between vaccinated and non-vaccinated groups (King et al.,
1997). In mice the R1 repeat region of M. hyopneumoniae fused to the subunit of E. coli
heat-liable enterotoxin produced anti-R1 systemic antibodies and cellular immunity;
however, intramuscular delivery favoured a type II helper T cell (Th2)-biased immune
response while intranasal administration produced a type I helper T cell (Th1)-biased
immune response and interferon-γ (IFN-γ) secretion from splenocytes (Conceicao et al.,
2006). A Salmonella-based DNA vaccine (Salmonella typhimurium aroA strain CS332 )
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harbouring an eukaryotic or prokaryotic expression vector encoding P97 R1 repeat
region (11 repeats) did not induce an R1-specific serum IgG or IgA response but
induced significant R1 specific IFN-γ production in orally immunised mice (Chen et al.,
2006a). Mice and pigs subcutaneously vaccinated with a conventional M.
hyopneumoniae vaccine then boostered with a vaccine containing R1 fused to a non
toxic form of Pseudomonas exotoxin A resulted in a higher specific IgG immune
response against tandem repeat region R1 compared to mice and pigs that were
immunised with M. hyopneumoniae whole cells (Chen et al., 2001). Intranasal
immunisation of pigs with an attenuated Erysipelothrix rhusiopathiae (an intracellular
organism) strain expressing the C-terminal region of P97 (R1 and R2 tandem repeat
regions) also reduced the severity of lung lesions upon challenge with M.
hyopneumoniae. In this trial significant humoral responses were not detected; however,
a cell-mediated response to the P97 protein was detected (Shimoji et al., 2003). A
different strain of E. rhusiopathiae expressing the C-terminal region of P97
administered as an oral pig vaccine against M. hyopneumoniae also reduced the severity
of lesions after challenge with M. hyopneumoniae (Ogawa et al., 2009). Significantly
higher concentrations of P97-specific IgA and IgG were detected in serum and in
BALF, respectively, at different times from the vaccinated pigs post-challenge.
However, the number of mycoplamas isolated from BALF were not different between
the vaccinated and non-vaccinated control group and no P97-specific antibody response
was detected in serum or lung washes.
An obvious challenge with developing a vaccine not only includes identifying
the right vaccine candidates but also the type of vaccine, as different adjuvants and
administration routes can result in a different immune response. The R1 repeat region is
recognised by convalescent phase swine sera (Minion et al., 2000) and P97-specific
mouse serum and P97 R1-specific mouse serum recognise each other; thus, the P97 R1
repeat region contains a functional antibody domain (Chen et al., 2008). However,
studies to date have not shown that vaccination with P97 or the P97 R1 repeat region
alone is sufficient for protection against M. hyopneumoniae infection.
The vaccine formulations containing immunogenic antigens NrdF (Chen et al.,
2006b; Fagan et al., 1997), heat shock protein P42 (Chen et al., 2003), the R1 repeat
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region of P97 (Chen et al., 2006a; Conceicao et al., 2006) and a pool of antigens
consisting of P36, P46, NrdF and P97 or P97 R1 repeat region (Chen et al., 2008) have
been trialled in mice, while vaccines containing P97 (King et al., 1997), NrdF (Fagan et
al., 2001) and M. hyopneumoniae antigens in the molecular size range of 70-85 kDa
(Djordjevic et al., 1997) have been trialled in swine. Although the swine administered
vaccines induced various humoral and/or cell-mediated responses, complete protection
was not achieved. Some protection from clinical pneumonia was seen in the reduction
of lesion formation upon challenge with a pathogenic strain of M. hyopneumoniae
(Djordjevic et al., 1997; Fagan et al., 2001). The use of DNA vaccines has grown in
popularity since they are capable of inducing both humoral and cell-mediated responses,
can be administered orally, intramuscularly, or subcutaneously and multiple antigens
can be delivered simultaneously (Chen et al., 2008). Strong Th1 and Th2 responses
were achieved by using a DNA cocktail vaccine boostered with a protein cocktail
vaccine against M. hyopneumoniae proteins, albeit in mice (Chen et al., 2008). This has
yet to be tested in swine. The ultimate goal is to determine which proteins are protective
and the most effective way of presenting these to the host to stimulate an immune
response.

1.3 Bacterial Adhesion and Entry into Host Cells
Critical to the pathogenesis of M. hyopneumoniae is the adherence of M.
hyopneumoniae to epithelial cilia lining the respiratory tract. In order for colonisation to
occur M. hyopneumoniae must overcome host defence mechanisms. The chronic nature
of M. hyopneumoniae infections indicates that M. hyopneumoniae is very efficient at
evading the host immune response and adapting to environmental changes within the
host. Microorganism interaction with host serum or cellular components appears to be
an important strategy in pathogenesis. The consequences of such interactions are
numerous from contributing to adherence to host cells, invasion of host cells, masking
the microbial surface from the host immune system, and nutrient acquisition. The
glycosaminoglycan (GAG) heparan sulfate, fibronectin and plasminogen are common
host molecules that are exploited by bacterial pathogens for survival within the host and
are discussed in the following sections.
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1.3.1

Glycosaminoglycans
GAGs are polyanionic acidic polysaccharides composed of linear repeating

disaccharides units, which consist of alternating hexosamine [D-glucosamine (GlcN) or
D-galactosamine (GalN)] and either hexuronic acid [D-glucuronic acid (GlcA) or Liduronic acid (IdoA)] or galactose (Islam and Linhardt, 2003; Kjellen and Lindahl,
1991; Zielinski and Ross, 1993). The variability in sulfation of the polysaccharides has
led to great heterogeneity within and between different GAG chains. GAGs are
distinguished by their disaccharide composition, the linkage between the sugars, and the
number and location of sulfated groups (Lindahl and Höök, 1978), summarised in Table
1.1. The most common GAGs are heparan sulfate, heparin, chondroitin sulfate,
dermatan sulfate, keratan sulfate and hyaluronic acid (Islam and Linhardt, 2003;
Jackson et al., 1991; Lindahl and Höök, 1978). GAGs are usually covalently linked to
core proteins to form proteoglycans (Islam and Linhardt, 2003; Jackson et al., 1991;
Lindahl and Höök, 1978). Proteoglycans can have from one, to greater than 100, GAG
substituents (Kjellen and Lindahl, 1991). The GAG side chains of cell surface
proteoglycans are involved in binding a variety of proteins to the cell surface (Islam and
Linhardt, 2003).
1.3.1.1 Heparin and Heparan Sulfate
Heparin is an anticoagulant found in the intracellular granules of mast cells that
line the arteries of the lungs, liver and skin (Dubreuil et al., 2002; Patti et al., 1994;
Rostand and Esko, 1997). It is often found at inflammation sites in tissues as a result of
mast cell degranulation (Stevens, 1987). On the other hand, heparan sulfate, a structural
relative of heparin, is an abundant constituent of cell surfaces and of the ECM
(Bernfield et al., 1999; Conrad, 1998; Jackson et al., 1991; Kjellen and Lindahl, 1991;
Patti et al., 1994; Yanagishita and Hascall, 1992). Heparan sulfates are present on the
surface of most animal cells (Bernfield et al., 1999), including the surface of cilia and
microvilli of porcine respiratory epithelia (Erlinger, 1995). Both heparin and heparan
sulfate are negatively charged, highly acidic polysaccharides due to their level of
sulfation, with heparin being more sulfated and having the highest charge of all the
GAGs (Kjellen and Lindahl, 1991; Rostand and Esko, 1997). Heparin can serve as an
analogous model for the highly sulfated IdoA-(1→4)-D-GlcN disaccharides domains of
heparan sulfate. Therefore, as a result of its abundance and commercial availability
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compared to heparan sulfate, numerous heparin-binding studies have been conducted
using heparin in preference to heparan sulfate (Montemurro et al., 2002; Rabenstein,
2002). Heparin and heparan sulfate also have a unique ability to bind to a large number
of different, primarily extracellular, host proteins (Bernfield et al., 1999; Islam and
Linhardt, 2003). Specific recognition sites that bind heparin and heparan sulfate are
present in numerous ECM proteins: fibronectin, collagen, laminin and vitronectin, but
also in enzymes and inflammatory and immunomodulatory factors (Conrad, 1998; Islam
and Linhardt, 2003).
Table 1.1 The structures of GAGs This table was adapted from (Jackson et al., 1991;
Lindahl and Höök, 1978; Mulloy and Forster, 2000).
Glycosaminoglycan

Repeating Disaccharidea

Sulfation Sitesb

Heparin

→4)-α-L-IdoA-α(1→4)-α-D-GlcN-(1- (major)e
or
→4)-β-D-GlcA-β(1→4)-α-D-GlcN-(1-

N2, O6, O3 of GlcN;
O2 of IdoA/GlcA

Heparan sulfate

→4)-β-D-GlcA-β(1→4)-α-D-GlcN-(1- (major)
or
→4)-α-L-IdoA-α(1→4)-α-D-GlcN-(1-

N2, O6, O3 of GlcN;
O2 of IdoA/GlcA; N2 of
GlcN may be acetylated.

Chondroitin sulfate B
(Dermatan sulfate)

→4)-α-L-IdoA-α(1→3)-β-GalNAc-(1- (major)
or
→4)-β-D-GlcA-β(1→3)-β-GalNAc-(1-

O4 and/or O6 of
GalNAc; O2 of
IdoA/GlcA

Chondroitin sulfate Ac

→4)-β-D-GlcA-β(1→3)-β-GalNAc-(1-

O4 of GalNAc;
occasionally O2, O3; C2
of GlcA

Chondroitin sulfate Cd

→4)-β-D-GlcA-β(1→3)-β-GalNAc-(1-

O6 of GalNAc;
occasionally O2, O3; C2
of GlcA

Hyaluronan

→4)-β-D-GlcA-β(1→3)-β-D-GlcNAc-(1-

none

Keratan sulfate

→3)-β-D-Gal-β(1→4)-β-D-GlcNAc-(1-

O6 on both sugars

a

Abbreviations: GlcN, glucosamine; GlcNAc, N-acetylglucosamine; GalNAc, N-acetlygalactosamine;
GlcA, glucuronic acid; IdoA, iduronic acid; Gal, galactose. For aldohexoses described, a β-anomer has a
hydroxyl group at C1 and CH2OH at C5 cis with respect to each other on the ring, and an α-anomer is in
trans-configuration.
b
O6 of GlcN means 6-O -sulfated GlcN
c
Chondroitin 4-sulfate (sulfated at position 4)
d
Chondroitin 6-sulfate (sulfated at position 6)
e
Major refers to the more common repeating disaccharide

Often, bacteria binding to heparan sulfate on the host cell surface is a first step
in the infection process (Finlay and Falkow, 1989). Several microbial pathogens utilise
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heparan sulfates on the mammalian cell surface for adherence to the host, including
Streptococcus pyogenes (Frick et al., 2003), Pseudomonas aeruginosa (Plotkowski et
al., 2001) and Bordetella pertussis (Menozzi et al., 1994). Helicobacter pylori, S.
pyogenes, Yersinia pestis, Yersinia enterocolitica, Staphylococcus aureus, Neisseria
meningitides and Neisseria gonorrhoeae bind heparin/heparan sulfate and then adhere
to other heparin-binding proteins (Duensing et al., 1999). Thereby heparin/heparan
sulfate act as a bridge to a large repertoire of heparin binding proteins found in the
extracellular milieu, on the surface of host cells and in the ECM. This may facilitate
adherence or the invasion of host cells, or might be a way to bind to a variety of host
proteins to avoid recognition by the host’s immune system. Mycobacterium tuberculosis
adheres to heparan sulfate proteoglycans on the surface of alveolar epithelial cells via
several lysine-rich repeats in the heparin-binding hemagglutinin adhesin (HBHA)
(Menozzi et al., 1996; Pethe et al., 2000). Mice trials with HBHA-disrupted M.
tuberculosis and Mycobacterium bovis strains and bacteria coated with anti-HBHA
antibodies resulted in fewer bacteria disseminating from the lungs to the spleen,
suggesting that HBHA plays a role in facilitating the translocation of the bacteria across
epithelial cells (Pethe et al., 2001).
1.3.2

Fibronectin
Fibronectin is a 440-kDa glycoprotein composed of two subunits, ranging from

230-270 kDa depending on alternative splicing, which are disulfide linked near the
carboxyl terminus of the protein (Hynes, 1990). This large glycoprotein is found in all
vertebrates in a soluble form, in plasma at approximately 300-400 µg/mL and other
body fluids, and as an insoluble (cellular) form in the ECM and on the surface of cells
(Proctor, 1987). Various cell types produce fibronectin; however, the majority of
fibronectin in the plasma is a product of hepatocytes, while cellular fibronectin is
secreted by fibroblasts and various other cell types (Hynes, 1990; Mao and
Schwarzbauer, 2005). Soluble fibronectin can be incorporated into a fibrillar matrix on
the surface of cells or in the ECM. There is only one copy of the gene encoding
fibronectin; however, at least 20 different forms of fibronectin can exist in humans as a
result of alternative splicing (Pankov and Yamada, 2002). Plasma fibronectin has a
relatively simple splicing pattern in contrast to cellular fibronectin, which is more
heterogeneous as a result of cell-type specific and species-specific splicing patterns
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generating fibronectins with different cell-adhesive, ligand-binding and solubility
properties (Pankov and Yamada, 2002).
Fibronectin plays a role in wound healing, blood clotting, hemostasis,
phagocytosis,

embryogenesis,

cellular

adhesion,

morphology,

migration

and

cytoskeletal rearrangement (Hynes and Yamada, 1982; Proctor, 1987). The protein is
composed mostly of three types of repeating units called modules: type I (Fn1), type II
(Fn2) or type III (Fn3) that are approximately 45, 60 and 90 amino acids long,
respectively, and arranged to make up functional domains that contain binding sites for
fibrin, heparin, collagen and for a number of cell surface integrins (Figure 1.5) (Proctor,
1987). Short hinge regions separate the modules allowing the molecule to adopt
different conformations (Johansson et al., 1997). The amino acid sequences of each
module within a particular type are not identical; however, they have similar 3D
structures (Henderson et al., 2011). There are 12 type I and two type II modules. Due to
splicing the number of type III modules can vary between 15-17 (Proctor, 1987). The
two exons corresponding to the extra domain regions, EDA and EDB, that are within
two type III modules, are spliced to either be included or excluded, while the variable
region (V) located near the C-terminus can be spliced in several places. Usually the
EDA and EDB regions are not present in soluble fibronectin, while the V region, which
is important for fibronectin dimer secretion, is only present in one of the two subunits of
a plasma fibronectin dimer. The V region is usually present in both cellular fibronectin
subunits (Mao and Schwarzbauer, 2005). Other modifications to fibronectin that can
affect the function of the molecule include glycosylation, phosphorylation and sulfation
(Romberger, 1997).

Fibronectin also possesses fibronectin-binding domains. These domains are
located within type I1-5, type III1-3, type III7 and type III12-14 (Figure 1.5) and are
important for maintaining compact formation in solution, but also in the process of
fibronectin matrix assembly (Mao and Schwarzbauer, 2005). The integrin α5β1, which is
expressed by many cell types, is the primary mediator of fibronectin matrix assembly.
The sequence Arg-Gly-Asp (RGD) in fibronectin repeat III10 is the critical α5β1 integrinbinding site; however, the synergistic sequence Pro-His-Ser-Arg-Asn (PHSRN) in the
adjacent module III9 results in high affinity binding and is necessary for fibril formation
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(Pankov and Yamada, 2002; Singh et al., 2010). Interaction of fibronectin with α5β1
integrin and other cell receptors, such as syndecan-4, leads to the reorganisation of the
actin cytoskeleton and the activation of intracellular signalling complexes (Mao and
Schwarzbauer, 2005). Cytoskeletal arrangements increase cell contractility resulting in
fibronectin conformational changes that promote fibronectin-fibronectin interactions.
These events eventually lead to the formation of an insoluble fibrillar matrix (Mao and
Schwarzbauer, 2005; Singh et al., 2010). The N-terminal assembly domain (modules
type I1-5) in fibronectin is essential for mediating fibronectin-fibronectin interactions in
the process of matrix assembly (Mao and Schwarzbauer, 2005; Singh et al., 2010).

Figure 1.5 Structure of fibronectin. Three types of repeating units primarily make up
fibronectin: type I, type II and type III. The V region is a non-homologous region and is
variable in length. EDB, EDA and V are all alternatively spliced domains. Binding
domains for fibrin, collagen, gelatine, fibronectin (FN), heparin and cells are indicated.
Fibronectin binds to integrins on the surface of cells via the cell-binding domain: III10
and III9, which include the integrin-binding sequence Arg-Gly-Asp (RGD) and
synergistic sequence Pro-His-Ser-Arg-Asn (PHSRN) that enhances α5β1 integrin
binding, respectively. Fibronectin forms a dimer via the cysteine residues (SS) at the Cterminus. The figure was derived from Potts and Campbell (1994).
Numerous bacteria exploit host fibronectin by expressing surface proteins that
bind fibronectin with high specificity and affinity. The fibronectin binding proteins
(FnBPs) of S. aureus and S. pyogenes have been well studied and continue to be the
subject of continuous research. The FnBPs from Gram-positive bacteria are usually
members of the microbial surface components recognizing adhesive matrix molecules
(MSCRAMMs). These proteins typically have an N-terminal signal sequence, a region
that binds to part of an ECM molecule, a short positively charged C-terminal
intracellular tail and a C-terminal LPXTG motif that is recognised by the sortase
enzyme, which sorts and anchors the proteins to the cell surface (Henderson et al.,
2011; Joh et al., 1999). The fibronectin binding regions of S. aureus and S. pyogenes
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FnBPs belonging to the MSCRAMM family are usually disordered regions composed
of tandem repeat units that bind to the five N-terminal type I modules of fibronectin
(Schwarz-Linek et al., 2006). These disordered regions become ordered upon binding to
fibronectin (Schwarz-Linek et al., 2006).
The molecular function of FnBPs is usually understood; however, the precise
biological role of a particular FnBP is often hard to determine due to existence of other
FnBPs, or virulence factors, or due to the different types of infections some bacteria,
such as S. aureus and S. pyogenes, may cause (Schwarz-Linek et al., 2004). The FnBPs
of S. aureus contribute to the pathogenicity of this bacterium by mediating adherence to
a number of host cell types, such as endothelial and epithelial cells, fibroblasts and
osteoblasts (Henderson et al., 2011). Fibronectin also facilitates S. aureus invasion of
host cells by providing a bridge between the FnBP and host cell surface integrin α5β1.
FnBPA and FnBPB are two well characterised S. aureus FnBPs; however, a study has
shown that the adherence of S. aureus isolates to fibronectin was not significantly
different irrespective of whether one or both of these proteins were present (Peacock et
al., 2000). In the clinical isolates studied, all contained at least FnBPA or FnBPB
(Peacock et al., 2000). Other FnBPs have been identified for S. aureus, including 36
kDa autolysin (Aaa), ECM-binding protein homologue (Ebh), secretable expanded
repertoire adhesive molecules (SERAM), extracellular adherence protein (Eap) and
ECM protein-binding protein (Emp) (Henderson et al., 2011). At least 12 FnBPs have
been described in S. pyogenes that can promote adherence to host cells and, in some
cases, cell invasion (Henderson et al., 2011). The streptococcal fibronectin binding
protein I (SfbI) protein of S. pyogenes interacts with fibronectin on the eukaryotic
epithelial cell line Hep-2 leading to bacterial internalisation (Molinari et al., 1997).
Binding of SfbI to fibronectin also results in collagen recruitment leading to bacterial
aggregate formation and evasion of phagocytosis (Dinkla et al., 2003). Binding to
fibronectin contributes significantly to the virulence of numerous pathogens,
particularly given that the interactions with fibronectin potentially have more than one
function.
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1.3.3

Plasminogen/Plasmin
Human plasminogen is a 92 kDa single chain glycoprotein that is primarily

synthesised in the liver; however, synthesis has also been demonstrated in adrenal
glands, kidney, brain, testis, heart, lung, uterus, spleen, thymus and gut (Zhang et al.,
2002). Plasminogen is a ubiquitous inactive pro-enzyme circulating in the plasma at an
approximate concentration of 2 µM (Andreasen et al., 1997). Host activators, urokinasetype plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), convert
plasminogen into the active serine protease, plasmin, via cleavage of the peptide bond
between Arg561 and Val562 (Petersen et al., 1990; Robbins et al., 1967). This cleavage
results in an N-terminal heavy chain disulfide linked to a C-terminal light chain (Figure
1.6). The heavy chain of plasminogen/plasmin contains five, approximately 80 amino
acids long, triple looped and triple disulfide-linked kringle domains. Within these
domains are lysine binding sites that contain a hydrophobic cleft formed by aromatic
residues that mediate binding to fibrin, ECM molecules and to lysine-containing
receptors found on the surface of mammalian cells (Ponting et al., 1992). The 25 kDa
light chain contains the amino acids His602, Asp645 and Ser740 that make up the catalytic
triad of the serine protease domain, which cleaves peptide bonds C-terminal to lysine or
arginine residues (Lahteenmaki et al., 2001; Ponting et al., 1992).

Figure 1.6 Structure of mature human plasminogen. Plasmin hydrolysis of the Nterminal leader peptide (NTP) after Lys77 results in the conversion of Glu-plasminogen
to Lys-plasminogen or Glu-plasmin to Lys-plasmin. The NTP is followed by five
consecutive kringle domains (K1-K5). Plasminogen activators uPA and tPA catalyse
cleavage at the peptide bond of Arg561-Val562 (indicated by arrows) resulting in the
formation of plasmin. The protease domain contains the serine catalytic triad.
Human plasminogen is synthesised as an 810 amino acid polypeptide; however,
the leader peptide of 19 amino acids is cleaved during secretion (Forsgren et al., 1987).
Therefore, the mature circulating form of human plasminogen is 791 amino acids and is
called Glu-plasminogen due to the presence of a glutamic acid residue at the N25

terminus. This form of plasminogen exists in what is known as a closed conformation as
a consequence of intra-molecular interaction between the lysine-binding site of kringle
5 with the N-terminal leader peptide, probably through amino acids Lys50 and/or Lys62
(Cockell et al., 1998). Upon binding to a lysine receptor or analogue, the conformation
of the plasminogen changes into an open, extended flexible conformation, and the
plasminogen has an enhanced activation rate (Claeys and Vermylen, 1974). This
plasminogen/plasmin is also protected from inactivation by inhibitors, such as α2antiplasmin, which are lysine dependent (Lahteenmaki et al., 2001). Native
plasminogen exists in two major glycoforms, type I is more glycosylated and binds
lysine residues with lower affinity than type II (Hayes and Castellino, 1979; Molgaard
et al., 1997; Ponting et al., 1992). Plasmin can also modify Glu-plasminogen by
cleaving between the residues Arg67-Met68, Lys76-Lys77 or Lys77-Val78, releasing the 8
kDa NTP, thereby forming what is generically referred to as Lys-plasminogen
(Lahteenmaki et al., 2001; Ponting et al., 1992). Lys-plasminogen has a more open or
relaxed conformation and is preferential for plasminogen activators; however, the
removal of the N-terminal leader peptide is not necessary for plasminogen activation
(Claeys and Vermylen, 1974; Lahteenmaki et al., 2001).
Due to the abundance of plasminogen circulating in plasma and the broad
substrate specificity of plasmin, the plasminogen activation system is tightly regulated.
Plasmin has a pre-eminent role in the dissolution of fibrin in the fibrinolytic system, an
anti-coagulative protease cascade, which is integrated into the wound healing process.
Another important role of plasmin is in the degradation of the ECM and basement
membrane components; fibronectin, laminin, vitronectin, proteoglycans, and precursors
of degradative matrix metalloproteases (MMPs) such as pro-collagenases. Plasmin can
also regulate growth factor release and activity (Rifkin et al., 1997). Consequently
plasminogen contributes to a variety of biological process such as cell adhesion, cell
migration,

tumour

invasion

and

metastasis,

ovulation,

angiogenesis,

airway

remodelling, inflammatory response and wound healing.
Due to its fibrin-specificity, tPA, a 70 kDa serine protease secreted mainly by
endothelial cells, is primarily involved in clot dissolution in fibrinolysis (Hoylaerts et
al., 1982; Lahteenmaki et al., 2001). Urokinase-type plasminogen activator, a 50 kDa
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protease secreted by various normal and malignant cells, binds to cells via cell surface
receptor urokinase-type plasminogen activator receptor (uPAR) (CD87). It is the most
significant activator of plasminogen for ECM degradation during inflammation, wound
healing, tissue remodeling and tumor metastasis (Andreasen et al., 1997; Lahteenmaki
et al., 2001; Moller, 1993). The activators are regulated by the serine protease inhibitors
(serpins), plasminogen activator inhibitor type 1 (PAI-1) and plasminogen activator
inhibitor type 2 (PAI-2), while the local activity of plasmin remains under the control of
α2-antiplasmin and to a lesser extent α2-macroglobulin (Lahteenmaki et al., 2001).
The high concentration of plasminogen in plasma provides pathogenic bacteria
with the potential to exploit the proteolytic system; therefore, it is not surprising that
over the last decade there has been a dramatic increase in the identification of
pathogenic bacteria that interact with the plasminogen activation system (PAS).
Numerous microorganisms express plasminogen receptors on their surface enabling the
bacteria to acquire a surface-associated host protease that can no longer be regulated by
α2-antiplasmin (Lahteenmaki et al., 2001). Activation by host or prokaryotic activators
provides the bacteria with plasmin-mediated proteolytic capabilities. Plasmin coated
bacteria have the ability to degrade fibrin clots, a host defence strategy that concentrates
the pathogen enabling a directed inflammatory response. Cell surface-bound plasmin
can also be utilised to penetrate the host ECM leading to microbial translocation and
dissemination, to release amino acids or peptides from mammalian tissues or increase
vascular permeability ensuring a supply of nutrients, to degrade complement and
immunoglobulins, or to evade of innate immune surveillance systems (Coleman and
Benach, 1999; Lahteenmaki et al., 2001). A large number of surface receptors bind
plasminogen in a lysine-dependent manner either via a C-terminal lysine or internal
lysine residues (Ranson and Andronicos, 2003). Some well known plasminogen
receptors are the streptococcal surface glycolytic enzymes: streptococcal surface
enolase (SEN), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the M-like
protein PAM (Coleman and Benach, 1999). The fimbriae and flagella of Gram-negative
bacteria have also been shown interact with plasminogen (Lahteenmaki et al., 2001).
Bacterial species can express multiple plasminogen receptors and often these proteins
have other important functions. Some pathogens also produce their own plasminogen
activator. The best characterised bacterial activators are staphylokinase from S. aureus,
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streptokinase produced by produced by group A, C and G streptococci, and the Pla
protease from Y. pestis. Staphylokinase and streptokinase are not proteases but initiate
plasminogen

activation

by

formation

of

stoichiometric

complex

with

plasminogen/plasmin. They are also not inhibited by lysine; therefore, their proteolytic
activity is not regulated by α2-antiplasmin. Pla is an aspartyl protease that
proteolytically converts plasminogen to plasmin at the same bond as uPA and tPA. It is
thought that these pathogen plasminogen activators play an important role in invasive
disease progression. In contrast there are a large number of bacteria that bind
plasminogen and rely on the use of host plasminogen activators, such as Borrelia
burgdorferi, H. pylori and E. coli (Coleman and Benach, 1999).

1.4 M. hyopneumoniae Interaction with Host Molecules
The necessity of M. hyopneumoniae to adhere to airway epithelium cilia for
colonisation indicates that cilia are an important host target for M. hyopneumoniae. In
an attempt to characterise the receptors on cilia, an inhibition study was performed
revealing that the sulfated molecules heparin, mucin, fucoidan and chondroitin sulfate B
significantly inhibit M. hyopneumoniae’s adherence to cilia (Zhang et al., 1994). This
was the first experiment to indicate M. hyopneumoniae interact with sulfated molecules.
In addition, heparin inhibits M. hyopneumoniae adherence to the porcine kidney
epithelial-like cell line PK15, a cell line that is often used as an adherence model for
swine (Burnett et al., 2006). Heparinase sensitive GAGs are present along the surface of
ciliated swine respiratory epithelium (Erlinger, 1995) and are a target for M.
hyopneumoniae. Therefore, the interaction of a number of M. hyopneumoniae adhesins
and putative adhesins with heparin has been investigated. The cilia binding activity of
recombinant P97 was inhibited by heparan sulfate and fucoidan (Hsu et al., 1997). Later
it was established that the N-terminus of P97 and the R1 and R2 repeat regions of P97,
when expressed together, bind heparin (Jenkins et al., 2006). Therefore, the cleavage
event separating the R1 and R2 repeat regions would abolish the heparin-binding ability
of the C-terminus; however, the N-terminal cleavage fragment would still be able to
bind heparin (Jenkins et al., 2006). Other paralogues that have been shown to bind cilia
and/or PK15 cells and/or heparin include: P102, P159 (not a P102 paralogue; however,
shares some similarity), P216, P116, Mhp107 and Mhp683 (Bogema et al., 2011;
Burnett et al., 2006; Seymour et al., 2010; Seymour et al., 2011; Seymour et al., 2012;
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Wilton et al., 2009). Heparin/heparan sulfate represent one host target of M.
hyopneumoniae; however, M. hyopneumoniae is likely to interact with a number of host
molecules in order to overcome the respiratory tract mucociliary system, penetrate the
mucus covering the surface of the epithelium and persist within the host for long
periods of time causing chronic disease.
Recently, it was reported that M. hyopneumoniae cells can dose-dependently
bind fibronectin (Seymour et al., 2010). ECM molecules such as fibronectin are
exposed as a result of epithelial cell damage during M. hyopneumoniae infection. The
biological consequences of the M. hyopneumoniae-fibronectin interaction in
pathogenesis are unknown, but the interaction is likely to be important, considering M.
hyopneumoniae expresses at least four fibronectin binding proteins on the cell surface;
P97, P102, Mhp107 and P116 all possess fibronectin binding domains (Seymour, 2011;
Seymour et al., 2010; Seymour et al., 2011; Seymour et al., 2012). With increasing
evidence of M. hyopneumoniae occupying host tissues away from the initial site of
infection in the respiratory tract, it has been hypothesised that fibronectin, with its
ability to form a bridge between FnBPs on the cell surface of bacteria and host cell
integrin α5β1 causing cytoskeleton rearrangements (Henderson et al., 2011), may
facilitate the movement of M. hyopneumoniae’s across epithelial barriers (Seymour et
al., 2010; Seymour et al., 2011; Seymour et al., 2012). In addition, interaction with
fibronectin may confer other advantages to M. hyopneumoniae, as demonstrated for
other bacterial pathogens (discussed in section 1.3.2).

1.5 Rationale and Aims of this Study
Porcine enzootic pneumonia is a major economic problem for the swine
industry, which is a growing industry with pig meat accounting for over 40% of meat in
the world market (FAO, 2010). Understanding the mechanisms by which M.
hyopneumoniae colonise the host is integral for the development of an effective vaccine
to treat and prevent infection. M. hyopneumoniae have the ability to remain within the
host for over 200 days (Pieters et al., 2009). An increasing number of studies indicate
that a population of M. hyopneumoniae cells are found distal from the site of
colonisation, such as in the liver, spleen, kidneys, brain and pericardial fluid
(Buttenschon et al., 1997; Friis, 1974; Le Carrou et al., 2006; Marois et al., 2007),
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which would potentially enable the bacteria to evade host immune responses and
antibacterial treatments. It is unknown how the bacteria disseminate to these sites;
however, numerous bacteria utilise host plasminogen/plasmin to dissolve fibrin meshes
and extracellular matrices, thereby favouring host tissue invasion and immune system
evasion.
P97 is a key adhesin of M. hyopneumoniae. A survey of the M. hyopneumoniae
genome revealed paralogues of both P97 and P102 (Minion et al., 2004). The presence
of these proteins in a bacterium that has evolved by genome reduction combined with
the uniqueness of these proteins to Mycoplasma spp., suggests that P97, P102 and their
paralogues are likely to be essential to M. hyopneumoniae niche specific survival. Two
proteins from M. conjunctivae, Lpps and LppT, that share similarity with P97 and P102
respectively, have been shown to be involved in the adherence of M. conjunctivae to
lamb joint synovial cells LSM 192 (Belloy et al., 2003; Zimmermann et al., 2010).
P102 and paralogues Mhp683 and Mhp108 (P116), and P97 and paralogues Mhp493
(P216) and Mhp107 have been characterised as adhesins of M. hyopneumoniae
(Bogema et al., 2011; Hsu et al., 1997; Seymour, 2011; Seymour et al., 2010; Seymour
et al., 2011; Seymour et al., 2012; Wilton et al., 2009). It is hypothesised that all the
paralogues are involved in bacterial adherence to host cells, thereby enabling
colonisation and perhaps survival of M. hyopneumoniae for long periods within the
host. However, it is uncertain how each of these proteins contribute to adherence and
whether they have other functions.
The first aim of this study was to investigate the plasminogen-binding activity of
M. hyopneumoniae and its subsequent activation into plasmin. In addition, the potential
of plasmin-coated M. hyopneumoniae to digest host proteins was examined. Cell surface
proteins with C-terminal lysines are often involved in plasminogen binding. P97, P102
and a number of their paralogues in M. hyopneumoniae strain 232, such as Mhp271,
Mhp385 and Mhp108, contain a C-terminal lysine residue. The second aim of this work
was to characterise the P97 paralogue Mhp271, and Mhp385 and Mhp384 (proteins
expressed in the same gene operon) that are paralogues of P97 and P102 respectively,
focussing on their expression within M. hyopneumoniae cells and their interaction with
host molecules.
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2.

Materials and Methods
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2.1 Bacterial Strains, Plasmids, Media and Growth Conditions
2.1.1

M. hyopneumoniae
Details of all M. hyopneumoniae strains used in this study are listed in Table 2.1.

All M. hyopneumoniae strains were low passage except for strains 232 and J, which
were high passage laboratory adapted strains. Strains 232 and J were originally isolated
in Great Britain (Goodwin et al., 1965) and the United States (Bereiter et al., 1990),
respectively. M. hyopneumoniae strains 95MP1509 and 00MP1301 were cultured from
case studies from the United States Midwest and strain 2-22421 was isolated from pig
lung samples collected from piggeries in Queensland, Australia. All M. hyopneumoniae
strains were grown to mid-log phase (pH 6.8-7.2 as indicated by media colour change)
in 0.22 µm filter sterilised modified Friis medium (Appendix I) on a rotary shaker at
37ºC. For all manipulations, mycoplasmas were pelleted by centrifugation for 30 min at
10,000 x g and washed twice in phosphate-buffered saline (PBS; Appendix I).
Table 2.1 M. hyopneumoniae strains used in this study.
M. hyopneumoniae
strain

Source

Reference

232

A. Pointon (South Australian Research
& Development Institute, Australia)

Goodwin et al. (1965)

J

T. Young (Iowa State University
Veterinary Research Medical School,
USA)

Bereiter et al. (1990)

00MP1301

E. Thacker (Iowa State University
Veterinary Diagnostic Laboratory,
USA)

Madsen et al. (2007)

95MP1509

E. Thacker (Iowa State University
Veterinary Diagnostic Laboratory,
USA)

Madsen et al. (2007)

2-22421

J. Forbes-Faulkner (Queensland
Department of Primary Industries,
Oonoonba Veterinary Laboratory,
Australia)

unpublished

2.1.2

Escherichia coli
Details of all E. coli strains and plasmids used in this study are given in Table

2.2. All E. coli strains were routinely grown in Luria-Bertani (LB) broth or on LB agar
(Appendix I) supplemented with appropriate antibiotics at 37ºC. Liquid cultures were
aerated by shaking at 200-250 rpm.
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Table 2.2 Details of the E. coli strains used in this study.
Strain/Plasmid

Source

Use

E. coli TOP10

Invitrogen™ (USA)

Plasmid maintenance strain

E. coli BL21™ Star (DE3)

Invitrogen (USA)

Expression strain for hexahistidine
(6xHis)-tagged or glutathione Stransferase (GST)-tagged
recombinant proteins

E. coli XL1-Blue

Stratagene® (USA)

Transformation strain for
mutagenised pET160/GW/DTOPO:f3384

E. coli CC118 (λpir)

Herrero et al. (1990)

Transformation strain for
pCR2.1:385 and pCR2.1:384

pET100/D-TOPO®

Invitrogen (USA)

6xHis-tagged protein expression

pET160/GW/D-TOPO®

Invitrogen (USA)

Lumio™* and 6xHis-tagged protein
expression

pCR®2.1:385

F. Chris Minion

Partially mutagenised mhp385 gene

pCR®2.1:384

F. Chris Minion

Partially mutagenised mhp384 gene

pGEX-2T

Smith and Johnson
(1988)

GST-tagged protein expression

Strain

Plasmid

pQE-9:f2P97
Jenkins et al. (2006)
Mutagenised f2P97 gene fragment
* Lumio refers to the tetracysteine Lumio tag (Cys-Cys-Pro-Gly-Cys-Cys)

2.2 DNA Manipulations
2.2.1

M. hyopneumoniae Genomic DNA Extraction
Genomic DNA extracted from M. hyopneumoniae strains 232 and J using the

phenol chloroform method followed by dialysis against TE buffer, as previously
described (Djordjevic et al., 1998), was kindly provided by Tracey Kuit. Genomic DNA
from all other M. hyopneumoniae strains was extracted from 200 µL of culture using
InstaGene™ Matrix (Bio-Rad® Laboratories, USA) according to the manufacturer’s
instructions.
2.2.2

Polymerase Chain Reaction Amplification
Primers were designed to enable directional cloning of gene fragments into the

pET100/D-TOPO, pET160/GW/D-TOPO or pGEX-2T vectors. The primers (SigmaAldrich®, Australia) used in this study are listed in Table 2.3. TGA codons encode
tryptophan in M. hyopneumoniae; therefore, all in-frame TGA codons were changed to
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TGG by PCR using mutated primers, or by site-directed mutagenesis as described in
section 2.2.8, or by using a DNA construct (pCR2.1:385 or pCR2.1:384) containing part
of the mhp385/mhp384 gene with a number of the TGAs mutagenised to TGGs, kindly
provided by F. Chris Minion.
Table 2.3 Sequences of PCR amplification primers used in this study.
Primer

Sequence (5’-3’)

Description

F1385F

CACCGCTAATTGGAAGATCAAAGATCCACGACTTCA
AGTACAAAATCAAG

F1385 forward primer

F1385R

TCAGGCTTCTAAATT TTTTTCAAAATTTATTTG

F1385 reverse primer

F2385F

CACCGAAATTAATGGTTGGGATTTTCTA

F2385 forward primer

F2385R

TCACCAATATTTTGCAACAAAACTG

F2385 reverse primer

F3385F

CACCTATGATCTTTTAAATAAATTTAAATTAATTG

F3385 forward primer

F3385R

TCACCAATATTTTAATCTTAAATTATTATTTAATCT

F3385 reverse primer

F4385F

CACCTATAAAATTGGTTCAGTTGATCAAAATGGG

F4385 forward primer

F4385R

TTATTTTAAAGCAAATAGTGATTCTGAACT

F4385 reverse primer

F1384F

CACCTCATCCCAAGCCGAAAAATATAATCTA

F1384 forward primer

F1384R

TCACCAGGACTCAAATTTAGTTAAATCAAG

F1384 reverse primer

F2384F

CACCTTTATTCAAAAATCAGTGCCAAATACA

F2384 forward primer

F2384R

TCACCAATCAAGGAATAAATCCGTATT

F2384 reverse primer

F3384F

CACCCGATCAAATATAACCACAACAACA

F3384 forward primer

F3384R

TTATTCCATATATTCGCTAAGGAATTTTTC

F3384 reverse primer

F3mut384F

GGAAATTTTTACCTGGAAAACCAAAATTGAGAGCC

F3mut384R

GGCTCTCAATTTTGGTTTTCCAGGTAAAAATTTCC

F1271F

CACCGCAAAATTAGATGATAATCTTAAATATTCG

F1271 forward primer

F1271R

TCACCATTCTTTAAATTCGCTTTGG

F1271 reverse primer

F2271F

CACCAGATTAGATGAGTCTGCATTTTC

F2271 forward primer

F2271R

TTATTTGACTTGTTTATTTTCTTTTTTTCTAATG

F2271 reverse primer

F2P97F

GGggatccAAATTAGACGATAATCTTCAG

F2P97 forward primer

F2P97R

GGgaattcTTAGGATCACCGGATTTTGAA

F2P97 reverse primer

F3384 forward sitedirected mutagenesis
primer
F3384 reverse sitedirected mutagenesis
primer

TGA codons modified to TGG are underlined.
Boxed is the modified nucleotide (changing a TGA codon to TGG).
Bold and underlined are the nucleotides ‘CACC’ that were added to the forward primers to
enable directional cloning into the pET160/GW/D-TOPO and pET100/D-TOPO vectors.
In lower case are the BamHI and EcoRI restriction sites incorporated into the primers to enable
directional cloning into the pGEX-2T vector.
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All PCR amplification reactions were carried out in a 50 μL volume containing
approximately 40 ng of M. hyopneumoniae strain 232 genomic DNA or 1 ng plasmid
DNA, 1X PCR buffer (provided with the polymerase) with MgSO4 or MgCl2, 0.2 mM
deoxynucleotide triphosphates (dNTPs; Astral Scientific Pty Ltd, Australia), 400 nM of
each primer and 1 U of DNA polymerase. Details of polymerase and cycling conditions
for each PCR performed are listed in Table 2.4 and a final 10 min extension at 68ºC or
72ºC. PCR amplification of f2P97 used only 25 cycles of the conditions listed in Table
2.4 with an extension time of 7 min at 72°C.
Table 2.4 PCR conditions used to amplify gene fragments.
Amplified
Primers
Product

Polymerase DNA Template

f1385

F1385F, F1385R

Taq

pCR2.1:385

f2385

F2385F, F2385R

Pwo

strain 232
chromosomal DNA

f3385

F3385F, F3385R

Pwo

pCR2.1:385

f4385

F4385F, F4385R

Pwo

strain 232
chromosomal DNA

f1384

F1384F, F1384R

Vent

pCR2.1:384

f2384

F2384F, F2384R

PfuUltra

f3384

F3384F, F3384R

PfuUltra

f1271

F1271F, F1271R

Pwo

f2271

F2271F, F2271R

Pwo

f2P97

F2P97F, F2P97R

Pfu

2.2.3

strain 232
chromosomal DNA
strain 232
chromosomal DNA
strain 232
chromosomal DNA
strain 232
chromosomal DNA
pQE-9:f2P97

Reaction Conditions
94ºC for 30 s, 56ºC for 30 s,
and 72ºC for 1 min 20 s
94ºC for 30 s, 56ºC for 30 s,
and 68ºC for 1 min
94ºC for 30 s, 56ºC for 30 s,
and 68ºC for 1 min
94ºC for 30 s, 59ºC for 30 s,
and 68ºC for 1 min
94ºC for 30 s, 58ºC for 30 s,
and 72ºC for 1 min
94ºC for 30 s, 58ºC for 30 s,
and 72ºC for 1 min
94ºC for 30 s, 58ºC for 30 s,
and 72ºC for 1 min
94ºC for 30 s, 56ºC for 30 s,
and 68ºC for 1 min
94ºC for 30 s, 58ºC for 30 s,
and 68ºC for 1 min
94ºC for 1 min, 50ºC for 1
min and 72ºC for 1 min

Agarose Gel Electrophoresis
DNA was resolved through 0.7-1.5% (w/v) agarose gels prepared in 0.5X Tris-

borate ethylenediamine tetraacetic acid (EDTA) buffer (TBE buffer; Appendix I), and
electrophoresed in 0.5X TBE buffer using a Wide Mini-Sub® cell or Mini-Sub® cell
electrophoresis chamber (Bio-Rad Laboratories). Approximately 2 µL of loading dye
(Appendix I) was added to all DNA samples prior to loading on an agarose gel.
Fermentas GeneRuler™ 100 bp DNA Ladder Plus or Fermentas GeneRuler™ 1 kb DNA
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Ladder (Thermo Fisher Scientific Inc., USA) was used as a sizing standard unless
otherwise noted. Agarose gels were routinely run at a constant voltage of 90-110 V until
the dye front migrated approximately three quarters along the gel. DNA was visualised
by ethidium bromide staining and imaged using a Gel Doc™ 1000 fluorescent imaging
system (Bio-Rad Laboratories) and Quantity One® software (Bio-Rad Laboratories).
2.2.4

Extraction and Purification of Polymerase Chain Reaction Amplicons
PCR products were purified using the QIAGEN® QIAquick® PCR purification

kit (USA), or Wizard® SV gel and PCR clean-up system (Promega, USA) if the PCR
product of interest was excised from an agarose gel, according to manufacturer’s
guidelines. Millipore Milli-Q® system (USA) water was used to elute the DNA from
the spin columns for both kits.
2.2.5

Plasmid DNA Extraction and Purification
Plasmid DNA was typically extracted from E. coli using the QIAprep® Spin

Miniprep kit (QIAGEN), or the Wizard® Plus SV Minipreps DNA Purification System
(Promega), following the manufacturer’s instructions. To quickly isolate plasmid DNA
for PCR analysis or to check whether an insert cloned into a vector was in the correct
orientation, plasmid DNA was isolated through boiling the E. coli. In this procedure a
loopful of transformed E. coli was added to 500 µL of Milli-Q water and centrifuged at
13,000 rpm using a microcentrifuge for 5 min. The pellet was resuspended in 100 µL of
Milli-Q water, heated for 5 min at 105ºC and centrifuged at 13,000 rpm for 5 min, after
which the supernatant (plasmid DNA) was collected.
2.2.6

Cloning of Polymerase Chain Reaction Products into the pET160/GW/DTOPO or pET100/D-TOPO Vectors
PCR products were ligated to commercial pET100/D-TOPO linearised vector

according to the manufacturer’s instructions. Ligated products were transformed into E.
coli TOP10 One Shot® chemically competent cells by heat shock. Cloned PCR
fragments were checked via DNA sequencing as per section 2.2.14. The mhp384 PCR
fragments were sub-cloned into the pET100/D-TOPO vector for binding studies, due to
the pET160/GW/D-TOPO expression vector adding a Lumio tag fused to the Nterminus of each expressed protein.
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2.2.7

Cloning f2P97 into the pGEX-2T Vector
The gene fragment f2P97 was amplified from the pQE-9:f2P97 construct from

Jenkins et al. (2006) via PCR with BamHI (5′-end) and EcoRI (3′-end) restriction sites
incorporated into the oligonucleotide primers. PCR amplification was carried out as
described in section 2.2.2. PCR products were digested with BamHI and EcoRI, and
ligated to BamHI and EcoRI digested and dephosphorylated pGEX-2T vector according
to manufacturer’s instructions (GE Healthcare, USA). The ligation mixture was
electroporated into electro-competent E. coli TOP10 cells as per section 2.2.12 and
cloned PCR fragments were checked via DNA sequencing as per section 2.2.14.
2.2.8

Site-directed Mutagenesis
The TGA in pET160/GW/D-TOPO:f3384 was converted to TGG using the

QuikChange® site-directed mutagenesis kit protocol (Stratagene) with PfuUltra
polymerase. PCR cycling parameters used for site-directed mutagenesis were: an initial
denaturation step of 95ºC for 30 s, followed by 15 cycles of 95ºC for 30 s, 50ºC for 1
min and 68ºC for 13 min. The Dpn I treated site-directed mutagenesis PCR product was
transformed into electro-competent E. coli XL1-Blue cells as per section 2.2.12. DNA
sequencing was performed as per section 2.2.14 to confirm presence of introduced
mutation and to check that no unwanted mutations had occurred.
2.2.9

Amplification of the Repeat Regions of Mhp271
To sequence the repeat regions of Mhp271 from M. hyopneumoniae field

strains, PCRs were carried out as described in section 2.2.2 with primers F1271F and
F2271R and an annealing temperature of 59°C, 1.5 min extension time and 72°C
extension temperature. The purified PCR products were then sequenced using the
primers F1271F and F2271R as described in section 2.2.14.
2.2.10 Determining DNA Concentration
DNA concentration was determined by the intensity of the DNA band in an
agarose gel, compared to the intensity of the bands of standards at known
concentrations run on the same gel. Hyperladder I DNA (Bioline, UK) was used as the
concentration standard.
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2.2.11 Preparation of Electro-competent Cells
A single colony taken from a freshly streaked selective agar plate was used to
inoculate 10 mL LB broth supplemented with the appropriate antibiotics and incubated
overnight at 37°C with shaking (200-250 rpm). The overnight culture was added to 190
mL LB broth, supplemented with the appropriate antibiotics, and grown at 37°C. When
an OD600 of 0.5 to 0.8 was reached, the culture was chilled on ice for 15 min then
centrifuged at 5000 x g for 15 min at 4°C. After the supernatant was completely
removed, the pellet was resuspsended in 200 mL sterile, ice-cold Milli-Q water. The
cells were harvested as before and the pellet sequentially washed in 100 mL sterile, icecold Milli-Q water and 4 mL sterile, ice-cold 10% (v/v) glycerol. The electro-competent
cells were resuspended in 600 µL of sterile, ice-cold 10% (v/v) glycerol and stored in 40
µL aliquots at -80°C.
2.2.12 Electro-transformation
Plasmid DNA (0.5-2 µL) was added to electro-competent E. coli cells (40 µL)
thawed on ice. After gently mixing the mixture was transferred into a sterile chilled 0.2
cm Gene Pulser®/ Micropulser™ cuvette (Bio-Rad Laboratories) and placed in a BioRad Gene Pulser® set at a voltage of 2.5 kV, a capacitance of 25 µF and a resistance of
200 Ω, which was used to deliver a single pulse with a time constant of between 4 and 5
ms. Immediately after, the transformed cells were added to 0.5 mL pre-warmed (37°C)
LB broth and incubated at 37°C for 1 h with shaking (200 rpm) before being plated onto
selective LB agar.
2.2.13 Polymerase Chain Reaction Analysis of E. coli Transformants
Insertion of PCR products cloned into a vector was typically confirmed by PCR.
Two µL of plasmid DNA extracted via boiling of transformed E. coli, as described in
section 2.2.5, was analysed using 20 pmol of a vector primer (Table 2.5) in conjunction
with the opposite direction PCR product primer (Table 2.3). The PCR reaction used the
same protocol as previously described in section 2.2.2, except the amounts of all the
reagents were adjusted for a total volume of 25 µL and Taq DNA polymerase (Roche,
Switzerland) was used. The same thermal cycler conditions used to originally amplify
the PCR product was used (Table 2.4).
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Table 2.5 Vector primers used to analyse the sequences of cloned inserts.
Primer
Modified T7F
Modified T7R
pGEX-2TF
pGEX-2TR

Sequence (5’-3’)
TAATACGACTCACTATAGGG
TAGTTATTGCTCAGCGGTGG
GGGCTGGCAAGCCACGTTTGGTG
CCGGGAGCTGCATGTGTCAGAGG

Description
T7 promoter forward primer
T7 terminator reverse primer
Forward pGEX-2T primer
Reverse pGEX-2T primer

2.2.14 DNA Sequencing
Each sequencing reaction contained 200-500 ng of plasmid DNA or 40-70 ng of
PCR product, 2 pmol of appropriate oligonucleotide primer, 2 µL 5X sequencing buffer
(Appendix I) and 0.5 µL Applied Biosystems™ (ABI) PRISM® BigDye™ terminator
ready reaction mix (USA). The volume was adjusted to 10 µL with Milli-Q water. The
samples were subjected to an initial 1 min denaturation step, followed by 25 cycles of:
10 s at 96°C, 5 s at 50°C and 4 min at 60°C.
Unincorporated dye was removed using ethanol/sodium acetate precipitation. To
the PCR product, 2 μL of 3 M sodium acetate (pH 4.5) and 50 μL of 95 % (v/v) ethanol
were added and incubated on ice for 10 min. Each tube was centrifuged at maximum
speed in a microcentrifuge for 20 min. After removal of the supernatant, 250 μL of 70%
(v/v) ethanol was added and centrifuged again for 10 min. The supernatant was
aspirated off and the pellet dried on a heating block for 1 min at 90˚C or at room
temperature (RT) until the ethanol had evaporated. DNA pellets were resuspended in
DNA sequencing loading dye (Appendix I) and electrophoresed using the ABI
PRISM® 377 DNA sequencer.
The plasmids pET100/D-TOPO:f1271 and pET100/D-TOPO:f2271 were sent for
sequencing by the Australian Genome Research Facility (AGRF), Australia. Sequencing
reactions followed the protocol of Perkin Elmer, using an ABI BigDye terminator
reaction.
Sequence data were compiled, edited and analysed using the ChromasPro
software (Technelysium Pty Ltd, Australia) and aligned using ClustalW2 multiple
alignment

tool

[European

Molecular

Biology

Laboratory

(EMBL)-European

Bioinformatics Institute (EBI), UK] (Goujon et al., 2010; Larkin et al., 2007).
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2.3 Protein Methods
2.3.1

Bioinformatic Analyses
To identify transmembrane domains the Tied Mixture Hidden Markov Model

(TMHMM) Server v. 2.0 (Krogh et al., 2001; Sonnhammer et al., 1998) and Phobius
(Käll et al., 2004), a combined transmembrane topology and signal peptide predictor,
were used. The ProtParam algorithm (Gasteiger et al., 2005) was used to calculate the
theoretical mass and pI of a protein. Basic Local Alignment Search Tool (BLAST)
searches, to identify proteins that share regions of identity or similarity, were performed
using the non-redundant protein database at the National Center for Biotechnology
Information (NCBI). Protein disorder was predicted using the Predictor of Naturally
Disordered Regions (PONDR)# algorithms VSL1 (Obradovic et al., 2005; Peng et al.,
2006) and PONDR-FIT (Xue et al., 2010), and the Intrinsically Unstructured Proteins
Predictor (IUPred) algorithm (Dosztanyi et al., 2005a, b). Amino acid scores above 0.5
are considered to be disordered. The search for coiled-coils was conducted by means of
the COILS2 algorithm (Lupas et al., 1991) with window widths of 14, 21, and 28 and
the MTIDK matrix. The outputs from both weighted and unweighted scans were
compared. In addition, the Paircoil2 algorithm (McDonnell et al., 2006), with a
minimum window size of 21 and a p-value cut-off of 0.025, was used.
2.3.2

Recombinant Protein Expression
Plasmids were transformed into BL21 Star™ (DE3) One Shot® chemically

competent E. coli cells by heat shock. Overnight cultures (50 mL) of transformed E. coli
BL21 Star (DE3) in LB broth containing 100 µg/mL ampicillin were grown and used to
inoculate 1 L LB broth supplemented with 100 µg/mL ampicillin. All E. coli BL21 Star
(DE3) cells were grown at 37ºC at 200-250 rpm. Once an OD600 of the cultures reached
0.5–0.8 (mid-log), cells were induced with isopropyl-β-D-thiogalactopyranoside
(IPTG). For the expression of 6xHis-tagged fusion proteins, 1 mM IPTG was added,
while 0.1 mM IPTG was added for the expression of recombinant GST-tagged fusion

#

Access to PONDR® was provided by Molecular Kinetics (6201 La Pas Trail - Ste
160, Indianapolis, IN 46268; 317-280-8737; E-mail: main@molecularkinetics.com).
PONDR is copyright ©1999 by the Washington State University Research Foundation,
all rights reserved.
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proteins. The incubation was maintained for a further 3-4 h at 37ºC at 200-250 rpm. E.
coli BL21 Star (DE3) cells transformed with plasmid construct pET100/D-TOPO:f1384
or pET100/D-TOPO:f2385 were grown at 37ºC to mid-log phase then induced with 1
mM IPTG and incubated overnight at 22ºC, or for 8 h at 30ºC, respectively. The cells
were harvested by centrifugation at 10,000 x g for 20-30 min.
2.3.3

Recombinant Protein Purification under Denaturing Conditions
Hexahistidine-tagged proteins were purified by nickel chromatography. E. coli

cells were lysed by gentle stirring in 40 mL buffer B (Appendix I) for 1 h. Unbroken
cells and cellular debris were removed by centrifugation at 10,000 x g for 30 min.
Lysate was mixed with 10 mL Profinity™ immobilized metal affinity chromatography
(IMAC) nickel-charged resin (Bio-Rad Laboratories) or 50% nickel-nitrilotriacetic acid
(Ni-NTA) superflow resin (QIAGEN) for 1 h, prior to being loaded into a column and
washed with 100 mL of buffer C (Appendix I). Hexahistidine-tagged recombinant
proteins were eluted with 20 mL of buffer D (Appendix I; 4 x 5 mL fractions collected),
and 60 mL of buffer E (Appendix I; 6 x 5 mL fractions collected). The purity of the
protein elution fractions were assessed by 1D SDS-PAGE, as described in section 2.3.5.
Purified recombinant proteins were dialysed against 4 or 5 x 1.8 L PBS containing 1%
(w/v) SDS for a minimum of 24 h with a minimum of 2 h between buffer changes.
Dialysed proteins were again examined by 1D SDS-PAGE, as described in section
2.3.5.
2.3.4

Recombinant Protein Purification under Native Conditions
Recombinant GST-tagged F2P97 and GST protein (from pGEX-2T vector with

no insert) were purified under native conditions, according to the protocol described in
the GST Gene Fusion Manual (GE Healthcare). Harvested cells from the protein
expression were resuspended in 45 mL ice-cold PBS containing 1% (v/v) Triton X-100
(TX-100). Ice cold native lysis buffer (Appendix I) (5 mL) was added to the cell
suspension and cell lysis was achieved by sonication of the suspension. Cellular debris
was removed from the lysate by centrifugation at 12,000 x g for 10 min at 4˚C and the
recombinant fusion proteins were purified from the lysate using a glutathione-agarose
(Bioline) column. The cleared lysate was passed over the column up to four times. The
column was washed with 50 mL of PBS and bound proteins were eluted with 20 mL of
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glutathione elution buffer (Appendix I) and stored at 4˚C prior to dialysis against 7-10 L
PBS or PBS containing 1% (w/v) SDS for a minimum of 24 h with multiple buffer
changes.
2.3.5

One-dimensional Sodium Dodecyl Sulphate-Polyacrylamide Gel
Electrophoresis
One-dimensional SDS-PAGE was performed using two different systems. All

protein samples were prepared in SDS-PAGE sample buffer (Appendix I) or SDSPAGE sample buffer made without the β-mercaptoethanol for when the proteins were to
be electrophoresed under non-reducing conditions. The samples were heated for 5 min
at 95°C prior to loading onto a polyacrylamide gel. PageRuler™ prestained protein
ladder (Thermo Fisher Scientific Inc.) or unstained Precision Plus Protein™ standards
(Bio-Rad Laboratories) were run on all SDS-polyacrylamide gels. Gels were stained
with either GelCode™ Blue (Thermo Fisher Scientific Inc.), Coomassie Blue G-250,
Flamingo™ fluorescent gel stain (Bio-Rad Laboratories), or silver stained as described
in section 2.3.7. For the analysis of M. hyopneumoniae entire proteome by SDS-PAGE
followed by 1D liquid chromatography-tandem mass spectrometry (LC-MS/MS) the
sample was resolved in a 4-12% Bis-Tris gel using a Criterion™ XT gel system (BioRad Laboratories). All other samples were resolved on SDS-7, 10, 12 or 15%
polyacrylamide resolving gels with a 4% stacking gel (Laemmli, 1970) (Appendix I)
and electrophoresis was carried out using a Hoefer® Mighty Small™ II SE 200
electrophoresis unit (GE Healthcare) and SDS-PAGE running buffer (Appendix I).
Stained SDS-PAGE gels were scanned using a GS-800™ calibrated densitometer (BioRad Laboratories) and analysed using PDQuest™ software (Bio-Rad Laboratories).
2.3.6

Two-dimensional Sodium Dodecyl Sulphate-Polyacrylamide Gel
Electrophoresis and Western Transfer
Two-dimensional gel electrophoresis (2DGE) combined with Western blotting

was employed to identify the C-terminal cleavage fragment of Mhp385. Whole cell
extracts of M. hyopneumoniae strain 232 cells were passed through a Nanosep® 300K
omega centrifugal filter (Pall, USA) prior to isoelectric focusing (IEF). Bio-Lyte® 3/10
ampholytes (Bio-Rad Laboratories) were added to a final concentration of 0.2% (v/v).
The proteins (250 µg in 75 µL) were cup loaded onto an 11 cm pH 6-11 Immobiline™
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DryStrip (GE Healthcare) according to manufacturer’s instructions. Focusing was
carried out using a Protean® IEF cell (Bio-Rad Laboratories) at a constant 20˚C and 50
μA current limit per strip with a 3-step program: slow ramp to 4000 V for 4 h, linear
ramp to 10,000 V for 4 h, then 10,000 V until 115 kilo volt hours (kVh) was reached.
Following IEF, the strips were equilibrated with 5 mL equilibration solution (Appendix
I) for 20 min before 2DGE. The 2DGE was carried out using the Bio-Rad Laboratories
Criterion™ gel system.
Two-dimensional polyacrylamide gels were visualised by staining with
Coomassie Blue G-250 or alternatively proteins were transferred to PVDF using a semidry transfer method (Kyhse-Andersen, 1984). Membranes were blocked with 5% (w/v)
skim milk powder in PBS-T (Appendix I) at RT for 1 h. Blots were probed with 1:100
dilution of anti-F4385 serum in PBS-T for 1 h and detected with anti-rabbit peroxidase
conjugate (Sigma-Aldrich, USA) diluted 1:3000 in PBS-T for 1 h. Between incubations,
membranes were washed in three changes of PBS-T. Membranes were developed with
SIGMAFAST™ 3,3´-diaminobenzidine tablets (Sigma-Aldrich) as per manufacturer’s
instructions.
2.3.7

Silver Staining of Sodium Dodecyl Sulphate-Polyacrylamide Gels
Gels for silver staining were rinsed in water then fixed with fixing solution

(Appendix I) for 1 h or overnight. After several 20 min washes in 50% (v/v) ethanol, the
gels were sensitised by incubating in 0.2% (w/v) sodium thiosulfate followed by several
20 min washes with Milli-Q water. The gels were incubated in silver nitrate solution
(Appendix I) for 20 min, followed by several 20 s washes with Milli-Q water, and
developed in developing solution (Appendix I). The reaction was terminated with 10%
(v/v) acetic acid.
2.3.8

Protein Quantification
Protein concentrations were estimated by the Bradford assay (Bradford, 1976) or

with a bicinchoninic acid (BCA) kit (Sigma-Aldrich). Bovine serum albumin (BSA)
protein standards were prepared ranging from 0.05-1 mg/mL in the same buffer as the
samples. For the Bradford assay, 20 µL of each standard and samples were added to 1
mL of Bradford reagent (Appendix I). The reaction mixture was allowed to stand for 5
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min at RT after thorough mixing, at which point the absorbance at 595 nm was
measured using an Ultrospec™ 3300 pro spectrophotometer (Amersham Biosciences –
GE Healthcare). The spectrophotometer was set to generate a regression line using the
absorbance of the standards. This regression line was used by the spectrophotometer to
calculate the concentration of the diluted samples. BCA assays were performed as a 96
well plate assay according to manufacturer’s instructions. The plate was read using an
xMark™ microplate absorbance spectrophotometer (Bio-Rad Laboratories).
2.3.9

Protein Concentration
Proteins were concentrated using Vivaspin® 6 centrifugal concentrator with a

10 kDa molecular mass cut off (Satorius, Germany), an Amicon® Ultra-4 or Ultra-15
centrifugal filter unit each with a 10 kDa molecular mass cut off (Millipore), as per
manufacturer’s instructions
2.3.10 Protein Biotinylation
Purified proteins were biotinylated with Sulfo-NHS-Biotin (Thermo Fisher
Scientific Inc.) according to the manufacturer’s instructions. To remove excess biotin,
biotinylated recombinant proteins were dialysed against 4 or 5 x 1.8 L PBS containing
1% (w/v) SDS for a minimum of 24 h at RT, while biotinylated plasminogen was
dialysed against 5 x 1.8 L PBS over two days at 4˚C.
2.3.11 Production of Rabbit Polyclonal Antibodies
Polyclonal antibodies to F2271, F1384-F3384 (pET160/GW/D-TOPO) and F1385F4385 fusion proteins were generated in New Zealand White rabbits with the assistance
of Graeme Eamens and Linda Falconer from EMAI. Ethical approval for the generation
of polyclonal antisera in rabbits was approved by the Animal Ethics Committee of
EMAI. A marginal ear vein bleed was performed prior to the first injection to collect
pre-immune serum. Blood from the ear bleed was collected into VACUETTE® Z
serum sep clot activator tubes (Greiner Bio-One, Austria). After 30 min incubation at
RT the tubes were centrifuged for 10 min at 1000 x g and the serum was collected. The
recombinant protein was mixed with an equal volume of Freund’s incomplete adjuvant
(Sigma-Aldrich) and approximately 300 µL was subcutaneously injected into each hind
leg, at two week intervals. Ten to 14 days after the secondary injection, a marginal ear
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vein test bleed was performed as described above. Western blotting was used to test the
immune response against the recombinant protein used in the injection and whole cell
lysates from M. hyopneumoniae strain 232 cells, as described in sections 2.3.12 and
2.5.2.1. If the serum did not demonstrate reactivity against the protein used in the
injection and the whole cell lysate, the rabbit received a tertiary injection. If the rabbit
serum response was adequate, the rabbit was anesthetized and cardiac bled. Collected
blood was left at RT for 3 h before storing at 4°C overnight. The next day the blood
clots were cut and the blood centrifuged for 10 min at 1000 x g. The serum was
collected and stored at -20°C.
2.3.12 Western Transfer of One-dimensional Polyacrylamide Gels
Western transfer and blotting techniques were performed using a previously
described method (Burnette, 1981; Towbin et al., 1979). Proteins resolved on 1D SDSpolyacrylamide gels were electrophoretically transferred to PVDF membrane using a
Hoefer® TE 22 Mighty Small™ transphor electrophoresis unit (GE Healthcare) and
Western transfer buffer (Appendix I). The transfer was performed at 20 - 30 V
overnight. After transfer, Western or ligand blotting was performed as described in
section 2.5.2.
2.3.13 Plasminogen Purification
2.3.13.1 Lysine Sepharose Chromatography
Porcine plasminogen was purified from citrated porcine plasma by affinity
chromatography as previously described (Andronicos et al., 1997; Sanderson-Smith et
al., 2006), with minor modifications. In summary, 300 mL of cold Milli-Q water
containing the protease inhibitors EDTA (10 mM) and phenylmethylsulfonyl (PMSF; 2
mM) was added to 300 mL of porcine plasma and left on ice for 30 min until the
precipitated proteins had separated from solution. From here all steps were performed at
4°C. The cleared plasma was further cleared by centrifuging at 1000 x g for 10 min
prior to filtration through a 0.45 µm filter. The filtered plasma was pumped, through a
Lysine Sepharose™ 4B (GE Healthcare) column using a peristaltic pump. Absorbance
of the elutions was monitored using an ISCO model UA-5 absorbance/fluorescence
monitor (USA) at 280 nm or by performing a Bio-Rad DC™ protein assay on elution
fractions collected using Gilson fraction collector FC 204 (USA) according to the
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manufacturer’s protocol. The column was washed with PBS containing 5 mM EDTA
and 1 mM PMSF until the absorbance of the elutions was the same as the buffer
(baseline was reached). Further removal of unwanted proteins was performed by
washing the column with high salt wash buffer (Appendix I) and the plasminogen was
eluted with epsilon-amino caproic acid (εACA) elution buffer (Appendix I) at 0.5
mL/min. Elution fractions of 2.5 mL were collected. The leading peak fractions were
collected while the tail fractions of the peak were discarded since these fractions may
contain plasmin. The collected fractions were dialysed against 2 x 5 L PBS (pH 7.5)
over two days with a buffer change after 24 h.
2.3.13.2 Gel Filtration
All steps were performed at 4°C. After dialysis, the leading peak fractions of the
plasminogen elutions were concentrated to a volume less than 2 mL, as described in
section 2.3.9. The concentrated sample was applied to an Amersham Pharmacia column
(2.5 x 70 cm) packed with Sephacryl™ S-200 superfine (Amersham Biosciences-GE
Healthcare) equilibrated with PBS. The sample was separated at a flow rate of 1
mL/min. The protein content in the elution fractions (2 mL) was monitored at 280 nm
using an ISCO model UA-5 absorbance/fluorescence monitor. Elution fractions were
collected using a Gilson fraction collector FC 204 until no more protein eluted from the
column. The elution fractions of the second peak, which contained the plasminogen,
were pooled and concentrated as described above in section 2.3.9. The purity of the
enzyme was analysed by 1D SDS-PAGE as per section 2.3.5.
2.3.14 Plasmin Activity Assay
The plasmin activity assay was used to check whether the purified plasminogen
can be activated into plasmin and whether activated plasminogen was present in the
purified plasminogen. The plasmin activation assay was adopted from McArthur et al.
(2008); however, human tPA or human uPA was used instead of streptokinase, because
streptokinase does not activate porcine plasminogen (Wulf and Mertz, 1969). Briefly,
plasminogen (1 µg) was incubated with 200 units of tPA at 37ºC in 50 mM Tris (pH
7.4) for 15 min, prior to the addition of chromogenic substrate specific for plasmin HD-norleucyl-hexahydrotyrosyl-lysine-p-nitroanilide diacetate salt (Spectrozyme® PL)
(20 µL of 2.5 mM). The absorbance at 405 nm was measured every 5 min, with an
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xMark microplate absorbance spectrophotometer, until the absorbance reached
saturation. The amount of activator, determined from a range of concentrations, that
produced a linear activation rate over 60 min with plasminogen (1 µg) was used. For
comparison purposes the assay was also performed with commercial human
plasminogen (Sigma-Aldrich).
2.3.15 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis Analysis of
Plasminogen Activation
To view the activation of plasminogen to plasmin over time, plasminogen
activation was analysed by 1D SDS-PAGE. Four µg of plasminogen was incubated at
37°C, for the time period indicated in the results section, with or without 2.4 µL of 25
mM εACA, 100 or 0.25 units of tPA or uPA respectively, made up to 24 µL with PBS.
At the end of the incubation period at 37°C, 16 µL of SDS-PAGE sample buffer was
added to each sample, boiled for 5 min, then 20 µL of each sample was electrophoresed
on a 1D SDS-PAGE gel as per section 2.3.5. In attempt to get the non gel-filtrated
porcine plasminogen to be completely activated, 10 µg of the plasminogen was
incubated with 200 or 1000 units tPA in the presence or absence of 10 µg fibrinogen
(Sigma-Aldrich), made up to a total volume of 45 µL with PBS, at 37°C for 96 h. SDSPAGE sample buffer was added to each sample and boiled for 5 min prior to running 15
µL on a 1D SDS-PAGE gel as described in section 2.3.5.

2.4 Mycoplasma Related Procedures
2.4.1

Preparation of Whole Cell Lysates of M. hyopneumoniae Cells
Whole cell lysates of M. hyopneumoniae strain 232 cells were prepared using

two different methods. For the analysis of M. hyopneumoniae proteome by “slice and
dice” of a 1D SDS-polyacrylamide gel, or by 2D SDS-PAGE, a 0.1 g pellet of M.
hyopneumoniae strain 232 cells was resuspended in solubilisation buffer (Appendix I)
and disrupted with four rounds of sonication, at 50% power for 30 s bursts, on ice.
Proteins were reduced and alkylated with 5 mM tributylphosphine and 20 mM
acrylamide monomers for 90 min. Insoluble material was pelleted by centrifugation.
Protein was precipitated in five volumes ice cold acetone for 30 min and the pellet air
dried. For all other experiments 0.1 g M. hyopneumoniae cell pellets were resuspended
in 5 mL of 0.5% (v/v) Triton X-100 in PBS. To these lysates SDS-PAGE sample buffer
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was added and the samples were placed in boiling water for 5 min prior to running 15
µL of each sample on a SDS-polyacrylamide gel as per section 2.3.5.
2.4.2

Triton X-114 Extraction
Triton X-114 (TX-114) was used to separate Mycoplasma components into

hydrophobic and hydrophilic fractions by using the partitioning method previously
described (Bordier, 1981). Approximately 0.1 g of a M. hyopneumoniae cell pellet was
resuspended with 1 mL ice cold 1% TX-114 buffer (Appendix I) and mixed overnight at
4°C. Insoluble components were removed by centrifugation at 4°C for 15 min at 10,000
x g. The supernatant containing the TX-114 solubilised material was incubated at 37°C
for 10 min and centrifuged at 10,000 x g for 5 min, RT. The aqueous (upper) phase was
aspirated and readjusted to a concentration of 2% (v/v) TX-114. The remaining
detergent phase was also readjusted to a concentration of 2% (v/v) TX-114 using TX114 buffer. Both TX-114 suspensions were then dissolved by incubating at 4°C for 4 h
before repeating phase partitioning. Proteins of the pooled aqueous and detergent phases
were precipitated in cold acetone overnight at -20ºC and then sedimented at 20,000 × g
for 30 min at 4°C. The acetone was poured off and the pellet dried at RT for 30 min.
The aqueous phase pellet was resuspended in standard solubilisation solution (SSS,
Appendix I), while the detergent pellet was resuspended in multiple surfactant solution
(MSS, Appendix I). Both samples were sonicated then centrifuged at 13,000 rpm for 15
min at RT using a microcentrifuge. The supernatants were collected.
2.4.3

Trypsin Treatment of M. hyopneumoniae Cells
Freshly cultured and washed M. hyopneumoniae cells were digested with

various concentrations of trypsin at 37ºC for 20 min. Cells were lysed in SDS-PAGE
sample buffer and placed in boiling water for 5 min. Lysates were subjected to 1D SDSPAGE and Western transferred onto PVDF membrane, as described in sections 2.3.5
and 2.3.12.
To determine the M. hyopneumoniae peptides released during trypsin digest, a
M. hyopneumoniae strain J culture was harvested, washed and divided into two equal
aliquots. The cells were incubated in 50 µg/mL trypsin in PBS or just PBS for 5 min at
37°C. To confirm that the cells remained intact during the trypsin digest procedure,
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after the shaved proteins were removed, the cells were lysed, run on a 1D SDSpolyacrylamide gel and Western blotted with antiserum raised against the ribosomal
protein L7/L12 (Burnett et al., 2006). Detection of L7/L12 is taken to indicate that the
ribosomal proteins inside the cells were not degraded because the cells have remained
intact during the trypsin digest. Tryptic peptides that were released into the incubation
buffer were analysed by 2D LC-MS/MS as described in section 2.4.4.5.
2.4.4

Mass Spectrometry

2.4.4.1 Matrix-assisted Laser Desorption Ionisation Time-of-Flight Mass
Spectrometry and Quadrupole Time-of-Flight Tandem Mass
Spectrometry
These procedures were used to analyse the purified plasminogen resolved by 1D
SDS-PAGE. Protein extraction from the 1D SDS-PAGE gels and mass spectrometry
(MS) were performed following the methods described by Henrich et al. (2007).
Matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) MS and
MALDI quadrupole time-of-flight (Q-TOF) tandem mass spectrometry (MS/MS) was
performed using an ABI QSTAR XL. The MALDI-TOF MS results were searched
using Mascot search engine Mascot Daemon, version 2.0 (Perkins et al., 1999) against
the LudwigNR database (comprised of the UniProt, plasmoDB and Ensembl databases;
http://www.ludwig.edu.au/archive/LudwigNR/LudwigNR.pdf) version Q108 (5760665
sequences; 2000343128 residues) with the taxonomy restricted to Mammalia (516284
sequences) with the following parameter settings: fixed modifications: none; variable
modifications: oxidised methionine, propionamide; enzyme: trypsin; number of allowed
missed cleavages: 1; peptide mass tolerance: 50 ppm; peptide charge state: 1+. The
MS/MS data were searched using Mascot against the LudwigNR database version Q308
database (7101271 sequences; 2477103392 residues) with the following parameter
settings: fixed modifications: carbamidomethyl; variable modifications: oxidised
methionine; enzyme: trypsin; number of allowed missed cleavages: 1; peptide mass
tolerance: 50 ppm; MS/MS mass tolerance: 0.5 Da; peptide charge state: 1+. For all
searches the search results were accepted if a protein hit included at least one unique
peptide with a p-value < 0.05.
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2.4.4.2 M. hyopneumoniae Protein Excision from Polyacrylamide Gels and
Digestion for Liquid Chromatography-Tandem Mass Spectrometry
The stained protein or proteins were cut from the gel, as indicated in the results
section, or for the analysis of the entire M. hyopneumoniae proteome by 1D SDS-PAGE
followed by LC-MS/MS the protein lane was cut into 15 equal slices. The gel pieces or
slices were destained by washing twice with 50% acetonitrile in 50 mM NH4HCO3 (pH
9) for 10 min with vortexing. Washes were discarded and the gel slices were dehydrated
with 100% acetonitrile for 10 min and rehydrated in 50 µL of 50 mM NH4HCO3 (pH 9)
containing 12.5 ng/µL of trypsin (Promega). After incubating at 4°C for 30 min, 50 µL
of 50 mM NH4HCO3 (pH 9) or 30 µL of 100 mM NH4HCO3 (pH 9) was added and the
samples incubated overnight at 37°C. The digest solution was removed to a new tube
and 50 µL of 50% acetonitrile-2% formic acid added and incubated for 10 min in a
sonicating water bath at full power. The solution was removed and pooled with the
digest solution and lyophilised to 15 µL, centrifuged and transferred to an autosampler
vial. LC-MS/MS of trypsin digested gel slices was performed as described in section
2.4.4.3.
2.4.4.3 One-dimensional Liquid Chromatography-Tandem Mass Spectrometry
Employed in Chapter 4
A QSTAR Elite hybrid Q-TOF mass spectrometer (ABI/MDS Sciex, USA) was
used following the method described by Szczepanek et al. (2010). The MS/MS spectra
were searched using the Mascot search engine Mascot Daemon, version 2.2.2; provided
by the Australian Proteomics Computational Facility (APCF) against the LudwigNR
database version Q209 (8785680 sequences, 3087386706 residues). The settings
specified included: MS/MS mass tolerance of 0.2 Da and fragment ions, trypsin as the
cleavage enzyme, three missed cleavages allowed, no fixed modifications, and
propionamide and methionine oxidation selected as variable modifications, peptide
mass tolerance of 100 ppm and charge state of 2+ and 3+. The search results were
accepted if a protein hit included at least one unique peptide with a p-value < 0.05. The
MS/MS spectra for the peptides identified by Mascot were manually validated to ensure
the b- and y-ion series were sufficiently extensive for an accurate identification.
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2.4.4.4 One-dimensional Liquid Chromatography-Tandem Mass Spectrometry
Employed in Chapter 5
Using an Eksigent AS-1 autosampler connected to a Tempo™ nanoLC system
(Eksigent, USA), 10 µL of sample was loaded at 20 µL/min with MS buffer A (2%
acetonitrile-0.2% formic acid) onto a C8 trap column (Michrom, USA). After washing
the trap for 3 min, the peptides were washed off the trap at 300 nL/min onto a PicoFrit®
column (75 µm x 100 mm) (New Objective, USA) packed with Magic C18AQ resin
(Michrom Bioresources, USA). Peptides were eluted from the column and into the
source of a QSTAR Elite hybrid Q-TOF mass spectrometer (AB Sciex™, USA) using
the following program: 5-30% MS buffer B (98% acetonitrile-0.2% formic acid) over
30 min, 30-80% MS buffer B over 3 min, 80% MS buffer B for 2 min, 80-85% MS
buffer B for 3 min. The eluting peptides were ionised at 2300 V. An information
dependent acquisition (IDA) experiment was performed, with a mass range of 375-1500
Da continuously scanned for peptides of charge state 2+-5+, with an intensity of more
than 30 counts/s. Selected peptides were fragmented and the product ion fragment
masses measured over a mass range of 100-1500 Da. The mass of the precursor peptide
was then excluded for 120 s. Peak list files generated by MSConvert from ProteoWizard
release 2.1.2674 (Kessner et al., 2008).
The MS/MS data files were searched using Mascot v.2.2.07 through the UNified
user InTErface (UNITE) interface provided by the APCF against the LudwigNR
database. The MS/MS results from the M. hyopneumoniae proteome “slice and dice”
experiment, and the polyacrylamide gel bands containing the Mhp385 preprotein and its
N-terminal cleavage fragment, were searched against version Q111 with 14359729
sequences and 4875314780 residues. The MS/MS results for the protein gel spots
containing the C-terminal cleavage fragment of Mhp385 were searched against version
Q311 with 16981479 sequences and 5747323621 residues. The MS/MS results for the
polyacrylamide gel bands containing the Mhp384 cleavage fragments were searched
against version Q211 with 12931687 sequences and 4483500103 residues. The
following parameter settings were used in all searches: fixed modifications: none;
variable modifications: propionamide, oxidised methionine, deamidated asparagine;
enzyme: semiTrypsin; number of allowed missed cleavages: 3; precursor ions mass
tolerance: 100 ppm; fragment ions mass tolerance: 0.2 Da; charge state: 2+ and 3+. The
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results of the search were then filtered by including only protein hits with at least one
unique peptide and excluding peptide hits with p-values of >0.05. Peptides identified by
Mascot were further validated by manual inspection of the MS/MS spectra for the
peptide to ensure that the b and y ion series were sufficiently extensive for an accurate
identification.
2.4.4.5 Two-dimensional Liquid Chromatography-Tandem Mass Spectrometry
Analysis of the M. hyopneumoniae strain J whole proteome or tryptic peptides
that were released into the incubation buffer by 2D LC-MS/MS. Lyophilised M.
hyopneumoniae strain J cells were resuspended in urea buffer (Appendix I), sonicated
and incubated at RT for 90 min with 10 mM tributylphosphine and 20 mM acrylamide
monomers. The alkylated proteins were acetone precipitated and pelleted by
centrifugation. The protein pellet was resuspended in urea buffer and proteolytically
digested with 2.5 µg endoproteinase LysC (Roche) at 37˚C overnight, diluted to 1 M
urea by adding 100 mM NH4HCO3, then digested with 2.5 µg of trypsin (Promega) at
37˚C for 16 h. The resulting complex peptide mixture was acidified with formic acid
(1% final concentration) and the peptides desalted and concentrated using an OASIS™
HLB SPE column (Waters, USA) as per manufacturer’s instructions. SCX buffer A
(Appendix I) was added to the sample and fractionated using a PolyLC polysulfoethyl
A™ column (2.1 x 100 mm) (USA) connected to an Agilent 1200 HPLC system (USA).
After collection of unbound peptides, retained peptides were fractionated by an
increasing gradient (0-50% in 50 min) of SCX buffer B (Appendix I). Eluting peptides
were monitored at 214 nm and collected by peak detection mode. Peptide fractions were
lyophilised to approximately 10 µL and desalted using OMIX® C18 SPE pipette tips
(Agilent) as per the manufacturer’s instructions. The sample was then transferred to an
autosampler vial and analysed with MS/MS as described in section 2.4.4.3.

2.5 Functional Characterisation of Recombinant Proteins
2.5.1

Dot Blot
Dot blots were performed using the Bio-Dot® microfiltration apparatus (Bio-

Rad Laboratories). One µg of protein in PBS (total volume of 50 µL) was added to each
well. Proteins were allowed to bind for 40 min unless the solution had drained through
the membrane. Unbound protein was removed by washing with 150 µL of PBS per well
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and the membrane was removed from the apparatus. The membrane was blocked and
probed as described in section 2.5.2. A duplicate dot blot was stained with amido black
protein stain (Appendix I) for 30 min followed by washes with amido black destain
(Appendix I).
2.5.2

Ligand and Western Blotting
All free sites on membranes were blocked with 5% (w/v) skim milk powder in

Tris-buffered saline (TBS, Appendix I) for 1 h at RT or overnight at 4°C, with gentle
shaking. Between incubations the membranes were washed (2 x 5 min) with Trisbuffered saline-Tween 20 (TBST) (Appendix I), rocking vigorously, followed by 1 x 5
min wash in TBS. All antibodies or ligands were diluted with 0.1% (w/v) skim milk
powder in TBS unless otherwise specified. Each membrane was equilibrated in 100 mM
Tris (pH 7.6) prior to membrane development with developing solution (Appendix I).
Once reactivity was clearly visible the membrane was transferred to Milli-Q water to
stop the reaction. The blots were scanned using a GS-800 calibrated densitometer and
analysed using PDQuest software.
2.5.2.1 Western Blots with Polyclonal Antisera Raised Against Recombinant
Proteins
Membranes were reacted with primary antibody, diluted as specified in each
chapter, for 1.5 h. After washing the membranes were incubated with horseradish
peroxidase (HRP) conjugated sheep anti-rabbit IgG polyclonal antibody (ChemiconMillipore) diluted 1:1000, or with HRP conjugated sheep anti-rabbit IgG polyclonal
antibody (Abcam®, UK) diluted 1:2000, for 1 h.
2.5.2.2 Plasminogen Related Ligand and Western Blots
For plasminogen ligand blotting, the membranes were probed with 10 µg/mL
biotinylated gel filtration-purified porcine plasminogen in the absence or presence of
100 mM εACA for 1.5 h. Following washing of the membranes they were probed with a
1:3000 dilution of streptavidin peroxidase (Roche) for 1 h.
For Western blots a 1:10,000 dilution of rabbit anti-porcine plasminogen
polyclonal antibody (AbD Serotec®, UK) or 1:5000 dilution of rabbit anti-human
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plasminogen polyclonal antibody (Sigma-Aldrich) was added and incubated with the
membrane for 1.5 h. After washing, the membrane was incubated with sheep anti-rabbit
IgG polyclonal antibody HRP conjugated (Chemicon-Millipore) diluted 1:1000, or with
HRP conjugated sheep anti-rabbit IgG polyclonal antibody (Abcam) diluted 1:2000, for
1 h.
2.5.2.3 Biotinylated Heparin Ligand Blots
Each membrane was probed with 10 µg/mL biotinylated heparin from porcine
intestinal mucosa (Calbiochem) for 1.5 h. After washing, the membrane was incubated
with streptavidin peroxidase diluted 1:3000 for 1 h.
2.5.2.4 Fibronectin Ligand Blots
Each membrane was probed with 10 µg/mL human fibronectin (Calbiochem) for
1.5 h, followed by rabbit anti-fibronectin antibody (MP Biomedicals, USA) diluted
1:3000 for 1 h and HRP conjugated-sheep anti-rabbit IgG antibody diluted 1:1500
(Abcam) for 1 h.
2.5.3

Solid Phase Mictrotitre Plate Assays
Each assay was performed as described below, with the following being

consistent between assays: all incubations were done at RT in a humidifier chamber;
after each incubation the 96-well microtitre plates were washed 5 x in PBS Tween20
(PBST; 200 µL per well; Appendix I) with a 96-well plate washer 96PW (SLT Lab
Instruments,

Germany);

each

plate

was

developed

with

2,2'-azino-bis(3-

ethylbenzthiazoline-6-sulfonic acid) solution (ABTS solution; Appendix I) and read on
an xMark microplate absorbance spectrophotometer at 414 nm. GraphPad Prism®
software v. 4.02 (USA) was used to analyse all data.
2.5.3.1 Heparin Binding Assays
For all heparin binding assays the plates were blocked with PBS containing 2%
(w/v) BSA for 1 h and all other dilutions were made in PBS containing 1% (w/v) BSA.
Briefly, wells of a 96-well microtitre plate were coated with 0.5 µg of recombinant
protein in carbonate coating buffer (Appendix I) overnight. For Mhp271 recombinants
96-well Nunc MaxiSorp™ plates (Thermo Fisher Scientific Inc.) were used, while Flat
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bottom Linbro/Titertek 96-well microtitre plates (MP Biomedicals) were used for
Mhp385 and Mhp384 recombinant proteins. After the plates were blocked and washed
the next morning, three-fold serial dilutions of biotinylated heparin from porcine
intestinal mucosa (Calbiochem) were added and incubated for 1.5 h. Bound biotinylated
heparin was detected using streptavidin peroxidase diluted 1:3000 for 1 h. Controls
included wells without protein, or biotinylated heparin, or streptavidin peroxidase. For
Mhp385 and Mhp384 assays background binding observed in wells with recombinant
protein but no biotinylated heparin were subtracted from all readings, while for Mhp271
assays the background binding observed in wells without recombinant protein were
subtracted from all readings. Controls were performed to confirm that protein adhered
to the microtitre plate. Each experiment was repeated on at least two independent days.
For the heparin inhibition assay, biotinylated heparin was added at various
concentrations with and without a 50-fold excess of unlabelled heparin from porcine
intestinal mucosa (Sigma-Aldrich). Binding in the presence of excess unlabelled
heparin was subtracted from the total binding to calculate the specific binding. Data
from triplicate samples from two independent assays (n = 6) were analysed using a one
site fit with nonlinear regression analysis in GraphPad Prism software to calculate the
equilibrium dissociation constant (KD).
Competitive binding experiments were performed with a saturating amount of
biotinylated heparin (20 µg/mL) and a range of 1, 2, 5, 10 and 30-fold excess of
unlabelled sulfated polysaccharides: heparin sodium salt from porcine intestinal
mucosa, fucoidan from Fucus vesiculosus, chondroitin sulfate A sodium salt from
bovine trachea, chondroitin sulfate B sodium salt from porcine intestinal mucosa and
porcine mucin type II (all from Sigma-Aldrich). Background binding observed in wells
without recombinant protein was subtracted from all readings. Triplicate wells per each
condition were used and the experiment repeated independently on two days. In both
assays the biotinylated heparin was mixed with the unlabelled sulfated polysaccharide
prior to addition to the plate.
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2.5.3.2 Fibronectin Binding Assays
Fibronectin binding assays were performed as above; however, PBS containing
2% (w/v) skim milk was used for blocking and all other dilutions were with PBS
containing 1% (w/v) skim milk. After blocking, human fibronectin (Calbiochem) was
added to wells and incubated for 1.5 h. Bound fibronectin was detected using rabbit
anti-human fibronectin antibody (MP Biomedicals) diluted 1:3000 (1 h incubation)
followed by HRP conjugated sheep anti-rabbit immunoglobulin G (IgG) antibody
(Chemicon-Millipore) diluted 1:1000 (1 h incubation). Background binding observed in
wells without recombinant protein were subtracted from all readings. The experiment
was repeated on an independent day.
2.5.4

Surface Plasmon Resonance
Protein-protein interactions were studied in real time using a Biacore T100

biosensor system (GE Healthcare), at 20˚C. The running buffer used for experiments
was HBS-EP+ (Appendix I) from GE Healthcare.
2.5.4.1 Fibronectin Surface Plasmon Resonance Assays
Fibronectin was diluted to 10 µg/mL in 10 mM sodium acetate (pH 4.0) and
covalently linked to the carboxylmethylated dextran matrix of an S Series sensor chip
CM4 using the amine coupling kit (GE Healthcare). The ligand contact time was set to
300 s and a 10 µL/min flow rate was used, resulting in approximately 4000 resonance
units (RUs) of fibronectin immobilised. This procedure was performed on another flow
cell, without fibronectin present, to provide an uncoated reference to correct for
background and bulk refractive index contributions. The binding of F1271 and F2271 to
immobilised fibronectin was assessed by running 100 nM of the analytes over both the
fibronectin-coated flow cell and the reference at a flow rate of 10 µL/min for 600 s.
Dissociation was monitored for 900 s, before the surface was regenerated using 6 M
urea in HBS-EP+ at 15 µL/min for 45 s. To perform kinetic assays, different
concentrations of the analyte (F2271) in running buffer were flowed over both the
fibronectin-coated flow cell and the reference at a flow rate of 10 µL/min for 600 s.
Dissociation was monitored for 1800 s, before the surface was regenerated as described
earlier. Since the binding curves suggested the presence of specific and non-specific
binding the association kinetics were analysed manually by Nicholas Dixon from UOW,
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using a two-component heterogeneous binding model. Data for each concentration of
F2271, [F2271], were fit to the sum of two exponentials, to give two first-order rate
constants (kobs) each with a corresponding value of Rmax, the response at infinite time;
each of the Rmax values represented about half of the total observed response, and the
two values of kobs differed by factors of 8–40, depending on [F2271]. Values of kobs for
the faster (specific) component showed a linear dependence on [F2271], yielding the
second-order association rate constant ka (± standard error) from the slope. The slower
(non-specific) component showed no dependence on [F2271], and was not further
analysed. Values of Rmax for the faster component fit well to a 1:1 Langmuir binding
isotherm, to yield a value for the dissociation constant, KD (± standard error).
Dissociation rate data also showed fast and slow components, but were not analysed.
2.5.4.2 Plasminogen Surface Plasmon Resonance Assays
Gel filtration-purified pig plasminogen was diluted to 11 µg/mL in 10 mM
sodium acetate (pH 4.0) and covalently linked to the carboxylmethylated dextran matrix
of an S Series sensor chip CM4 using the amine coupling kit (GE Healthcare), with
contact time set to 300 s and flow rate to 5 µL/min. Immobilisation of soluble
plasminogen generated RUs of 600-700. A separate flow channel on the same sensor
chip was subjected to blank immobilisation, to be used as a reference flow cell, by
preparing it in the same way but without the plasminogen. To determine whether the
recombinant fragments bind to the immobilised plasminogen, two concentrations (100
and 200 nM) of the recombinant fragments, prepared in running buffer, were flowed
over the plasminogen coated and reference flow cells at 10 µL/min for 600 s. The
following dissociation phase (injection of only running buffer) was monitored for 1000
s, before the surface was regenerated using 4 M MgCl2 in HBS-EP+ at 40 µL/min for
60 s, followed by a 600 s stabilisation period. The experiment was performed twice on
two independent days on separate CM4 chips. All association and dissociation curves
were corrected for non-specific binding by subtraction of signal from the reference flow
cell.
To further examine the interaction of F2271 with immobilised plasminogen,
increasing concentrations of F2271 prepared in running buffer were flowed over the
plasminogen coated and reference flow cells using the conditions as above. The binding
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curves suggested the presence of specific and non-specific binding. The association
kinetics were analysed manually by Nicholas Dixon from UOW, as described in section
2.5.4.1 using a two-component heterogeneous binding model.
2.5.5

Cilia Adherence Assay
Cilia were harvested from tracheal ciliated cells from a specific-pathogen-free

swine, purified and 100 µL was coated (0.5 µg/mL) to the wells of flat-bottom
microtitre plates in 0.1 M sodium carbonate buffer (pH 9.5) for 3 h at 37°C. Plates were
washed with TBST and then blocked with 200 µL Neptune Block blocking buffer
(Immunochemistry Technologies, USA) for 2 h at 37°C and then overnight at 4°C and
washed once with TBST buffer. After washing, 6xHis-tagged recombinant proteins
were added at 0.5 µg/mL (100 µL per well) and incubated for 4 h at 37ºC. After the
plates were washed, polyclonal antiserum raised against the recombinant protein,
diluted 1:100 in TBST, was added (100 µL per well) and incubated for 2 h at 37ºC.
Following, plates were washed before donkey anti-rabbit alkaline phosphatase diluted
1:2000 with TBST was added (100 µL per well) and incubated for 1.5 h at 37 ºC. Plates
were washed and then developed by adding 100 µL of p-nitrophenyl phosphate
substrate buffer (Appendix I) to each well followed by incubation at 37°C for 25 min.
Colour development ceased with the addition of 1 N NaOH (25 µL) and plates read at
405 nm. Each protein was tested in triplicate, and the background control (wells without
cilia) was tested in duplicate for each protein. A positive control antigen F2P97 derived
from M. hyopneumoniae strain J (Jenkins et al., 2006), containing the cilium binding R1
repeat region and an R2 repeat region, was also included in each assay. The experiment
was performed independently on two independent days and the data were pooled.
Statistical significance was determined using an unpaired Student t-test by comparison
of protein binding to the background control. A p-value < 0.05 was considered
significant. To examine the ability of heparin to inhibit the adherence of the
recombinant proteins to cilia, each recombinant protein was pre-incubated for 30 min at
37˚C with 100 µM of heparin from porcine intestinal mucosa (Sigma-Aldrich) before
incubation with cilia as described earlier. An unpaired Student t-test comparing the level
of cilia binding between proteins with and without pre-incubation with heparin was
performed and a p-value < 0.05 was considered significant.
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2.6 M. hyopneumoniae Plasminogen-binding and Activation Assays
2.6.1

M. hyopneumoniae Cells Bind Plasminogen in Modified Friis Medium
To assess whether M. hyopneumoniae cells recruit plasminogen or plasmin from

the serum in modified Friis medium, a Western blot using anti-pig plasminogen
polyclonal antibodies (AbD Serotec) was performed. Non-tPA activated and tPA
activated porcine plasminogen were included as references. Porcine plasminogen (10
µg, not purified by gel filtration) was incubated in the presence or absence of 250 units
of tPA in PBS for 23.5 h at 37°C. SDS-PAGE sample buffer was added to each sample,
and to PBS washed cultured M. hyopneumoniae strain 232 cells. All samples were
placed in boiling water for 5 min prior to loading onto a 1D SDS-PAGE gel as
described in 2.3.5. Proteins were transferred onto PVDF membrane as described in
section 2.3.12. Following the method described in section 2.5.2, the detection of
plasminogen/plasmin was with rabbit anti-pig plasminogen polyclonal antibody (AbD
Serotec) diluted 1:2000 in TBS for 1.5 h and HRP conjugated sheep anti-rabbit IgG
antibody (Chemicon-Millipore) diluted 1:1000 in TBS for 1 h.
2.6.2

Plasminogen Binding to Immobilised M. hyopneumoniae Cells
Freshly cultured M. hyopneumoniae strain 232 cells were washed with PBS and

resuspended in 1% (w/v) paraformaldehyde in PBS. M. hyopneumoniae cells were
coated onto a Linbro/Titertek 96-well microtitre plate at an optical density of 0.04 at
600 nm in carbonate coating buffer. The plate was centrifuged at 1000 x g for 10 min.
After removing the liquid in each well, the wells were blocked with 2% (w/v) BSA in
PBS for 1 h. The plate was washed x 5 in PBST as described in section 2.5.3, followed
by 1.5 h incubation with a two-fold serial dilution of biotinylated gel filtration-purified
porcine plasminogen in 1% (w/v) BSA in PBS (100 µL per well). Bound plasminogen
was detected with streptavidin peroxidase diluted 1:3000 in 1% (w/v) BSA in PBS for 1
h. The plate was developed and read as per section 2.5.3. The assay was performed in
duplicate on separate days with triplicate wells per assay. For the competitive inhibition
assay, 10-fold serial dilution of 1 M εACA was added to 412.5 nM biotinylated gel
filtration-purified porcine plasminogen before incubation with the cells as described
above.
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2.6.3

Immunofluorescence Staining of Plasminogen on the Surface of M.
hyopneumoniae Cells
M. hyopneumoniae strain 232 cells from several 6 mL cultures were pooled and

centrifuged at 10,000 x g for 5 min to remove the culture supernatant. The cell pellet
was washed in 30 mL PBS and centrifuged as before. The pellet was resuspended in 1
mL PBS and centrifuged for 2 min at 13,000 rpm in a microcentrifuge. The pellet was
resuspended in 0.5 mL 2% (v/v) paraformaldehyde in PBS and incubated for 20 min at
4ºC. After washing the cells once with 0.5 mL PBS, the pellet was resuspended in 0.8
mL 3% (w/v) BSA in PBS and incubated for 30 min at 37°C. The cells were then
centrifuged as before and the pellet resuspended in 0.8 mL PBS and divided amongst
four tubes (one per each sample), centrifuged, then 1 of the 4 pellets was incubated with
5 µg/mL gel filtration-purified pig plasminogen in 0.3% (w/v) BSA in PBS (200 µL) for
1 h at 4°C, while the other pellets were incubated in 0.3% (w/v) BSA in PBS (200 µL)
for 1 h at 4°C. The cells were washed twice in 0.2 mL PBST, followed by one wash
with 0.2 mL PBS. From here on the washes were done in 0.2 mL volumes. The cells
were incubated overnight in anti-porcine plasminogen antibodies or anti-F2P97 serum
(Jenkins et al., 2006), both at a dilution of 1 in 200 with 0.3% (w/v) BSA in PBS, or
only 0.3% (w/v) BSA in PBS (200 µL). The cells were washed twice in PBST, followed
by one wash with PBS. All pellets were then incubated with 200 µL Invitrogen donkey
anti-rabbit Alexa Fluor® 568 (1:1000) for 2 h at 4°C with rotation. The cells were
washed once in PBST, followed by one wash with PBS. The pellets were resuspended
in 10 µL PBS. Three µL of the cell suspension mixed with 3 µL of Vectashield®
mounting medium (Vector laboratories, Inc., USA) was deposited onto a SuperFrost®
Plus slide (Menzel-Gläser, Germany), covered with a coverslip, and sealed with nail
polish. Cells were viewed with an Olympus IX71® inverted fluorescence microscope
(USA) under a 100× oil immersion objective. Images were captured using an
Evolution™ MP colour camera and Image-Pro® software (Media Cybernetics, USA).
The experiment was repeated on an independent day.
2.6.4

Activation of M. hyopneumoniae Surface-bound Plasminogen to Plasmin
Freshly cultured M. hyopneumoniae strain 232 cells, washed in PBS, were added

to wells of a Linbro/Titertek microtitre plate and the plate was blocked as described in
section 2.6.2. Five µg human plasminogen (Sigma-Aldrich) or gel filtration-purified
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porcine plasminogen in 1% (w/v) BSA in PBS was added to each well and incubated at
37°C for 1 h with shaking. Unbound plasminogen was removed by washing the plate
three times with PBS containing 0.5% (v/v) Tween 20, and once with 50 mM Tris (pH
7.4). A two-fold serial dilution of tPA was added in 50 mM Tris (pH 7.4), to determine
the concentration where the activator was saturating. The plate was incubated at 37°C
for 15 min with shaking prior to the addition of 20 µL of 2.5 mM Spectrozyme PL. The
absorbance at 405 nm was measured using a Multiskan Ascent plate reader (Thermo
Labsystems, USA) every hour for the first 5 h, then again from 20 h until the
absorbance for wells with human plasminogen reached saturation (when the absorbance
no longer increased with time due to depletion of the chromogenic substrate). Between
reads the plate was incubated at 37°C with shaking. Maximum plasmin activity (100%)
was taken as the average of the maximum absorbance at 405 nm of wells with human
plasminogen and tPA added to M. hyopneumoniae cells. Absorbance measured in wells
without cells was subtracted from the absorbance of wells with cells.
2.6.5

Cleavage of Fibrinogen by M. hyopneumoniae Surface-bound Plasmin
M. hyopneumoniae cells were grown to log phase, washed and resuspended in

PBS to an OD600 of 0.9. M. hyopneumoniae cells (50 µL) were preincubated with 10 µg
gel filtration-purified porcine plasminogen in PBS for 30 min at 37°C. The cells were
pelleted by centrifugation at 13,000 rpm using a microcentrifuge, then washed x 3 with
PBS and incubated with 5 µg plasminogen-depleted human fibrinogen (Calbiochem) for
30 min at 37°C. After washing the cells as before, cleavage of fibrinogen occurred in
the presence of 225 units of tPA (Calbiochem) (total volume of 90 µL) at 37°C. After
the set incubation time the cells were pelleted by centrifugation. SDS-PAGE sample
buffer was added to the supernatant and placed in boiling water for 5 min. The samples
(10 µL per sample) were separated by 1D SDS-PAGE followed by transfer of the
proteins onto a PVDF membrane, as described in sections 2.3.5 and 2.3.12. Detection of
fibrinogen peptides was carried out following the method in section 2.5.2 using goat
anti-human fibrinogen antiserum (Sigma-Aldrich) diluted 1:10,000 in TBS for 1.5 h and
a peroxidase-conjugated anti-goat IgG antibody (Sigma-Aldrich) diluted 1:7500 in TBS
for 1 h.
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3. Binding and Activation of Host Plasminogen at the Cell
Surface of Mycoplasma hyopneumoniae
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3.1 Introduction
The prevalence of M. hyopneumoniae in the swine producing regions worldwide
is indicative of the success of this pathogen to evade host defence mechanisms and to
adapt to the changing host environment during natural infection. It is unknown how M.
hyopneumoniae is able to persist for months in the lungs of infected pigs, which
consequently maintains the presence of the bacteria within the herd. Although M.
hyopneumoniae is generally considered to be a non-invasive pathogen, several papers
have reported the presence of M. hyopneumoniae in tissues distal to the site of infection,
such as the liver, spleen, kidneys, brain and pericardial fluid (Buttenschon et al., 1997;
Friis, 1974; Le Carrou et al., 2006; Marois et al., 2007). This suggests that M.
hyopneumoniae possesses a mechanism to disseminate to sites peripheral from the site
of infection. The factors that influence or enable this movement of the bacteria and the
consequences are unknown; however, it is likely to contribute to M. hyopneumoniae’s
evasion of the host immune system.
The binding and activation of plasminogen on the surface of bacterial cells is a
common mechanism used by bacteria to facilitate movement through normal tissue
barriers. Plasminogen is a ubiquitous pro-enzyme protein circulating in plasma. Upon
activation by physiological activators such as tPA and uPA, or by bacterial activators,
plasminogen is converted to the serine protease plasmin. Plasmin can degrade fibrin
clots and the majority of ECM protein components either directly or by the activation of
matrix metalloproteinases (MMPs) (Kucharewicz et al., 2003; Lahteenmaki et al.,
2005). Plasmin also stimulates proinflammatory cytokine release (IL-1α, IL-1β, TNF-α)
at the site of an inflammatory response (Syrovets et al., 2001). Human plasminogen
circulates in a closed formation, called Glu-plasminogen; however, upon binding to
plasminogen-binding proteins in solution or on cell surfaces, typically via its lysine
binding sites of the kringle domains, the Glu-plasminogen changes to a more open
conformation that is more readily activated (Castellino and Ploplis, 2005). Hydrolysis of
the N-terminal 77 amino acids of Glu-plasminogen by plasmin, to form Lysplasminogen, is also enhanced when bound to the surface of cells. Both Lysplasminogen and cell-bound plasminogen are more readily activated in contrast to
circulating Glu-plasminogen.
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Bacteria interact with plasminogen/plasmin and various other components of the
PAS as part of their pathogenesis. B. burgdorferi, the etiological agent of Lyme disease,
is transmitted to humans by tick vectors. B. burgdorferi utilises vertebrate plasminogen
and uPA, obtained by feeding ticks, to disseminate from the midgut epithelium of the
tick to become systemic and invade the salivary glands where it deposited in the
mammalian skin (Coleman et al., 1997). A number of invasive bacteria produce their
own plasminogen activators, including S. pyogenes, S. aureus and Y. pestis
(Lahteenmaki et al., 2005). In addition to binding and activating plasminogen, the
pathogenic bacteria Porphyromonas gingivalis and Y. pestis enhance host proteolysis by
suppressing host plasmin inhibitors α2-antiplasmin and α2-macroglobulin (Grenier,
1996; Kukkonen et al., 2001).
The interaction of M. hyopneumoniae with the PAS has not been investigated.
Interactions with plasminogen have only been reported for two invasive mycoplasmas,
Mycoplasma leachii sp. nov. (formerly Mycoplasma sp. bovine group 7) and
Mycoplasma fermentans. Both species bind plasminogen that can be activated via
mammalian activators (Bower et al., 2003; Tarshis et al., 1993; Yavlovich et al., 2004).
Plasmin coated M. fermentans are capable of invading HeLa cells (Yavlovich and
Rottem, 2007). Plasminogen is primarily synthesised by liver tissue; however, other
minor sources of plasminogen have been identified, including the lung (Zhang et al.,
2002). In addition airway cells are key sources of many of the components of the PAS,
including plasminogen activators (tPA and uPA) and inhibitors (PAI-1 and PAI-2)
(Kucharewicz et al., 2003). Evidence for the PAS in the airways has been demonstrated
in various studies of airway inflammatory and lung diseases, such as bronchial asthma
(Swaisgood et al., 2007) and pulmonary fibrosis (Swaisgood et al., 2000). The PAS is
involved in the acute and chronic stages of airway inflammatory response and in lung
repair

through

plasmin-mediated

directional

cell

migration

and

proteolysis

(Kucharewicz et al., 2003). The involvement of plasminogen in the airway
inflammatory response and tissue repair, the increasing evidence of other bacteria
utilising the PAS in disease progression, and evidence of M. hyopneumoniae within
tissues at sites distal from the respiratory tract led us to assess whether M.
hyopneumoniae can bind to and activate plasminogen.
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3.2 Results
3.2.1

Sequence Comparison of Human versus Porcine Plasminogen
Human plasminogen activators and the mechanism of human plasminogen

activation have been well studied; however, porcine plasminogen activation is not as
well characterised. For the investigation of M. hyopneumoniae’s interaction with
plasminogen, porcine plasminogen is the most physiologically relevant plasminogen. A
BLAST search showed that at the protein level porcine plasminogen (NCBI accession
number NP_001038055.1) shares 80% identity with human plasminogen (GenBank
accession number AAA60113.1) and 88% similarity (Expect value of 0.0). The Expect
value of 0.0 indicates that the two proteins are highly likely to be the same protein,
which is unsurprising as they are both plasminogen sequences, though from different
species; however, the small sequence differences between the plasminogens could result
in minor structure and functional variations between the species. An alignment of the
sequences is shown in Figure 3.1. One difference of interest is that the N-terminal
residue of native human plasminogen is a glutamic acid followed by a proline residue
(Glu-Pro-Leu-Asp-Asp-) (Wiman, 1973); therefore, this form is often referred to as
Glu-plasminogen. However, the N-terminal sequence of native porcine plasminogen
determined from Edman degradation is an aspartic acid residue followed by a serine
residue (Asp-Ser-Leu-Asp-Asp-) (Brunisholz and Rickli, 1981), and will be referred to
as Asp-plasminogen in this work. Although human and porcine plasminogens share a
high level of identity, several studies have reported variations in the activation of
plasminogen between different mammalian species (Nieuwenhuizen and Keyser, 1985;
Wohl et al., 1983; Wulf and Mertz, 1969; Yakovlev et al., 1995).
3.2.2

Purification of Porcine Plasminogen
Porcine plasminogen is currently not commercially available. Therefore, porcine

plasminogen was purified from porcine plasma using lysine affinity chromatography
(Andronicos et al., 1997; Sanderson-Smith et al., 2006) (Figure 3.2A). The elution
profile of the purification shows three peaks that correspond with the initial wash step
of the lysine column with PBS, followed by a high salt wash to remove non-specific
binding protein, and lastly the elution of porcine plasminogen, achieved by adding 200
mM εACA (Figure 3.2A).
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*
human : DCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCFTTDPSVRWEYCN : 450
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: DCYRGNGESYRGTSSTTITGRKCQSWVSMTPHRHEKTPGNFPNAGLTMNYCRNPDADKSPWCYTTDPRVRWEYCN : 450
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human : LKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAG : 525
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: LKKCSETEQQVTNFPAIAQVPSVEDLS-EDCMFGNGKRYRGKRATTVAGVPCQEWAAQEPHRHSIFTPETNPRAG : 524
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pig
: RYGGHFCGGTLISPEWVLTAKHCLEKSSSPSSYKVILGAHEEYHLGEGVQEIDVSKLFKEPSEADIALLKLSSPA : 674
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pig
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pig
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Figure 3.1 ClustalW alignment of human and pig plasminogen sequences. The black
background indicates identical amino acids.
The purified plasminogen and a commercial preparation of human plasminogen
were analysed by 1D SDS-PAGE (Figure 3.2B). The purified porcine plasminogen had
a molecular mass of approximately 90 kDa under reducing conditions, while the human
plasminogen had a molecular mass of approximately 92 kDa. The dual bands in the
purified porcine plasminogen sample, which are more apparent in the non-reduced
sample, are due to two different glycoforms of the plasminogen in the plasma
(Molgaard et al., 1997).
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Figure 3.2 Lysine affinity chromatography-purified porcine plasminogen. (A) Elution
profile from the lysine affinity chromatography purification of plasminogen from
porcine plasma. (B) 12% polyacrylamide gel and anti-plasminogen antibody blotting
analysis of purified porcine plasminogen and commercial human plasminogen. Porcine
plasminogen was electrophoresed under non-reducing (no β-mercaptoethanol) (lane 1)
and reducing (containing β-mercaptoethanol) (lane 2) conditions. Human plasminogen
was also electrophoresed under non-reducing (lane 3) and reducing (lane 4) conditions.
Duplicates of the unstained gels were directly transferred onto to PVDF membranes and
probed with rabbit polyclonal anti-porcine or anti-human plasminogen antibodies,
diluted 1:10,000 and 1:5000, respectively. Molecular mass markers are provided on the
left.
The identity of the plasminogen was confirmed by Western blotting with a
polyclonal rabbit anti-porcine plasminogen (IgG) antibody and by MS (Figure 3.2B).
Anti-porcine plasminogen antibodies recognised both porcine and human plasminogen
under non-reducing conditions; however, they only weakly detected reduced porcine
plasminogen and failed to detect human plasminogen. The reciprocal results occurred
with anti-human plasminogen antibodies. These Western blots highlight the importance
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of plasminogen folding for antibody recognition. MALDI-TOF MS of the purified pig
plasminogen confirmed that the protein was porcine plasminogen (UniProtKB accession
number P06867), with a score of 108, 18 matched peptides and an Expect value of 8.2e006 (Figure 3.3). MALDI Q-TOF MS/MS was also performed confirming the MALDITOF MS data and is discussed in the next section.

Figure 3.3 The amino acid sequence of plasminogen precursor (UniProtKB accession
number P06867) showing the tryptic peptides identified by MS analysis of the purified
swine plasminogen. Purified porcine plasminogen was electrophoresed on a 1D SDSPAGE gel and the 90 kDa band (Figure 3.2) was excised and analysed by MALDI-TOF
MS and MALDI Q-TOF MS/MS. The peptides identified by MALDI-TOF MS are in
bold, while the peptides identified by MALDI Q-TOF MS/MS are underlined. One
peptide (boxed) matched within the N-terminal peptide, which when cleaved off forms
Lys-plasminogen.
3.2.3

Activation of Porcine Plasminogen
A chromogenic substrate specific for plasmin, Spectrozyme PL, was utilised to

determine the plasmin activity of the sample in the presence and absence of an activator.
The Spectrozyme PL assay used was modified from that described by McArthur et al.
(2008). Previously this assay was used to determine the plasmin activity of human
plasminogen in the presence and absence of streptokinase. Since streptokinase does not
activate porcine plasminogen (Wulf and Mertz, 1969) and human plasminogen has a
different activation rate compared to porcine plasminogen (Flight et al., 2006;
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Nieuwenhuizen and Keyser, 1985; Yakovlev et al., 1995), a two-fold serial titration of
human tPA and uPA was performed to observe the effect of activator type and
concentration on the activation of porcine plasminogen under the experimental
conditions (Figure 3.4A and B). Porcine plasminogen activators are not commercially
available. The assay was also repeated with human plasminogen with uPA (Figure
3.4C). In the presence of either tPA or uPA, porcine plasminogen was activated to
plasmin. The activation profile was similar for both types of activator. Human
plasminogen was more readily activated with uPA than porcine plasminogen, with less
time and a lower concentration of activator required to reach optical density saturation.
Importantly for both porcine and human plasminogen, no significant increase in
absorbance at 405 nm was observed in the absence of an activator, indicating the
absence of plasmin.
To determine whether the porcine plasminogen was being completely digested
into plasmin, an activation assay was undertaken with tPA and uPA followed by 1D
SDS-PAGE analysis. Human plasminogen was also activated with uPA. When porcine
plasminogen was activated with tPA or uPA, bands with molecular masses of
approximately 65, 55 and 25 kDa bands were observed (Figure 3.5A). These molecular
masses correspond with the sizes of porcine Asp-plasmin heavy chain (65 kDa), Lysplasmin heavy chain (54.5 kDa) and plasmin light chain (25 kDa). The intensity of the
55 kDa band increased with time while the intensity of the 65 kDa decreased,
suggesting that with the formation of plasmin the N-terminal peptide of Asp-plasmin
was being cleaved off to form Lys-plasmin. However, after 24 and 30 h of activation
with either tPA or uPA, a doublet with a molecular mass similar to that of native
plasminogen still remained suggesting that under these experimental conditions the
porcine plasminogen was not completely activated into plasmin, and that cleavage may
be complex in porcine plasminogen. Even in the presence of εACA, which when bound
to plasminogen changes the conformation of the plasminogen enhancing activation
(Castellino and Ploplis, 2005; Machovich et al., 1992; Violand et al., 1978; Violand et
al., 1975), porcine plasminogen was not completely digested (Figure 3.5B). In
comparison, human plasminogen was almost completely activated into the 65 kDa Gluplasmin heavy chain and 25 kDa light chain plasmin within 2 h (Figure 3.5C). The
activation of human plasminogen occurred more rapidly than for porcine plasminogen,
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Figure 3.4 Activation of porcine and human plasminogen by mammalian activators.
Porcine plasminogen (A and B) or human plasminogen (C). Purified plasminogen (1
µg) was incubated with increasing amounts of tPA or uPA as listed on the right. The
activation of plasminogen was determined by cleavage of the plasmin-specific
chromogenic substrate Spectrozyme PL. Data are from duplicate readings and error bars
represent standard deviation.

corresponding with the Spectrozyme PL assays described above. The activation of
porcine plasminogen was also attempted in the presence and absence of 10 µg
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fibrinogen with 200 and 1000 units tPA for 96 h prior to analysis, to determine whether
a five fold increase in the amount of tPA, or the addition of fibrinogen that has been
reported to increase activation rate (Takada et al., 1986), or increasing the incubation
period would lead to complete digestion of the plasminogen into plasmin (Figure 3.5D).
Irrespective of any of these changes, complete activation of purified porcine
plasminogen was not seen, although the Lys-heavy chain plasmin was very prominent
and the Asp-heavy chain plasmin was absent.

Figure 3.5 One-dimensional SDS-PAGE analysis of porcine and human plasminogen
activation with tPA and uPA over time. (A) Porcine plasminogen was incubated in the
absence (lane 1) or presence of 100 units tPA (lanes 2-5) or with 0.25 units uPA (lanes
6-9). (B) Digestion of porcine plasminogen in the absence (lane 1) or presence of 25
mM εACA and 100 units tPA (lanes 2-5), and 25 mM εACA and 0.25 units uPA (lanes
6-9). (C) Digestion of human plasminogen in the absence (lane 1) or presence of 100
units of tPA (lanes 2-5) and 0.25 units of uPA (lanes 6-9). (D) Porcine plasminogen was
incubated with 200 units tPA (lanes 1 and 3) or with 1000 units tPA (lanes 2 and 4), and
in the presence of fibrinogen (lanes 3 and 4). The time of the digestion (in hours) is
given at the bottom of each lane. All gels were stained with GelCode Blue.
To determine whether the non-digestible protein is plasminogen or another
protein MALDI Q-TOF MS/MS was performed on the doublet seen in 1D SDS-PAGE
analysis of porcine plasminogen incubated with tPA (Figure 3.6). The top band
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(labelled A in Figure 3.6) matched to the protein sequence of pig plasminogen precursor
(UniProtKB accession number P06867) with the two peptides HSIFTPETNPR (Mascot
score 64) and FVTWIEEIMR (Mascot score 62). To determine the identity of the lower
band (labelled B in Figure 3.6) the most likely amino acid sequences for the top three
peptides were run in a BLAST search against all non-redundant protein sequences in the
GenBank

database

with Sus

scrofa as

the

organism.

The

peptide

2163

VxxxSTGVETLQSSPVTYR matched to IgM heavy chain constant region [Sus scrofa]
(GenBank accession number BAI82566.1) with an Expect value 5e-07. Peptide 1589
VxxxNIQDFPSVLR matched to constant region domain 4 for the heavy chain (CH4)
and secrete domains of swine IgM [Sus scrofa] (GenBank accession number
AAC48775.1) with an Expect value of 3e-04, and the last peptide 1525
LVESGGGLVQPGGSLR matched to immunoglobulin heavy chain variable region
[Sus scrofa] (GenBank accession number CAJ45454.1) with an Expect value of 7e-08.
Based on these results it was determined that porcine IgM co-purified with porcine
plasminogen and does not appear to be digested by porcine plasmin.

Figure 3.6 Gelcode Blue stained 12% polyacrylamide gel of tPA activated lysine
affinity chromatography-purified porcine plasminogen. Porcine plasminogen (10 µg)
was incubated at 37°C in the presence of 250 units tPA for 21.5 h prior to 1D SDSPAGE. MALDI Q-TOF MS/MS identified protein A as porcine plasminogen and
protein B as porcine IgM.
IgM normally exists as a pentamer with a molecular mass of approximately 900
kDa; however, can also exist as a monomer. Each monomer has a molecular mass of
150 kDa, consisting of a light and heavy chain that run as 25 and 75 kDa proteins in
SDS-PAGE under reducing conditions, respectively (Hill et al., 2009). It would be
difficult to discriminate the heavy chain of IgM from porcine plasminogen based on size
via electrophoresis under reducing conditions on a 12% polyacrylamide gel. The
intensity of the IgM band observed by 1D SDS-PAGE compared to the porcine
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plasminogen (Figure 3.5 and Figure 3.6) indicates that the concentration of IgM in the
sample is also considerably less than that of the plasminogen. When the purified
plasminogen was separated on a 7% polyacrylamide gel under non-reducing conditions
followed by silver staining, a very large molecular mass protein which migrated close to
the top of the gel and an 80 kDa protein were present (Figure 3.7). Since this sample
was run in the absence of a disulfide bond reducing agent it is likely that the high mass
protein is porcine IgM and the 80 kDa protein is porcine plasminogen. Under reducing
conditions a strong band of approximately 90 kDa and a considerably weaker 75 kDa
band were present, which match the size of plasminogen and the heavy chain sub-unit
of IgM, respectively. The smaller IgM subunit of approximately 25 kDa would have
migrated off the base of this gel. The molecular masses of these proteins support the
MALDI Q-TOF MS/MS results. No literature evidence was found to confirm whether it
is common for porcine IgM to co-purify with plasminogen during lysine affinity
chromatography or whether IgM binds to plasminogen.

Figure 3.7 Silver stained 7% polyacrylamide gel of lysine affinity chromatographypurified porcine plasminogen. The sample was electrophoresed under non-reducing
(lane 1) and reducing (lane 2) conditions. Porcine plasminogen and IgM are labelled as
A and B, respectively. Molecular mass markers are given on the left.
3.2.4

Removal of the IgM from Purified Porcine Plasminogen
Gel filtration was employed to remove the IgM from the porcine plasminogen

sample (Figure 3.8A). Elution fractions were monitored at 280 nm to determine when
the proteins eluted from the column. When the plasminogen from the lysine sepharose
column was chromatographed on Sephacryl S-200, two major peaks of activity were
seen (Figure 3.8A). One-dimensional SDS-PAGE analysis and silver staining of
selected fractions from each peak illustrated that each peak contained a different protein
(Figure 3.8B). When electrophoresed on a 7% polyacrylamide gel the first peak
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contained a very large molecular mass protein (> 170 kDa) under non-reducing
conditions, which migrated at 75 kDa under reducing conditions. The protein present in
elution fractions of the second peak migrated at approximately 80 kDa and 90 kDa,
under non-reducing and reducing conditions, respectively. Based on these
electrophoretic profiles the first peak corresponds to IgM and the second peak
corresponds to plasminogen. A small incremental slope in the chromatogram was
always present leading up to the second peak. Elutions of this fraction contained a
protein that migrated at 55 kDa under reducing conditions in 1D SDS-PAGE, which
may be Lys-heavy chain plasmin. Since the 55 kDa protein was at a similar
concentration to the native plasminogen present in this sample, the fractions of the
incremental slope prior to the second peak were not used. The ability of the porcine IgM
to be separated from porcine plasminogen by gel filtration suggests that porcine IgM
and plasminogen are not covalently linked. A covalent linkage between plasminogen
and IgM could explain the co-purification of the plasminogen with IgM during lysine
affinity chromatography.
3.2.5

Activation of Porcine Plasminogen after Gel Filtration Purification
Elution fractions from the second peak of the gel filtration (the fractions

containing plasminogen) were pooled and its activation by human tPA and uPA was
tested as described previously (Figure 3.9). The activation curves are similar to the
previous activation results when contaminating IgM was present (Figure 3.9A),
indicating that the presence of IgM did not significantly change the rate of activation.
To assess whether the gel filtration-purified plasminogen could be completely
digested/activated, the activation of this plasminogen with tPA and uPA was assessed
by 1D SDS-PAGE. Porcine plasminogen, after gel filtration, was able to be completely
digested by tPA and uPA within 48 h as observed by this analysis (Figure 3.10A).
Digestion was more rapid in the presence of εACA, with complete digestion occurring
almost within 24 h with 100 units tPA or within 8 h with 0.025 units uPA (Figure
3.10B). However, the rate of digestion was still lower than commercially sourced
human plasminogen (Figure 3.5C).
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Figure 3.8 Sephacryl S-200 gel filtration chromatography of porcine plasminogen
purified by lysine sepharose chromatography. (A) Elution profile of gel filtration
column. Fractions (2 mL) were collected from the column at a flow rate of 1 mL/min.
Each marking represents the start of the fraction collected. IgM eluted in the first peak,
whilst the plasminogen eluted in the second peak. (B) 7% polyacrylamide gel
electrophoresis analysis of elution fractions (55, 72, 80 and 86) shown in A. The elution
fractions were electrophoresed under non-reducing or reducing (*) conditions. Proteins
were detected by silver staining.
3.2.6

M. hyopneumoniae Binds Plasminogen
Interaction with plasminogen is a characteristic shared by numerous pathogens.

Western blotting with anti-porcine plasminogen antibodies of whole cell lysates of
washed M. hyopneumoniae cells detected the presence of a band of approximately 55
kDa, which is of the same size as Lys-heavy chain of plasmin (Figure 3.11). The 25 kDa
band, the light chain of plasmin, does not appear to be present or is not detected by the
anti-porcine plasminogen antibodies; however, the 25 kDa band is also not obvious in
the 12% polyacrylamide gel of plasminogen after incubation with tPA after 96 h (Figure
3.5D). The presence of plasmin in the whole cell lysate of M. hyopneumoniae cells
indicates that M. hyopneumoniae cells recruit plasminogen/plasmin from the serum that
supplements the modified Friis medium.
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Figure 3.9 Activation of gel filtration-purified porcine plasminogen by tPA (A) and
uPA (B). Plasminogen (1 µg) was incubated with decreasing amounts of activator in
units as listed on the right. Data are from duplicate readings and error bars represent
standard deviation.
To confirm the presence and location of plasminogen/plasmin on the cell surface
of

M.

hyopneumoniae,

immunofluorescence

was

performed

with

anti-M.

hyopneumoniae and anti-plasminogen antibodies. Paraformaldehyde fixed M.
hyopneumoniae strain 232 cells stained with M. hyopneumoniae specific anti-F2P97
serum (Jenkins et al., 2006), resulted in fluorescence on the cell surface, indicating that
the M. hyopneumoniae cells were not lysed (Figure 3.12). Labelling with the antiporcine plasminogen antibody, irrespective of whether the cells were pre-incubated with
porcine plasminogen, was also positive. Cells probed with only anti-rabbit Alexa Fluor
568 antibody (negative control) did not result in significant fluorescence.
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Figure 3.10 One-dimensional SDS-PAGE analysis of gel filtration-purified porcine
plasminogen activation with tPA and uPA over time. (A) Porcine plasminogen was
incubated in the absence (lane 1) or presence with 100 units tPA (lanes 2-6) or in the
presence with 0.025 units uPA (lanes 7-11). (B) Activation of porcine plasminogen in
the absence (lane 1) or presence of 25 mM εACA and 100 units tPA (lanes 2-5), and 25
mM εACA and 0.25 units uPA (lanes 6-9). The time of the digestion (in hours) is
written at the bottom of each lane. Both gels were stained with GelCode Blue.
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Figure 3.11 M. hyopneumoniae cells bind plasminogen/plasmin in modified Friis
medium. Whole cell lysates from M. hyopneumoniae strain 232 cells (lane 1), pig
plasminogen (lane 2), and tPA activated porcine plasminogen (lane 3), were
electrophoresed on a 12% polyacrylamide gel and stained with GelCode Blue. A
duplicate copy of the gel was transferred onto PVDF membrane and probed with antiporcine plasminogen antibodies diluted 1:2000. The arrows indicate the presence of
Lys-heavy chain of plasmin. Molecular mass markers are given on the left.
To further investigate the interaction of M. hyopneumoniae with plasminogen,
M. hyopneumoniae cells were coated onto a microtitre plate, and after blocking of nonspecific binding sites, the cells were incubated with biotinylated gel filtration-purified
porcine plasminogen. M. hyopneumoniae cells bound plasminogen in a dose-dependent
manner (Figure 3.13A). To determine the role of lysine residues in this interaction,
biotinylated plasminogen in the presence of a ten-fold serial dilution of the lysine
analogue εACA, was added to M. hyopneumoniae cells coated onto a microtitre plate.
Almost complete inhibition of plasminogen binding to M. hyopneumoniae cells was
observed in the presence of 1 mM εACA (Figure 3.13B). This suggests that the binding
is specific and that the lysine binding sites in the kringle domains of plasminogen are
involved in the M. hyopneumoniae-plasminogen interaction.
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Figure 3.12 Visualisation of plasminogen/plasmin on the cell surface of M.
hyopneumoniae by fluorescent microscopy. M. hyopneumoniae strain 232 cells were
probed with anti-F2P97 serum (Jenkins et al., 2006) (A), gel filtration-purified pig
plasminogen followed by anti-pig plasminogen IgG antibody (B), anti-pig plasminogen
IgG antibody (C) and donkey anti-rabbit Alexa Fluor 568 as a negative control (D).
Scale bars represent 5 µm.
In order to determine whether M. hyopneumoniae has one or multiple
plasminogen binding receptors, a ligand blot of whole cell lysates from M.
hyopneumoniae cells was probed with biotinylated porcine plasminogen (Figure 3.14).
Several bands were detected and the majority of plasminogen binding to M.
hyopneumoniae was abolished in the presence of 100 mM εACA (Figure 3.14, lane 3).
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Figure 3.13 Binding of biotinylated porcine plasminogen to immobilised M.
hyopneumoniae cells. (A) Freshly cultured M. hyopneumoniae strain 232 cells were
coated on a microtitre plate and incubated with increasing amounts of biotinylated
porcine plasminogen. Bound plasminogen was detected using streptavidin peroxidase.
Absorbance readings were taken at 10 min in triplicate and results are representative of
three independent experiments. Error bars indicate standard error. (B) Inhibition of
biotinylated porcine plasminogen (412.5 nM) binding to immobilised M.
hyopneumoniae cells with increasing amounts of εACA. Bound plasminogen was
detected with streptavidin-peroxidase. Absorbance was read after 45 min of incubation
in the developing substrate. Each sample was performed in triplicate and results were
derived from two independent experiments. The error bars indicate standard error. The
asterisks denote statistically significant (P < 0.05) differences compared to plasminogen
binding observed in the absence of εACA added.

Figure 3.14 Biotinylated plasminogen ligand blot of whole cell lysates from M.
hyopneumoniae cells. Whole cell lysates of M. hyopneumoniae strain 232 cells were
separated by 12% SDS-PAGE under reducing conditions and either stained with
GelCode Blue (1) or transferred onto PVDF membrane and probed with 10 µg/mL
biotinylated plasminogen in the absence (2) or presence of 100 mM εACA (3).
Molecular mass markers are given on the left.

3.2.7

Activation of M. hyopneumoniae-bound Plasminogen
To determine whether M. hyopneumoniae surface-bound plasminogen can be

converted to plasmin, microtitre plates were coated with M. hyopneumoniae cells and
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incubated with plasminogen and tPA. The proteolytic activity was investigated using a
plasmin-specific chromogenic substrate, Spectrozyme PL. The experiments were
performed with both human and porcine plasminogen because it has been reported that
porcine plasminogen is not as readily activated as human plasminogen irrespective of
the origin of the activator (Flight et al., 2006; Nieuwenhuizen and Keyser, 1985). Both
human and porcine plasminogen bound to the cell surface of M. hyopneumoniae were
activated to plasmin by tPA (Figure 3.15A and Figure 3.15B). The titration of tPA
showed that less activator was required for human plasminogen to reach maximal
activation under the experimental conditions than for porcine plasminogen. Porcine
plasminogen activation saturated at approximately 200 units tPA; therefore, this amount
of activator was used to compare between porcine and human plasminogen activation
(Figure 3.15C).
M. hyopneumoniae-bound human plasminogen was activated more readily than
M. hyopneumoniae-bound porcine plasminogen (Figure 3.15). No substrate cleavage
was detected when tPA was excluded from the assay, indicating that M. hyopneumoniae
does not produce its own activator. Minimal activation was seen when the bacteria were
only incubated with tPA, which is most likely the result of M. hyopneumoniae cells
recruiting plasminogen (porcine and horse) from the serum in the modified Friis media
that is used to culture the bacteria.

3.2.8

Degradation of Fibrinogen by Plasmin Coated M. hyopneumoniae
To determine if M. hyopneumoniae surface-bound plasminogen has biological

activity, the ability of M. hyopneumoniae cells coated with plasminogen to degrade
fibrinogen in the presence and absence of tPA was examined. Fibrinogen degradation
was illustrated by immunblots using anti-fibrinogen antibodies (Figure 3.16).
Plasminogen coated M. hyopneumoniae cells were able to degrade full length fibrinogen
in the presence of tPA within 6 h. No fibrinogen degradation was observed in the
absence of an activator and very little degradation occurred when tPA was added to M.
hyopneumoniae cells not incubated with plasminogen. These data demonstrate that M.
hyopneumoniae-bound plasminogen is accessible to activators and can be converted
into the active enzyme plasmin.
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Figure 3.15 Activation of M. hyopneumoniae surface-bound plasminogen to plasmin.
M. hyopneumoniae cells coated onto microtitre plates were incubated with 5 µg porcine
plasminogen (A) or human plasminogen (B). After unbound plasminogen was washed
off, the surface-bound plasminogen was converted to plasmin by the addition of a
saturating amount of tPA, measured by adding plasmin-specific chromogenic substrate
(Spectrozyme PL). The increase in absorbance at 405 nm, over a 5 h incubation with
Spectrozyme PL, is shown in A and B. (C) The percentage of total plasmin activity of
M. hyopneumoniae surface-bound human and porcine plasminogen with 200 U tPA
after 5 h incubation with Spectrozyme PL. Values are calculated as the percentage of
the absorbance after 5 h incubation of the saturation absorbance for human (from (A) or
porcine (B) plasminogen). See Material and Methods for an explanation of how the
saturation absorbance is derived. All data represent the mean values ± the standard error
of two assays carried out in triplicate.
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Figure 3.16 M. hyopneumoniae cells coated with plasminogen can degrade human
fibrinogen in the presence of tPA. M. hyopneumoniae cells were incubated with or
without gel filtration-purified plasminogen, in the presence or absence of tPA, at 37˚C
before incubation with plasminogen-depleted human fibrinogen. M. hyopneumoniae
cells only (lane 1), M. hyopneumoniae cells in the presence of tPA (lane 2), M.
hyopneumoniae cells coated with plasminogen in the absence of tPA (lane 3), M.
hyopneumoniae cells coated with plasminogen in the presence of tPA (lanes 4-7). The
length of the incubation period with fibrinogen is indicated in hours at the bottom of
each lane. The reaction mixtures were separated by 1D SDS-PAGE, transferred onto
PVDF membrane and probed with anti-human fibrinogen antiserum. Molecular mass
markers are on the left.

3.3 Discussion
Recently it was shown that plasminogen is present at the site of M.
hyopneumoniae colonisation in pigs and that there is a significant increase in plasmin
activity in swine BALF 2.5 weeks post M. hyopneumoniae-challenge (Seymour et al.,
2012). These results indicate that M. hyopneumoniae infection affects components of
the PAS in the swine airways. Our results demonstrate that M. hyopneumoniae cells are
capable of capturing plasminogen on their outer surface. The recruitment of
plasminogen to the cell surface of M. hyopneumoniae is not uniform (Figure 3.12),
suggesting the cell surface plasminogen receptors may not be expressed over the entire
cell surface. Multiple plasminogen-binding proteins were detected in plasminogen
ligand blots of whole cell lysates from M. hyopneumoniae cells. Plasminogen binding to
M. hyopneumoniae cells and their whole cell lsyates was significantly inhibited with
εACA, indicating that the M. hyopneumoniae-plasminogen interaction is of both high
affinity and specificity, and that the lysine-binding sites in the kringles of the
plasminogen are primarily responsible for the interaction of plasminogen with M.
hyopneumoniae proteins. A number of the M. hyopneumoniae strain 232 protein
members of the P97 and P102 paralogue families, such as Mhp183 (P97), Mhp184
(P102), Mhp385, Mhp271 and Mhp108 (P116), contain a C-terminal lysine residue.
Mhp684 has a C-terminal arginine residue in M. hyopneumoniae strain 232 and a Cterminal lysine in strain J. Arginine residues can also contribute to plasminogen binding
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(Sanderson-Smith et al., 2007). Recently it was shown that P102 and Mhp108 (P116)
bind plasminogen via their C-terminal lysine(s) (Seymour et al., 2010; Seymour et al.,
2012). A recombinant N-terminal fragment of Mhp107 was also shown to bind
plasminogen via the lysine-binding kringle domains in plasminogen (Seymour et al.,
2011). The next two thesis chapters include the investigation of whether the C-terminal
lysine containing M. hyopneumoniae proteins Mhp271 and Mhp385 are potential
plasminogen binders.
Lysine affinity chromatography was used to isolate native plasminogen from
porcine plasma to investigate M. hyopneumoniae’s interaction with plasminogen.
Porcine IgM co-purified with the plasminogen during the lysine sepharose
chromatography; however, this is not the case with human plasminogen purification
using the same procedure (Martina Sanderson-Smith, personal communication). Gel
filtration of the lysine sepharose-purified porcine plasminogen separated the IgM from
the porcine plasminogen, suggesting that plasminogen and the IgM do not form a
complex. Despite extensive literature searches, no information about the interaction of
plasminogen with IgM was found. Plasminogen does bind to immobilised IgG (Harpel
et al., 1989). Since the interaction of plasminogen with IgM was not the focus of this
work it was not further investigated, but should be considered during the purification of
porcine plasminogen via lysine affinity chromatography.
In the presence of exogenous activator, M. hyopneumoniae surface-bound
plasminogen can be converted into enzymatically active plasmin; however, the
activation of M. hyopneumoniae surface-bound porcine plasminogen was slower than
M. hyopneumoniae surface-bound human plasminogen. Even in the absence of M.
hyopneumoniae, porcine plasminogen was not as readily activated as the commercial
human plasminogen regardless of whether or not IgM was present in the porcine
plasminogen. The activation rate of porcine plasminogen has been shown to be slower
than plasminogens of different mammalian species, such as humans, monkeys, cats,
dogs and rats (Nieuwenhuizen and Keyser, 1985). The activity of porcine plasminogen
appears to be higher when a porcine activator is present; however, the rate of activation,
despite whether the activator is of porcine origin, is still slower than human
plasminogen activation in vitro (Flight et al., 2006; Nieuwenhuizen and Keyser, 1985).
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Flight et al. (2006) used euglobin clot lysis time to measure the activation of porcine
versus human plasminogen by endogenous activators, albeit in vitro; however, the
conditions of their experiment should be suitable for plasminogen conformational
change. In their study, the fibrinogen concentrations of the pig and human plasma were
similar, yet the euglobin clot lysis time for pigs was significantly longer than for
humans. Therefore, the differences in activation rate seen in this study appear to be the
result of the inherent poor activation of porcine plasminogen.
Plasmin coated M. hyopneumoniae is capable of degrading fibrinogen and,
therefore, are likely to participate in the degradation of other ECM components. The
increase in the presence of plasmin activity in BALF during infection (Seymour et al.,
2012), suggests that plasminogen bound to the surface of M. hyopneumoniae is likely to
be activated and may lead to proteolysis of extracellular matrix. Degradation of the
ECM will provide M. hyopneumoniae with the ability to traverse across epithelial
barriers and disseminate within the host. M. hyopneumoniae binds a variety of host
molecules (Bogema et al., 2011; Burnett et al., 2006; Jenkins et al., 2006; Seymour et
al., 2010; Seymour et al., 2011; Seymour et al., 2012; Wilton et al., 2009) that may aid
in bringing M. hyopneumoniae bound-plasminogen/plasmin in contact with the cell
surface and ECM.
M. hyopneumoniae relies on host plasminogen activators, which are tightly
regulated by the PAS, to generate enzymatically active plasmin. Following colonisation
M. hyopneumoniae triggers an inflammatory response that is likely to increase the
activity of the PAS. The main physiological inhibitor of plasmin, α2-antiplasmin, binds
to the lysine binding sites of plasmin (Lahteenmaki et al., 2001). The lysine binding
sites of plasminogen are responsible for the interaction of plasminogen with M.
hyopneumoniae receptors; therefore, M. hyopneumoniae-bound plasmin is likely to be
protected from α2-antiplasmin and consequently host regulation. M. hyopneumoniae
bound-plasminogen may promote or exacerbate the inflammatory response associated
with M. hyopneumoniae infection. Plasmin can stimulate proinflammatory cytokines
and tissue factor expression (Syrovets et al., 2001) and ovalbumin-induced pulmonary
inflammation was significantly lower in the lungs of plasminogen deficient mice
compared to normal mice (Swaisgood et al., 2007). Although an inflammatory response
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is important for removal of pathogens, the inflammatory response induced by M.
hyopneumoniae infection appears to be responsible for the damage that occurs to the
host, such as the typical lesions associated with infection (Tajima et al., 1984).
In summary, the interaction of M. hyopneumoniae with plasminogen potentially
provides the bacteria with numerous mechanisms that enhance survival within the host.
It is not clear what factors influence the movement of bacteria from the initial site of
infection, or what is the purpose of this translocation from the site of infection.
However, such movements may provide a mechanism to avoid immune detection.
Plasmin-coated bacteria can also assist in the degradation of complement,
immunoglobulins and membranes of phagocytes (Coleman and Benach, 1999). Such
interactions may result in an ineffective inflammatory response against M.
hyopneumoniae and enable M. hyopneumoniae to survive longer within the host.
Further study is required to determine the functional significance of the M.
hyopneumoniae interaction with plasminogen. The ability of M. hyopneumoniae to
interact with plasminogen/plasmin is likely to contribute to its pathogenesis and evasion
of the host immune system.
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4. Molecular and Functional Characterisation of the
Repeat Regions R1 and R2 in the P97 Paralogue Mhp271 of
Mycoplasma hyopneumoniae
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4.1 Introduction
M. hyopneumoniae is a ubiquitous and economically significant pathogen of
swine that causes chronic pneumonia, resulting in reduced weight gain and feed
conversion efficiency and increased susceptibility to secondary pathogens. Current
commercial vaccines comprise whole cell bacterin formulations. Although these
vaccines alleviate some losses incurred through retardation of growth rate, they are
costly to produce, provide limited protection against the clinical symptoms of infection
and do not prevent M. hyopneumoniae colonisation (Djordjevic et al., 1997; Fagan et
al., 1996; Thacker et al., 1998; Thacker et al., 2000).
Adherence of M. hyopneumoniae to bronchial and bronchiolar epithelial cilia is
a crucial step in the establishment of infection (Blanchard et al., 1992; DeBey and Ross,
1994). Colonisation of ciliated epithelia elicits ciliostasis and epithelial cell death and
severely compromises mucociliary function (DeBey and Ross, 1994). To prevent
infection it is essential to identify cilium adhesion proteins and understand the processes
that underpin how M. hyopneumoniae adheres to and colonises cilia.
Adherence-blocking mAbs F1B6 and F2G5 played a pivotal role in the
identification of P97 (Mhp183) as an important cilium adhesin of M. hyopneumoniae
(Zhang et al., 1994, 1995). The carboxyl terminus of P97 contains two repeat regions
designated R1 and R2 (Hsu et al., 1997). R1 comprises tandem pentapeptide repeats
with the sequence AAKPV(E), while R2 comprises tandem decapeptide repeats with the
sequence GTPNQGKKAE (Hsu et al., 1997). Apart from the number of repeats in R1
and R2, the amino acid sequences of P97 in different strains of M. hyopneumoniae are
highly conserved (Jenkins et al., 2006; Stakenborg et al., 2006; Wilton et al., 1998).
The number of repeats within the repeat regions is not known to change with passage in
vitro, suggesting that selective pressure from the host immune system may be
responsible for the variation seen between strains (de Castro et al., 2006; Stakenborg et
al., 2006; Wilton et al., 1998). R1 is the cilium binding region of P97 (Hsu and Minion,
1998a; Minion et al., 2000). MAbs F1B6 and F2G5 recognise a minimum of three R1
tandem repeats (Hsu and Minion, 1998a; Minion et al., 2000). For P97 to bind porcine
cilia, a minimum of eight pentapeptide tandem repeats in R1 are required (Minion et al.,
2000); however, colony isolates of M. hyopneumoniae strain 232A with identical P97
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sequences display different binding affinities for porcine cilia (Hsu and Minion, 1998a).
Despite the importance of the R1 region in P97, adherence to ciliated respiratory
epithelia is a multifactorial process that also involves adhesins that lack R1 (Burnett et
al., 2006; Jenkins et al., 2006; Wilton et al., 2009; Zhang et al., 1995).
A function for the R2 region of P97 in binding cilia has not been established but
both R1 and R2 are required for binding the sulfated GAG heparin (Jenkins et al.,
2006). GAGs sensitive to heparinase are prevalent at the surface of cilia and microvilli
of porcine airway epithelial cells (Erlinger, 1995). M. hyopneumoniae expresses many
heparin-binding proteins, several of which have recently been characterised and shown
to reside on the cell surface (Burnett et al., 2006; Jenkins et al., 2006; Wilton et al.,
2009). Furthermore, heparin inhibits the adherence of M. hyopneumoniae to cilia and to
PK15 cell monolayers (Burnett et al., 2006; Zhang et al., 1994). Consequently, heparinbinding surface proteins of M. hyopneumoniae are likely to play important roles in the
colonisation of ciliated respiratory epithelia.
Bioinformatic analyses of M. hyopneumoniae genome sequences derived from
strains 232, J and 7448 identified six P97 paralogues in each genome. Most of these P97
paralogues are found in two-gene operons with paralogues of P102 (Mhp182) and are
transcribed during infection (Adams et al., 2005). Mhp271, a paralogue of P97, also
contains R1 and R2 repeats, though very little attention has been given to this protein.
Mhp271 is the only other protein in the proteome of M. hyopneumoniae that displays
both R1 and R2 repeats. The aim of this study is to assess the function of the R1 and R2
regions within Mhp271.

4.2 Results
4.2.1

Sequence Analysis of Mhp271
mhp271 encodes a P97 paralogue with a theoretical molecular mass of 118.8

kDa and a pI of 9.11. Sequence analysis of Mhp271 using the combined transmembrane
topology and signal peptide predictor program Phobius predicted a putative
transmembrane region between residues 12-34 and no signal peptide. The TMHMM
Server v. 2.0 also identified the same putative transmembrane domain (probability:
0.99893). mhp271 comprises an operon with mhp272, which encodes a P102 paralogue.
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Both are co-transcribed during infection of the porcine respiratory tract (Adams et al.,
2005). A putative Shine-Dalgarno sequence (5’-GGAGG-3’) was identified within the
20 nucleotides separating mhp271 and mhp272.
A BLAST search of Mhp271 against the protein databases at NCBI showed that
Mhp271 has highest identity with P97 (Mhp183) (51% identity; 65% similarity).
Outside the M. hyopneumoniae genome, Mhp271 shares significant similarity (Expect <
1e-09) with a number of Mycoplasma conjunctivae proteins. These include:
hypothetical proteins MCJ_005100, MCJ_004150, MCJ_004230, MCJ_003150, and
MCJ_004240 and the adhesin LppS lipoprotein (MCJ_004030). This finding highlights
the presence of a paralogue family in M. conjunctivae that shares sequence similarity
with the P97 paralogue family from M. hyopneumoniae.
Two R1 regions, designated here as R1A271 and R1B271 and an R2 region,
designated R2271, (Figure 4.1A) were found in the C-terminus of Mhp271. A noteworthy
feature of these repeats is the significant similarity they have with domains found in
swine proteins. A BLAST search of the repeat regions against the NCBI non-redundant
protein sequences database, revealed that the R1 pentapeptide repeat shows substantial
similarity to the repeats within the C-terminal region of porcine collagen type VI (α3
isoform) (accession number XP_001928122.1) (Figure 4.1B), while the R2 decapeptide
repeat is almost identical to a decapeptide motif repeated 54 times in the N-terminus of
porcine KIAA1398 protein (accession number XP_001926148.1), also known as
ribosome-binding protein 1 or p180 (Figure 4.1C).
4.2.2

Mhp271 is Conserved Among Strains of M. hyopneumoniae
Alignment of Mhp271with homologues derived from the genome sequences of

strains J (MHJ_0105) and 7448 (MHP7448_0108) revealed 99% identity (100%
similarity) over the first 337 amino acids (Figure 4.2A). As with inter-strain
comparisons of P97 sequences (de Castro et al., 2006; Wilton et al., 1998), most of the
sequence variation among homologues of Mhp271 occurred within the repeat regions,
in particular R1B271 and R2271 (Figure 4.2). To further investigate the level of variation
in the repeat regions the C-terminal of Mhp271, homologues from M. hyopneumoniae
field strains 00MP1301, 95MP1509 and 2-22421 were sequenced. These sequences also
93

showed differences within the repeat regions R1B271 and R2271 (Figure 4.2).
Homologues from all strains displayed three R1 repeats that exhibited little sequence
variation within R1A271; however, the number of R1 repeats in R1B271 ranged from
three to eight. Eight tandem R1 repeats are considered sufficient for binding cilia
(Minion et al., 2000). The Mhp271 homologue from strain 95MP1509 displayed eight
tandem R1 repeats in R1B1509; thus, this region is a potential porcine cilial binding
domain. The number of R2 reiterated repeats in R2271 is the same for all strains except
00MP1301, which is missing one of the two repeats.

Figure 4.1 Location of the R1 and R2 regions in Mhp271. (A) Schematic representation
of Mhp271 and recombinant constructs, F1271 and F2271, used for binding studies. The
numbers above represent amino acid positions within Mhp271. The molecular mass of
each recombinant does not include the 4.1 kDa vector N-terminal 6xHis-tag. The
asterisks indicate the presence of a TGA codon. (B) Amino acid sequence alignment of
R1B271 with porcine collagen type VI (α3 isoform 5) and (C) amino acid sequence
alignment of R2271 with swine protein KIAA1398. Shading represents shared sequence
identities. Numbers refer to location of the residues within the proteins.
Tandem repeats of the amino acids ‘TN’ occur in P97 immediately after the R1
repeat region (de Castro et al., 2006; Wilton et al., 1998), which is an endoproteolytic
cleavage site that separates R1 from a 28 kDa C-terminal fragment containing R2
(Djordjevic et al., 2004). In Mhp271, a serine rich region is found directly after R1A271
and no tandem repeats are present either side of R1B271. The significance of this is
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unknown but may suggest this region of Mhp271 is not subjected to the same cleavage
that occurs in the C-terminal region of P97.

Figure 4.2 Alignment of sections of Mhp271 amino acid sequence with homologues
from M. hyopneumoniae strains. (A) Alignment of the amino terminal region amino
acid sequences from Mhp271 (strain 232) and homologues in M. hyopneumoniae strains
J (MHJ_0105) and 7448 (7448_0108). The numbers above the sequences refer to amino
acid positions in Mhp271. Residues conserved in all proteins are shaded in black, while
amino acids shared by two sequences are shaded in grey. (B) Alignment of the carboxyl
region amino acid sequence from Mhp271 (strain 232) and homologues in M.
hyopneumoniae strains J and 7448 and field strains 00MP1301, 95MP1509 and 222421. The partial gene sequences of the Mhp271 homologues in field strains
00MP1301, 95MP1509 and 2-22421 were deposited in the GenBank database under
accession numbers HM135103, HM135102 and HM135104, respectively. The numbers
above the sequences refer to amino acid positions in Mhp271. Residues conserved in all
proteins are shaded in black, while amino acids shared by five or four sequences are
shaded in dark or light grey, respectively. Dashes represent gaps.
95

4.2.3

Characterisation of the Repeat Regions of Mhp271
Two regions of Mhp271 (F1271 and F2271) were cloned and expressed as 6xHis-

tagged fusion proteins (Figure 4.1A). Since neither R1 region contains the number of
R1 repeats sufficient for binding cilia, F1271 was designed to encompass R1A271, and
F2271 to include both R2271 and R1B271 to mimic the C-terminal recombinant protein
F2P97 that binds heparin (Jenkins et al., 2006). Both F1271 and F2271 migrated during 1D
SDS-PAGE with masses close to their predicted values of 20 and 21 kDa, respectively
(Figure 4.3A).
The presence of mRNA transcripts of mhp271 from M. hyopneumoniae infected
pigs suggests that Mhp271 is expressed in vivo (Adams et al., 2005). Also, mhp271 was
up-regulated during heat shock (Madsen et al., 2006) confirming its transcription in
cells growing in vitro. Therefore, various proteomic strategies were employed to
characterise the expression of Mhp271 in cells growing in vitro. To examine the
expression of Mhp271 in M. hyopneumoniae cells, we first attempted to identify the
protein by immunoblotting. Rabbit polyclonal antiserum was raised against recombinant
F2271, and as expected, anti-F2271 serum not only detected F2271 but also recognised
F1271 and both GST- and 6xHis-tagged versions of F2P97 (a recombinant fragment of
P97 containing R1 and R2 repeat regions) (Figure 4.3A). Monoclonal antibodies to the
R1 region, F2G5 and F1B6, recognise a minimum of three tandem pentapeptide repeats
(Hsu and Minion, 1998a; Minion et al., 2000). MAb F1B6 detected F2271 and F2P97 but
did not recognise F1271. This may be because a number of residues in F1271 differ
compared to the mAb-reactive amino acid sequence shown in the study by Minion et al.
(2000) (Figure 4.3B).
Rabbit anti-F2271 serum was then tested for its ability to identify Mhp271 in
whole cell lysates from M. hyopneumoniae cells. Immunoblot patterns generated using
rabbit anti-F2271 serum predominantly recognised P97 and the P97 post-translational
endoproteolytic cleavage fragment P70 in whole cell lysates from M. hyopneumoniae
strain 232 cells (P94 and P66 in cell lysates of M. hyopneumoniae strain J cells) (Figure
4.3C) (Djordjevic et al., 2004). The pattern was not as complex as that generated in
identical blots of whole cell lysates from M. hyopneumoniae strains 232 and J cells
probed with anti-F2P97 serum. Strongly reactive proteins with masses ~ 26-30 kDa were
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notably absent. These proteins include the C-terminal 28 kDa cleavage fragment of P97
which contains R2 but not R1 (Djordjevic et al., 2004), and this was confirmed by
probing identical blots with anti-R2P97 serum (see arrowheads Figure 4.3C). Consistent
with this interpretation, anti-R2P97 reactive proteins with masses ~ 26-30 kDa were not
recognised by mAb F1B6 (Figure 4.3C). Collectively, our immunoblotting studies
confirmed that i) we could not reliably identify Mhp271 in 1D immunoblots because
anti-F2271 serum cross-reacted with major P97 proteins (P97 and P70); ii) anti-F2271
serum does not detect R2-containing cleavage fragments of P97; and iii) anti-F2271
serum is unable to recognise the complex pattern of proteins recognised both by F1B6
or anti-F2P97 antibodies. Interestingly, immunoblots probed with anti-F2P97, F1B6 and
anti-R2P97 sera show that P94 is more readily cleaved to P66 and P28 in strain J
compared to strain 232 (see asterisks and arrowheads in Figure 4.3C). This suggests that
the degree of proteolytic cleavage of the cilium adhesin also varies between strains,
supporting earlier 2DGE studies of adhesin cleavage products (Djordjevic et al., 2004).
Following our failure to identify Mhp271 by 1D immunoblots, and the lack of
success in finding Mhp271 by peptide mass fingerprinting (PMF) of M. hyopneumoniae
whole cell lysates and aqueous phase TX-114 protein extract from M. hyopneumoniae
cells (S. P. Djordjevic, personal communication), a hybrid approach combining 1D
SDS-PAGE and LC-MS/MS was employed to find Mhp271. A SDS-polyacrylamide gel
of an aqueous phase TX-114 protein extract of M. hyopneumoniae strain 232 cells was
horizontally sliced into sections. Each section was in-gel trypsin digested and subjected
to LC-MS/MS analysis. Mhp271 was detected in gel slices B and C (Figure 4.3D). Four
peptides unique to Mhp271 were identified in gel slice B (Figure 4.4), which were
manually validated (Table 9.1), and one peptide was found in gel slice C (Figure 4.4)
(Mascot ion score of 97, Table 9.2). Peptides unique to P97 were also found in gel
slices B and C (Table 9.3). Gel slice B approximately covers proteins that migrated with
a molecular mass of 95 to 115 kDa and slice C approximately covers proteins that are
75 to 95 kDa. These size ranges suggest that full-length Mhp271 is expressed and that it
is also cleaved to form a slightly smaller protein. Interestingly, Mhp271 has the same
amino acid sequence as the P97 endoproteolytic cleavage site at amino acid 195
(TNF↓AD) (Djordjevic et al., 2004; Hsu et al., 1997) (Figure 4.5), suggesting that
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Mhp271 may also be cleaved at this site (between amino acids 197 and 198) resulting in
a protein with a theoretical molecular mass of 96.6 kDa.

Figure 4.3 Immunoblot analyses comparing the reactivity of anti-F2271 and anti-F2P97
sera and mAb F1B6 ascites fluid. (A) Cross reactivity of anti-F2271 and anti-F2P97
(Jenkins et al., 2006) sera and mAb F1B6 (Zhang et al., 1995) ascites fluid with
recombinant fragments of Mhp271 and P97. Recombinant 6xHis-tagged F2P97 (Jenkins
et al., 2006) contains nine R1 repeats and five R2 repeats. The cross denotes that the
recombinant protein is GST-tagged, otherwise all recombinant proteins are 6xHistagged. (B) Alignment of the amino acid sequence reported to bind mAb F2G5 with
R1A271 and R1B271. The cross indicates that the sequence was from Minion et al.
(2000). Residues sharing identity with all amino acid sequences are shaded in black.
Residues shared by four amino acid sequences are shaded in grey. Dashes represent
gaps. (C) Reactivity of anti-F2271, anti-F2P97, mAb F1B6 and anti-R2P97 (Djordjevic et
al., 2004) sera or ascites fluid against whole cell lysates from M. hyopneumoniae strains
232 and J cells. Proteins were resolved on 12% SDS-polyacrylamide gels. The stars
indicate P97 (232) and P94 (J) proteins. The arrows indicate cleavage fragments
resulting from the removal of the R2-containing C-terminal 28 kDa fragment from
P97/P94 generating P70 (232) and P66 (J) as described by Djordjevic et al. (2004). (D)
One-dimensional SDS-polyacrylamide (15%) gel of a TX-114 aqueous phase protein
extract prepared from M. hyopneumoniae strain 232 cells that was sliced, trypsin
digested and analysed by LC-MS/MS. Peptides unique to Mhp271 were found in gel
slices labelled B and C.
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To determine the cell location of Mhp271 we combined proteolytic shaving of
freshly cultured M. hyopneumoniae strain J cells with 2D LC-MS/MS analysis. Firstly
the expression of the J strain homologue of Mhp271 (MHJ_0105) was determined via
2D LC-MS/MS analysis of the whole M. hyopneumoniae strain J proteome. Five
peptides unique to MHJ_0105 were identified (Figure 4.4). One of these peptides had a
Mascot ion score of 67 while the remaining four were manually validated. These were
found to have a sufficient number of fragment ions reflecting the peptide sequence
(Table 9.4). Since this method was successful for identifying MHJ_0105, proteolytic
shaving of M. hyopneumoniae strain J cells followed by 2D LC-MS/MS analysis was
performed. Analysis of the released tryptic peptides identified one unique peptide
(Mascot ion score of 93, Table 9.5) that matched to the C-terminal sequence of
MHJ_0105 (Figure 4.4). No peptides matching to MHJ_0105 were found in the proteins
shed from the cells that had not undergone trypsin treatment. These observations
indicate that MHJ_0105 is translated in cells growing in vitro and that it is located on
the surface of M. hyopneumoniae cells.
4.2.4

F2271 Binds Heparin
Heparan sulfate and the chemically related heparin have been suggested as

receptors for M. hyopneumoniae. M. hyopneumoniae cells bind heparin (Burnett et al.,
2006), heparin significantly inhibits M. hyopneumoniae adherence to cilia (Zhang et al.,
1994) and heparan sulphate proteoglycans sensitive to heparinase are found along
respiratory cilia (Erlinger, 1995). Ligand dot blots showed that F2271 and the positive
control protein F2P97, but not F1271, bound biotinylated heparin (Figure 4.6A). Saturable,
dose-dependent binding of biotinylated heparin to immobilised F2271 was observed in
microtitre plate binding assays. Consistent with dot blot experiments, F1271 failed to
bind heparin in plate binding assays (Figure 4.6B). Inhibition assays with a saturating
amount of unlabelled heparin showed that F2271 displayed strong binding affinity for
heparin (KD = 8.1 ± 0.4 nM) (Figure 4.6C).
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Figure 4.4 Tryptic peptides unique to Mhp271 or its homologue in J strain (MHJ_0105)
identified by 1D SDS-PAGE combined with LC-MS/MS and 2D LC-MS/MS analysis,
respectively. Peptides unique to Mhp271 from gel slices B and C (Figure 4.3D) of an
aqueous phase TX-114 extract of M. hyopneumoniae strain 232 cells identified by LCMS/MS are in bold and underlined. Peptides unique to MHJ_0105 from 2D LC-MS/MS
of M. hyopneumoniae strain J proteome are in bold and italicised. The single peptide
identified by 2D LC-MS/MS after shaving M. hyopneumoniae strain J cells with trypsin
is in bold and boxed. F1271 and F2271 are shaded in dark and light grey, respectively. A
dot or asterisk indicates that the amino acids from both strains are identical or different,
respectively. The arrow indicates a potential endoproteolytic cleavage site.
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Mhp183 : --MSKKSKTFKIGLTAGIVGLGVFGLTVGLSSLAKYRSESPRKIANDFAAKVSTLAFSPYAFETDSDYKIVKRWL :
Mhp271 : MSKLTKSKTFKIGLVGSIIGLGVFGLTVGLSSLAKYRSEHPRKVVNDFATKVSTLSFSPDAFFANSDYWTIKNHL :

73
75

Mhp183 : VDSNNNIRNKEKVIDSFSFFTKNGDQLEKINFQDPEYTKAKITFEILEIIPDDVNQNFKVKFQALQKLHNGDIAK :
Mhp271 : LDSKNQIKNSEKVLKSFSFFSKNGDQLEKINLEDPEYKNAGISFHILEIIPDDVNQNFKVKFQLWQKFANGDIAK :

148
150

Mhp183 : SDIY-EQTVAFAKQSNLLVAEFNFSLKKITEKLNQQIENLSTKITNFAD------EKTSSQKDPSTLRAIDFQYD :
Mhp271 : SDIYQEESVAFIKQSNLLVAEFNFSLKKITDKLNQQVGNLSLKSTNFADDLAKLTKPTSSYKNPASFRVLDFQED :

216
225

Mhp183 : LNTARNPEDLDIKLANYFPVLKNLINRLNNAPENKLPNNLGNIFEFSFAKDSSTNQYVSIQNQIPSLFLKADLSQ :
Mhp271 : LNQARNSEELVKKLAIYFPSLDNLITKLNESSENKLPGNSGHIFEFSLRKSQATNQYVSVQNQIPFLFLEADLSQ :

291
300

Mhp183 : SAREILASPDEVQPVINILRLMKKDNSSYFLNFEDFVNNLTLKNMQKEDLNAKGQNLSAYEFLADIKSGFFPGDK :
Mhp271 : SARDLIGQDFNFRPIVSSIKLQKQDNSSYFLDFNQFLGNLKLKDISKTDFNEQGLKTSAYEILSTIRSGFFDNND :

366
375

Mhp183 : RSSHTKAEISNLLNKKENIYDFGKYNGKFNDRLNSPNLEYSLDAASASLDKKDKSIVLIPYRLEIKDKFFADDLY :
Mhp271 : LRSDQAKESINKILKNKIKFDFGKLDAIFSDKGNSESLQYYLDVKKASLDKTDKSTILIPFRLKVDESFFKTSTN :

441
450

Mhp183 : PDTKDNILVKEGILKLTGFKKGSKIDLPNINQQIFKTEYLPFFEKGKEEQAKLDYGNILNPYNTQLAKVEVEALF :
Mhp271 : -LPENIIARKDGIFKLTGFDQGLNNQLPKINQEIYKTKYLSFFEKGKENQDLVDFGSEPINGPLLISKVEADALF :

516
524

Mhp183 : KGNKNQEIYQALDGNYAYEFGAFKSVLNSWTGKIQHPEKADIQRFTRHLEQVKIGSNSVLNQPQTTKEQVISSLK :
Mhp271 : KENKPEAIHKVLETNYNYQFNPYQSLLDSWTGNLVQPKLENIKALN-------------ENEKAAVSEAGIAEIL :

591
586

Mhp183 : SNNFFKNGHQVASYFQDLLTKDKLTILETLYDLAKKWGLETNRAQFPKGVFQYTKDIFAEADKLKFLELKKKDPY :
Mhp271 : SRDFFLDGHQVASFYQDLLTKDRLTVIETLYELGKKWGLHTNTANFPRWKFRNAKNIFEEATQYKFLLGKKGKEN :

666
661

Mhp183 : NQIKEIHQLSFNILARNDVIKSDGFYGVLLLPQSVKTELEGKNEAQIFEALKKYSLIENSAFKTTILDKNLLEGT :
Mhp271 : --FRKITKLTFNGLYRNEKGQ--GFYATLVLPKEIKDKLANKTDAEVFAELKKHSLIDSSGFKTINIDKNLLEGE :

741
732

Mhp183 : DFKTFGDFLKAFFLKAAQFNNFAPWAKLDDNLQYSFEAIKKGETTKEGKREEVDKKVKELDNKIKGILPQPPAAK :
Mhp271 : DFENFGDLLKAFFLKAAQFNNFAPWAKLDDNLKYSFVPKK-GDQEKEGKKAEIDKKVKELTDKIS---------- :

816
796

Mhp183 : PEAAKPVAAKPETTKPVAAKPEAAKPEAAKPVAAKPEAAKPVAAKPEAAKPVAAKPEAAKPVAAKPEAAKPVATN :
Mhp271 : -----------------------------------------------SPGSVLPKSEAGKPVAAKPEAAKPSSST :

891
824

Mhp183 : TGFSLTNKPKEDYFPMAFSYKLEYTDENKLSLKTPEINVFLELVHQSEYEEQEIIKELDKTVLNLQYQFQEVKVT :
Mhp271 : TSSVSSASLEGNYLPISFEFKLSYRDGAKSELKTPEIKVFLELQTDKDYQENKIIKELDKTVLELQSEFKEWRLD :

966
899

Mhp183 : SDQYQKLSHPMMTEGSSNQGKKSEGTPNQGKKAEGAPNQGKKAEGTPNQGKKAEGAPSQQSPTTELTNYLPDLGK : 1041
Mhp271 : ESAFSSLTFPKSQ--------KSEGTQNQGKKAEGAPNQSKKSEENSNK----------------LTEYIQELGT : 950
Mhp183 : KIDEIIKKQGKNWKTEVELIEDNIAGDAKLLYFILRDDSK----------------------------------- : 1081
Mhp271 : KVEKSLKSKGKNYSAEVEKIIEAFSGGYKFLDFALVEQTPKPETPKTEAAKPETTKPVAARPEAAKVAAKPSAAK : 1025
Mhp183 : ---SGDPKKSSLKVKITVKQSNNNQEPESK : 1108
Mhp271 : PVSSPAPKKSTLYVRVLIRKKENKQVK--- : 1052

Figure 4.5 Amino acid sequence alignment of Mhp271 and Mhp183 (P97). Shaded in
black are identical amino acids. Similar amino acids are shaded in grey. The arrow
indicates the endoproteolytic cleavage site at amino acid 195 in P97.
Competition binding experiments with the sulfated polysaccharides fucoidan,
mucin, chondroitin sulfates A and B and unlabelled heparin showed that unlabelled
heparin and fucoidan inhibit the binding of biotinylated heparin to F2271 (Figure 4.6D).
Both fucoidan and heparin contain a higher level of sulfation compared to chondroitin
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sulfate A and B and mucin, suggesting that the degree of sulfation is important in
mediating F2271 binding to heparin.

Figure 4.6 F2271 binds heparin. (A) Dot blot of F1271, F2271 and positive control, F2P97
(Jenkins et al., 2006), proteins stained with amido black or probed with biotinylated
heparin. (B) Binding curves of biotinylated heparin to F1271 (●) and F2271 (■)
immobilised on a microtitre plate. (C) Biotinylated heparin binding curves for F2271
showing total binding (■), non-specific binding (●) and specific binding (□). (D)
Competitive-binding assays for F2271 with biotinylated heparin and various unlabelled
sulfated polysaccharides: heparin (●), fucoidan (■), porcine mucin type II (○),
chondroitin sulfate A (x) and chondroitin sulfate B (□). All data represent the mean and
standard error of triplicate readings, except in C where the data represent the mean and
standard error of triplicate readings from two independent experiments (n = 6).
4.2.5

F2271 Binds Fibronectin
During colonisation of the porcine respiratory tract, M. hyopneumoniae is likely

to encounter various ECM components, such as fibronectin. A common feature of many
fibronectin-binding molecules in Gram-positive bacterial pathogens is the presence of
proline-rich repeat regions (Joh et al., 1999). In addition, porcine collagen VI (α3
chain), which shares considerable sequence identity between the R1 repeat of Mhp271,
is a known fibronectin-binding protein (Sabatelli et al., 2001). To determine whether
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Mhp271 is a fibronectin-binding protein, ligand dot blots and microtitre plate binding
assays were employed (Figure 4.7A and B). F2271 bound soluble fibronectin in a dosedependent manner in both ligand dot blots and microtitre plate binding assays. No
binding was observed with F1271. To complement these data with more detailed
quantitative kinetic analysis, F1271 and F2271 binding interactions were also examined in
real-time by SPR. No interaction was detected when F1271 was passed over immobilised
fibronectin; however, F2271 bound to immobilised fibronectin, in a dose-dependent
fashion (Figure 4.7C). To calculate the association rate constant (ka) representative of
the molecular interaction between fibronectin and F2271 and the dissociation constant
(KD), increasing concentrations of F2271 were allowed to associate with the immobilised
fibronectin (Figure 4.7D). The binding of the F2271 was evaluated using a heterogeneous
binding model. The specific dose-dependent binding component that describes binding
of F2271 to immobilised fibronectin was characterised by a second-order rate constant ka
= (4.8 ± 0.8) x 105 M-1 s-1 and a KD of 174 ± 13 nM. Both of these values are consistent
with expectations for a specific, moderately-strong interaction between proteins of this
size.
4.2.6

F2271 Binds Porcine Plasminogen
In the previous chapter it was shown that plasminogen binds to the surface of M.

hyopneumoniae cells. Both accessible C-terminal and internal lysine residues of
bacterial cell surface proteins have been described as binding sites for the kringle
domains of plasminogen. The presence of a C-terminal lysine residue in Mhp271,
included in the construction of the recombinant protein F2271, prompted the
investigation as to whether F1271 and F2271 bind porcine plasminogen. SPR
spectroscopy was carried out by flowing F1271 and F2271 over porcine plasminogen
immobilised on a sensor chip (Figure 4.8A). As expected no binding was observed with
F1271. A dose-dependent response was observed with 100 and 200 nM F2271, although
the maximum response value (RUmax) with 200 nM (16 RUs) was not high compared to
positive control P42 (Seymour et al., 2012); a RUmax of approximately 105 RUs was
recorded when 200 nM of P42 was flowed over the chip, ensuring that the immobilised
plasminogen is in a conformation capable of binding proteins.

103

Figure 4.7 F2271 binds fibronectin. Dot blot of F1271 and F2271 protein stained with
amido black or probed with fibronectin (Fn) or rabbit anti-fibronectin antibody only
(control blot). (B) Binding of fibronectin to immobilised F1271 (○) and F2271 (■) proteins.
Data represent the means and standard errors of the results from triplicate readings per
ligand. (C) SPR sensorgram of F1271 and F2271 interacting with fibronectin. 100 nM of
each protein was injected at a flow rate of 10 µL/min for 600 s over immobilised
fibronectin. The arrow indicates the end of protein injection, at which stage the
dissociation phase was monitored for 900 s by allowing buffer to flow over the chip.
The difference between the experimental and control flow cell is shown in resonance
units (RU). (D) SPR analysis of interactions of F2271 with fibronectin. Increasing
concentrations of the F2271 protein (10, 20, 50, 100, 200, 500 nM) were injected at a
flow rate of 10 µL/min for 600 s over immobilised fibronectin. The arrow indicates the
end of protein injection, at which stage the dissociation phase was monitored for 1800 s.
A representative experiment out of two experiments performed on separate days is
shown.
To investigate the interaction of F2271 with plasminogen, various concentrations
of F2271 were passed over the plasminogen immobilised chip (Figure 4.8B). A
heterogeneous surface model was applied to the association data. The fast rate constant
was essentially too fast for the Biacore to measure (half lives of a few seconds at most);
however, the fast-on and fast-off interaction were linearly dependent on ligand
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Figure 4.8 Porcine plasminogen binding studies with F1271 and F2271. (A) SPR
sensorgram of F1271, F2271 and P42 (positive control) (Seymour et al., 2012) interacting
with porcine plasminogen. Each protein (100 and 200 nM) was injected at a flow rate of
10 µL/min for 600 s over immobilised porcine plasminogen. (B) SPR analysis of F2271
with plasminogen. Increasing concentrations of the F2271 protein (from bottom to top 5,
10, 20, 50, 100, 200, 500 nM) were injected at a flow rate of 10 µL/min for 600 s over
immobilised plasminogen. A representative experiment out of two experiments
performed on separate days is shown. The arrows indicate the end of protein injection,
at which stage the dissociation phase was monitored for 1000 s by allowing buffer to
flow over the chip. The difference between the experimental and control flow cell is
shown in resonance units (RU).
concentration but analysing the rate constants to give the second-order ka was not
reliable. The slow rate constants are dose dependent, more-or-less linearly; linear
regression gives ka = (9 ± 3) x 103 M-1 s-1. The RUmax corresponding to the fast and slow
rates were plotted against the concentration of the analyte (protein flowed over the chip)
and fitted using a one-site specific binding algorithm to produce a KD for the fast rate of
128 ± 11 nM, and a RUmax of 18 ±1 RU (65% of binding), and for the slow rate a KD of
48 ± 10 nM and RUmax of 10 ± 1 RU (35%). Considering Rmax is approximately 160 RU
for F2271 taking into account the amount of plasminogen immobilised, the level of
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binding is rather low. This suggests that F2271 is not an efficient plasminogen-binder,
perhaps due to F2271 rapidly associating and dissociating from the plasminogen.
4.2.7

F2271 Binds Porcine Cilia
Although R1A271 and R1B271 do not contain the requisite number of R1 repeats

considered sufficient to bind cilia we explored the possibility that F1271 and F2271
interact with porcine cilia. A cilia microtitre plate based assay as described by Zhang et
al. (1994), showed that F2271 but not F1271 significantly bound immobilised cilia (Figure
4.9). F2P97, which contains R1 and R2 regions previously shown to bind cilia (Jenkins et
al., 2006), was used as a positive control. To determine if this interaction was specific
for heparin-like GAG moieties known to exist on the surface of cilia (Erlinger, 1995),
an inhibition adherence assay was performed using an amount of heparin determined to
be saturating in earlier heparin-binding assays (Figure 4.9). Heparin significantly (P <
0.05) reduced both F2271 and F2P97 adherence to cilia by 68.8% and 38.4%, respectively.

Figure 4.9 F2271 binds to swine cilia. Recombinant proteins F1271, F2271 and positive
control, F2P97 (Jenkins et al., 2006), were added to swine cilia immobilised on microtitre
plates. Bound proteins were detected using polyclonal antiserum raised against the
respective recombinant protein. In the case of F1271, anti-F2271 serum was used. Proteins
were either incubated with (white bars) or without (black bars) heparin prior to being
added to the cilia. Each bar represents the mean response above background plus the
upper standard deviation from two independent experiments. Bars marked with an
asterisk represent results that are significantly different (P < 0.05) from background. A
cross denotes a significant difference (P < 0.05) in binding when the protein was
incubated with heparin compared to the without heparin adherence value.

4.3 Discussion
The R1 and R2 repeat regions in the C-terminus of P97 have been extensively
studied. Mhp271 carries two R1 domains separated by a single R2 domain but the
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number of tandem R1 repeats is insufficient to promote cilium binding. Here we show
that F2271, with two copies of GT(A)PNQG(S)KKA(S)E in R2 followed by only six
tandem copies of the AAKPV(E) pentapeptide repeat in R1, bind heparin, fibronectin
and porcine cilia. These observations suggest that in the absence of a minimum of eight
R1 repeats, an R2 domain located in close proximity to R1 may function to assist in
binding porcine cilia. We cannot, however, rule out the possibility that Mhp271 adopts
a 3D structure in vivo that alleviates a strict requirement for eight tandem R1 repeats.
Both R1A271 and R1B271 repeat regions in Mhp271 contain multiple proline residues.
The bulkiness of the proline side chain and replacement of the amide proton by a
methylene group disrupts α-helix and β-sheet formation, creating regions with intrinsic
disorder and flexibility (Macarthur and Thornton, 1991; Williamson, 1994). Regions
within proteins displaying intrinsic disorder are important as hubs for protein-protein
interactions (Dunker et al., 2005; Patil and Nakamura, 2006) and this may be critical to
the ability of Mhp271 to bind host molecules. The possibility that cilium binding
domains of unknown sequence exist within the confines of F2271 or in regions within
Mhp271 cannot be excluded.
The R1 and R2 regions exhibit amino acid sequence homology with swine
proteins. R1 shares sequence similarity to collagen type VI, a fibronectin-binding
protein (Figure 4.1B); however, the function of the R1-region in collagen VI is
unknown. Unlike the R1 region, function(s) for the R2 region in P97 have not been well
defined. Cumulative evidence suggests that an R2 domain, in conjunction with R1,
plays an important role in pathogenesis since it is required for binding GAGs such as
heparin (Jenkins et al., 2006). Here we show that R2 repeats in Mhp271 and in P97 bear
striking homology to a large reiterated-repeat region found in the N-terminus of
KIAA1398 (also known as ribosomal binding protein 1 or p180), an integral membrane
protein found in the endoplasmic reticulum of higher vertebrates (Figure 4.1C). Within
KIAA1398 the R2 repeat region is a ribosome-binding domain (Wanker et al., 1995)
and is also the region that interacts with human cytomegalovirus (HCMV) to facilitate
intracellular transport of HCMV capsids (Ogawa-Goto et al., 2002). A microtubule
binding domain lies downstream of the R2 repeat region in p180. Microtubule bundling
is pronounced when part of the R2-like region is available (Ogawa-Goto et al., 2007).
These observations suggest that R1 and R2 may be sites for interactions with different
eukaryotic proteins, or may represent molecular mimicry of host proteins. The
107

biological significance of the repeats matching eukaryote protein sequences requires
investigation; however, the presence of repeat regions sharing homology with structural
eukaryote proteins is not uncommon in Mycoplasma adhesins (Baseman et al., 1996;
Dallo et al., 1996).
Sequence comparisons between Mhp271 and homologues in strains J and 7448,
show that apart from the repeat regions, these proteins are highly conserved. Protein
sequence analyses of the C-terminal region of Mhp271 of three additional field strains
(00MP1301, 95MP1509 and 2-22421) also demonstrate that the number of repeats in
R2271 and R1B271 vary (Figure 4.2B). This pattern of sequence conservation among
important adhesion molecules, but with variation in the number of repeats, has been
previously reported (de Castro et al., 2006; Stakenborg et al., 2006; Wilton et al., 1998)
and may reflect strains with different binding avidities for target receptors. It is
interesting that the field strain 95MP1509 is more virulent compared to strain
00MP1301 (Strait et al., 2008). Compared to strain 95MP1509, the Mhp271 homologue
in strain 00MP1301 has one less R1 repeat in R1B271 and is also missing an R2 repeat.
Further study is necessary to ascertain whether a correlation between the number of R1
and R2 repeats in Mhp271 and the virulence of M. hyopneumoniae strains exists.
Using 1D SDS-PAGE combined with LC-MS/MS we were able to identify
Mhp271 in a TX-114 aqueous phase extract of M. hyopneumoniae cells. Although we
cannot ascertain which bands on the SDS-polyacrylamide gel belong to Mhp271 these
results indicate that at least one protein between 95 and 115 kDa and between 75 and 95
kDa are Mhp271. These sizes suggest that full-length Mhp271 is expressed (118.8 kDa)
and that it is endoproteolytically cleaved to form a smaller (75-95 kDa) protein.
Mhp271 contains an identical sequence motif (TNFAD) to where P97 is cleaved at
amino acid position 195 (Djordjevic et al., 2004; Hsu et al., 1997); therefore, like P97,
Mhp271 could also be cleaved within the N-terminus. If Mhp271 is cleaved at this
point, a protein with a theoretical weight of 96.6 kDa will be formed. It is possible that
this protein will migrate quicker than expected in SDS-PAGE, as P97 cleaved at amino
acid 195 results in a 102.9 kDa protein that behaves as a 97 kDa protein in SDS-PAGE
(Hsu et al., 1997). There is no evidence to suggest that Mhp271 is subject to further
proteolytic processing. Consistent with this the NTNT cleavage site in the C-terminus
of P97 (Djordjevic et al., 2004) is absent in Mhp271.
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This is the first study to provide evidence that Mhp271 may be a target of
endoproteolytic cleavage events in cells growing in vitro. P97, P102 and a number of
paralogues undergo processing in cells growing in vitro; however, processing has not
been observed in housekeeping proteins or some other high mass proteins (Burnett et
al., 2006; Djordjevic et al., 2004; Pinto et al., 2007; Wilton et al., 2009). Proteinprotein interactions via the disordered R1 and R2 regions may enable adhesin cleavage
fragments to attach to the cell surface in the absence of a transmembrane domain. The
functional significance of this processing is yet to be demonstrated; however, it can
alter the function(s) of a protein. Separation of R1 and R2 in P97 diminishes it’s ability
to bind the GAG heparin (Jenkins et al., 2006), an effective inhibitor of

M.

hyopneumoniae binding to cilia and to PK15 cells (Burnett et al., 2006; Zhang et al.,
1994).
Heparan sulfate proteoglycans sensitive to heparinase are found along the
surface of cilia and microvilli in the respiratory tract of pigs (Erlinger, 1995) and might
serve as receptors for M. hyopneumoniae. Therefore, we sought to determine if
fragments of Mhp271 could bind these proteoglycans and cilial surfaces on which they
reside. Despite carrying fewer repeats in R1 and R2, F2271 binds heparin (KD = 8.1 ± 0.4
nM) with a higher affinity than F2P97 (KD = 1.89 ± 0.33 µM) (Jenkins et al., 2006). Like
F2P97, F2271 also binds to porcine cilia (Figure 4.9). Pre-incubation of F2271 and F2P97
with heparin significantly reduced their ability to adhere to cilia (Figure 4.9). These data
provide evidence that M. hyopneumoniae proteins P97 and Mhp271 may mediate
adherence to porcine cilia via interactions with highly sulfated GAG side chains on
proteoglycans that line the cilia and microvilli in the porcine respiratory tract. Other
heparin-binding adhesins that do not carry R1 and R2 domains (P216 and P159) may
also adhere to the heparan sulfate proteoglycans on the surface of cilia (Burnett et al.,
2006; Wilton et al., 2009), although not all heparin-binding cleavage fragments of P97
(e.g. F1P97) bind cilia (Hsu and Minion, 1998a; Jenkins et al., 2006). This may
potentially be explained by heparan sulfate being more heterogeneous and less sulfated
than heparin (Salmivirta et al., 1996), thus protein sequences that may bind to heparin
may not bind to heparan sulfate. However, often it is the electrostatic interaction of the
negatively charged sulfates of heparin/heparan sulfate with basic residues in the protein
that plays a dominant role in heparin-protein interactions (Mulloy and Linhardt, 2001;
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Rabenstein, 2002). Strong inhibition of the heparin-F2271 interaction by the sulfated
polymer fucoidan indicates that an electrostatic interaction is occurring, most likely
between the sulfated GAGs on the cilia and the large number of positively-charged
lysine residues within the R1 and R2 regions. For both F2271 and F2P97 inhibition of cilia
binding by heparin was not complete. Given that heparin and heparan sulfate are not
identical GAGs, although they share some structural similarities, and the
multifunctional binding capacities of P97 and Mhp271, the inability of heparin to
completely abolish cilia binding may be due to interactions between these proteins and
other not highly sulfated host molecules on cilia.
Mhp271 is the first M. hyopneumoniae protein reported to bind fibronectin.
Many pathogens possess surface adhesins that interact with fibronectin and these play a
role in mediating host cell adherence and cell invasion. Fibronectin is prevalent in the
host ECM and a soluble form circulates in blood plasma. F2271 bound fibronectin with
an affinity in the nanomolar range and is comparable to other biologically important
bacterial FnBPs (Mullen et al., 2008). Fibronectin and its cellular receptor α5β1 integrin
are apically exposed and expressed by undifferentiated airway epithelium cells during
the repair of damaged tissue (Hérard et al., 1996). Initially M. hyopneumoniae may
interact with highly charged regions of heparan sulfate proteoglycans along epithelial
cilia and microvilli via electrostatic interactions. As infection evolves and M.
hyopneumoniae elicits epithelial cell damage (DeBey and Ross, 1994), other ECM
components become exposed that M. hyopneumoniae may bind leading to stronger and
more complex interactions. Numerous bacterial FnBPs are also involved in host cell
invasion (Dziewanowska et al., 1999; Gillen et al., 2008; Secott et al., 2004; Sinha et
al., 1999; Talay et al., 2000). M. hyopneumoniae has been isolated from liver, spleen,
kidneys and lymph nodes of pigs experimentally-challenged and contact-exposed
cohorts (Le Carrou et al., 2006; Marois et al., 2007) and from the pericardium fluid of
commercially-reared swine (Buttenschon et al., 1997). Future study is necessary to
evaluate whether fibronectin-binding Mhp271 plays a role in the dissemination of M.
hyopneumoniae within the host to tissues distal to the primary colonisation site, and in
the process enable the bacteria to evade host defence mechanisms and antimicrobial
agents.
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Numerous bacteria exploit host plasminogen to disseminate within the host. In
the previous chapter it was shown that M. hyopneumoniae binds to porcine
plasminogen. Since Mhp271 contains a C-terminal lysine and is a cell surfaceassociated protein, the interactions of F1271 and F2271 with plasminogen were explored.
F2271 bound plasminogen in SPR assays; however, the binding response was lower than
the positive control. The SPR sensorgrams indicated that there was more than one type
of interaction occurring between the plasminogen and F2271. This is not surprising since
amine coupling was used to immobilise the plasminogen; thus, the orientation of the
plasminogen on the chip would not be uniform and it is possible that F2271 has more
than one plasminogen-binding site, with each potentially differentially accessible
depending on how F2271 folds in solution. When the total binding was divided amongst
the fast and slow interactions of F2271 with plasminogen, the responses were low; thus,
creating some uncertainty on the type of interactions that were occurring. These results
suggest that F2271 interacts with plasminogen but further study is required to determine
the significance of this interaction.
In summary, the data presented here suggest that Mhp271 and P97 represent two
closely related ECM and cilium-binding proteins that are involved in interactions with
host cells. Both proteins are expressed during culture in vitro, are proteolytically
processed and surface-exposed, and mRNA transcripts encoding both proteins are
detectable during infection in BALF. The conservation of Mhp271 and P97 in field
strains within a bacterium that has evolved by genome reduction indicates that both
proteins are potentially important to the survival of the Mycoplasma within the host.
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5. Mycoplasma hyopneumoniae Surface Proteins Mhp385
and Mhp384 Bind Cilia and Glycosaminoglycans and are
Processed by Proteases that Recognise Different Cleavage
Motifs
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5.1 Introduction
M. hyopneumoniae is a genome-reduced, geographically widespread pathogen
that causes porcine enzootic pneumonia (PEP), a chronic, non-fatal respiratory disease
that inflicts significant economic losses on swine production worldwide. The M.
hyopneumoniae genome is approximately 900 kb (~ 700 coding sequences) and has
limited coding capacity compared to other medically significant Gram-positive
pathogens to which it is phylogenetically most closely related, such as Clostridium and
Streptococcus (Minion et al., 2004). Mycoplasmas are thought to have evolved by a
process of degenerative evolution from the low G + C Firmicutes (Dybvig and Voelker,
1996). Genes that encode enzymes for cell wall biosynthesis, the tricarboxylic acid
cycle and many anabolic biosynthetic pathways are absent from the genome. In M.
hyopneumoniae, glycolysis and the associated ‘pyruvate roundhouse’, are the principal
means by which adenosine triphosphate (ATP) is derived (Matic et al., 2003; Pollack et
al., 1997). Analysis of the M. hyopneumoniae strain 232 genome showed that 182 of
692 (~26%) open reading frames could be assigned to a paralogous gene family
(Minion et al., 2004). Prominently featured paralogue families include ABC
transporters with ATP binding site motifs and the P97 and P102 paralogue families.
Ciliostasis, cilial shedding and epithelial cell death are pathological hallmarks in
the development of PEP (Livingston et al., 1972; Mebus and Underdahl, 1977; Tajima
and Yagihashi, 1982; Underdahl et al., 1980). Adherence to target host cells is a critical,
early step in pathogenesis and is a complex multifactorial process involving adhesins
that directly target host cell receptors, ECM components and host molecules that act as
a bridge between microbe and host receptors (DeBey and Ross, 1994; Duensing et al.,
1999; Zhang et al., 1994, 1995). Members of the P97 and P102 paralogue families in M.
hyopneumoniae play critical roles in binding porcine cilia, highly sulfated GAGs,
fibronectin and plasminogen (Bogema et al., 2011; Burnett et al., 2006; Deutscher et
al., 2010; Hsu et al., 1997; Jenkins et al., 2006; Seymour et al., 2010; Seymour et al.,
2011; Seymour et al., 2012; Wilton et al., 2009; Zhang et al., 1995). Interactions with
heparinase sensitive GAGs displayed on the surface of porcine epithelial cilia provide a
mechanism by which M. hyopneumoniae overcomes the mucociliary escalator during
the early stages of colonisation (Deutscher et al., 2010). In addition, interactions with
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various host molecules enable the pathogen to remain within the host as infection
proceeds and epithelial shedding occurs.
RT-PCR studies performed on M. hyopneumoniae taken from bronchoalveolar
lavage fluid of experimentally M. hyopneumoniae-challenged pigs confirmed that
mRNA encoding almost all members of the P97 and P102 paralogue families are
simultaneously expressed (Adams et al., 2005). Members of the P97 and P102
paralogue families are targets for post-translational endoproteolytic cleavage by
unknown proteases (Bogema et al., 2011; Burnett et al., 2006; Djordjevic et al., 2004;
Hsu et al., 1997; Seymour et al., 2010; Seymour et al., 2011; Seymour et al., 2012;
Wilton et al., 2009), a feature that distinguishes them from all other previously
described gene families in the Mollicutes. All P97 and P102 paralogues are the products
of gene fusion events (Minion et al., 2004). The processing of these proteins generates
endoproteolytic cleavage fragments comprising novel C-terminal sequences and Nterminal sequences that share sequence similarity to other paralogue family members.
All of these fragments are displayed on the surface of M. hyopneumoniae cells (Bogema
et al., 2011; Djordjevic et al., 2004; Seymour et al., 2010; Seymour et al., 2011;
Seymour et al., 2012; Wilton et al., 2009). Initial studies of the archetype cilium
adhesin P97 indicate that this molecule undergoes extensive processing (Djordjevic et
al., 2004) but further work is required to understand this complexity. Recently, we
showed that several members of the P97 and P102 paralogue families possess a
sequence motif S/T-X-F↓X-D/E that delineates the site of proteolytic cleavage (Bogema
et al., 2011). Cleavage occurs after the phenylalanine (F) residue. A negatively charged
amino acid [glutamic acid (E) or aspartic acid (D)] typically occupies the +2 position
and an alcohol-containing residue (S/T) is often found in the -3 position. Cleavage
efficiency seems to be influenced by the cleavage motif residing within disordered
regions spanning at least 40 amino acids (Bogema et al., 2011). Our prevailing
hypothesis is that a single protease is responsible for cleavage at the S/T-X-F↓X-D/E
site. However, at least one other protease may play an important role in processing
members of the P97 and P102 paralogue families. In strain J, an inefficient cleavage
event, which separates the C-terminal 230 amino acids that comprise P28 from the P97
homologue MHJ_0194, occurs at the site

862

T↓NTNTSKF869 (Djordjevic et al., 2004).
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This sequence is structurally unrelated to the one described above; therefore, its
cleavage is thought to be performed by a different protease.
Our proteome studies indicate that most representatives of the P97 and P102
paralogue families are very highly expressed during broth culture. Given the limited
capacity of M. hyopneumoniae to generate ATP, it is significant that considerable
energy is expended to express, secrete and extensively proteolytically process members
of the P97 and P102 paralogue families. To gain a better understanding of the surface
topography of M. hyopneumoniae it is important to precisely map the cleavage events in
the P97 and P102 paralogue families and identify the proteases responsible for their
cleavage. Here we examine the expression patterns of Mhp385 and Mhp384, P97 and
P102 paralogues respectively, whose genes reside in a two-gene operon. We show that
Mhp384 undergoes one major cleavage event at an S/T-X-F↓X-D/E-like motif while
Mhp385 undergoes inefficient endoproteolytic cleavage at a unique site. We precisely
mapped cleavage sites in Mhp384 and Mhp385 and examined the association between
the location of proteolytic cleavage sites and protein disorder in these and other P97 and
P102 paralogues. Finally, we determined whether these proteins play a role in adherence
to porcine cilia and GAGs.

5.2 Results
5.2.1

Molecular Analysis of Mhp385 and Mhp384
mhp385 shares a two-gene operon with a gene encoding the P102 paralogue

Mhp384 (GenBank accession number AAV27855) (Figure 5.2A). A possible ribosome
binding sequence (AGGAG) is located within the twelve nucleotides that separate the
genes. Mhp385 (GenBank accession number AAV27856) consists of 988 amino acid
residues and has a theoretical molecular mass and pI of 114.8 kDa and 8.87,
respectively. A putative transmembrane region resides between residues 22-44 (score
0.99993, TMHMM 2.0). No signal peptide is predicted. A feature of the mhp385 gene
locus is the presence of a homopolymeric tract of 22 thymine residues located 100 base
pairs upstream of the start codon of mhp385. This repeat region is potentially placed
between a Pribnow box (TATAAT) and a possible -35 region (TTGAGA). In addition,
a homopolymeric tract of 19 adenines is located 25 base pairs downstream of the start
codon for mhp385. Such regions are known hot spots for slipped-strand mispairing
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(Citti et al., 2005), which could result in frameshift mutations affecting the expression
of mhp385. The presence of thymine and adenine tracts in very close proximity of each
other may also lead to hairpin formation, which would interfere with gene transcription.
Mhp385 is one of three M. hyopneumoniae proteins that contain tandem R1
pentapeptide repeats. Cilium-binding occurs in the presence of eight of these repeats
(Minion et al., 2000). Mhp385 contains four tandem R1 repeats (AAKV-AAKPSAAKPV-AAKPE) within the C-terminus of the protein. The number of tandem R1
repeats in both P97 and Mhp271 can vary between strains of M. hyopneumoniae (de
Castro et al., 2006; Deutscher et al., 2010; Minion et al., 2000; Stakenborg et al., 2006;
Wilton et al., 1998). Alignment of the R1 region in Mhp385 with homologues in M.
hyopneumoniae strains J (GenBank accession number AAZ44457), 7448 (AAZ53744)
and 168 (ADQ90625) shows this region is not highly variable (Figure 5.1). Based on
the number of repeats, this region is expected to be recognised by the cilia adherenceblocking mAb F2G5 (Minion et al., 2000).

232
J
7448
168

:
:
:
:

SSKP-----EAAKVAAKPSAAKPVAAKPEQQEIHQSEEIPG
SSKP-----EAAKVAAKPSAAKPVAAKPEQQEIHQSEEIPG
SSKPEVTKPVAARPVAAKVAAKPSAAKPEQQEIHQSEEIPG
SSKP-----EAAKVAVKPSAAKPVAAKPEQQEIHQSEEIPG

:
:
:
:

938
932
931
931

Figure 5.1 Alignment of the R1 repeat region in Mhp385 (strain 232) and homologues
in M. hyopneumoniae strains J, 7448 and 168. Residues conserved in all proteins are
shaded in black, while amino acids shared by three sequences are shaded in grey,
respectively. Dashes represent gaps. The numbers at the end of the sequences refer to
position of the last amino acid listed in the respective strain.
Mhp385 amino acid sequence shares greater than 96% identity with its
respective homologues in M. hyopneumoniae strains J, 7448 and 168, and possesses a
hexapeptide ‘NNNLRL’ that is repeated twice in strain 232 but not in any of its
homologues. Outside the M. hyopneumoniae proteome Mhp385 shows greatest
similarity to LppS, a putative adhesin of M. conjunctivae (Belloy et al., 2003)
(GenBank accession number CAC87274; the Mhp385 amino acids 39-399 share 30%
identity and 50% positives; and the amino acids 360-735 share 25% identity and 42%
positives). The majority of the homology that Mhp385 shares with P97 and its
paralogues is within its first 780 amino acids. Apart from the similarity of the R1 repeat
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region with P97 and Mhp271, the C-terminal sequence of Mhp385 only shares some
similarity with collagen alpha-3(VI) chain isoform 1 (Sus scrofa) (NCBI accession
number XP_001928122; 25% identity, 42% positives with Mhp385 amino acids 723930). The last 58 amino acids of Mhp385 do not share any significant similarity to
proteins in the NCBI protein database.
Mhp384 (GenBank accession number AAV27855) consists of 957 amino acids
and has a theoretical molecular mass of 109.2 kDa and a pI of 8.97. Between residues 931 lies a putative transmembrane region (score 0.99876, TMHMM 2.0) and no signal
peptide is predicted. Mhp384 amino acid sequence shares greater than 96% identity
with its respective homologues in M. hyopneumoniae strains J, 7448 and 168. Outside
the M. hyopneumoniae proteome Mhp384 shows greatest similarity to the M.
conjunctivae putative adhesin LppT (Zimmermann et al., 2010) (GenBank accession
number CAC87275; the Mhp384 amino acid residues 13-501 share 23% identity and
44% positives). The genes of the putative adhesins LppS and LppT reside in a two-gene
operon (Belloy et al., 2003; Zimmermann et al., 2010). The similarity Mhp384 shares
with P102 and its paralogues is within the first 324 amino acids, while the last
approximately 450 amino acids of the protein do not share significant sequence
similarity to proteins in the NCBI protein database. Both Mhp385 and Mhp384 protein
sequences do not contain any cysteine residues.
5.2.2

Cloning and Expression of Mhp385 and Mhp384 Recombinant Protein
Fragments
Lack of genetic tools to mutate and transform M. hyopneumoniae and reliable

growth on agar medium are major impediments to generating knockout mutants in this
species. To characterise the functions of Mhp385 and Mhp384, non-overlapping
fragments of the mhp385 and mhp384 genes were cloned and expressed in E. coli. Due
to the high A + T content of mhp385 (72%) and mhp384 (71%) and the potential
difficulty in expressing A + T rich genes in E. coli (Burnett et al., 2006; Notarnicola et
al., 1990) the entire genes were not cloned. Fragments that span mhp385 and mhp384,
apart from the transmembrane domains (Figure 5.2B), were PCR amplified, cloned and
expressed as N-terminal 6xHis-tagged fusion proteins (F1385-F4385, F1384-F3384). Onedimensional SDS-PAGE analysis of the 6xHis-tagged proteins (Figure 5.2C) confirmed
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predicted molecular masses for F1385 (41.1 kDa); F2385 (32.4 kDa); F3385 (25.9 kDa);
F4385 (26.9 kDa); F1384 (40.4 kDa); and F3384 (38.7 kDa). F2384 travelled more slowly
than its theoretical mass of 39.2 kDa, but this aberrant migration may be due to a cluster
of

acidic

and

charged

amino

acids

within

its

sequence

(NEEVKQQESQVKDQAKQEKSSKDSQSKQ), since abnormal migration occurs with
proteins enriched in acidic residues (Burnett et al., 2006; Li et al., 2006).

Figure 5.2 Cloning and expression of Mhp385 and Mhp384 recombinant proteins. (A)
Schematic of mhp385 and mhp384 in the chromosome of M. hyopneumoniae strain 232.
The arrows show the direction of translation and sizes are in base pairs. (B) Schematic
of recombinant constructs relative to the Mhp385 and Mhp384 proteins. Numbers refer
to amino acid positions. * indicates the presence of a TGA codon. (C) GelCode Blue
stained SDS-12% polyacrylamide gel of purified recombinant Mhp385 and Mhp384
6xHis-tagged fragments. Molecular mass markers are indicated on the left.
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5.2.3

Expression of Mhp385 in M. hyopneumoniae
To detect the expression of Mhp385 by M. hyopneumoniae cells, whole cell

lysates of M. hyopneumoniae strain 232 cells were probed with rabbit immune sera
raised against each of the Mhp385 recombinant fragments (Figure 5.3A). All antiMhp385 sera detected a protein with an approximate molecular mass of 115 kDa
(P115385), which corresponds to the theoretical molecular mass of the Mhp385
preprotein. Anti-F1385, anti-F2385 and anti-F3385 sera also detected an 88 kDa protein
(P88385), while anti-F3385 and anti-F4385 sera also detected a 27 kDa protein (P27385).
P88385 and P27385 are most likely N-terminal and C-terminal cleavage fragments of
P115385, respectively. Since anti-F3385 serum detected all three bands, the cleavage site
of Mhp385 is likely to fall within the sequence of F3385. To confirm the identities of the
115 and 88 kDa proteins, the respective protein bands were cut from a 1D SDS-7%
polyacrylamide gel, digested with trypsin and analysed by LC-MS/MS (Figure 5.3B).
Peptides unique to Mhp385 were found in both the 115 kDa and 88 kDa bands (Figure
5.3D and Table 9.6, Table 9.7 and Table 9.8). Blots of a 2D gel (pI range 6-11) of
whole cell lysates from M. hyopneumoniae strain 232 cells probed with anti-F4385 serum
identified two spots with mass of approximately 27 kDa (Figure 5.3C). The identities of
these proteins were confirmed to be the C-terminal fragment of Mhp385 by LC-MS/MS
(Figure 5.3D and Table 9.6, Table 9.9 and Table 9.10).
Currently all cleavage sites in the P97 and P102 paralogue families, except for
the cleavage event that generates P28 from the C-terminus of the P97 homologue in
strain J (Djordjevic et al., 2004), adhere to the motif S/T-X-F↓X-D/E (Bogema et al.,
2011). Analysis of M. hyopneumoniae strain 232 proteins separated by 1D SDS-PAGE,
extracted and characterised by LC-MS/MS, identified a semi-tryptic peptide with the
sequence

752

Table

9.11).

752

IQFELEPISLNV763 matching to Mhp385 (Figure 5.3D and Figure 9.1 and
This

peptide

falls

within

the

38

amino

acids

IQFELEPISLNVAVSQEKTNPNNNLRLNNNLRLKYWYK789 that separate the

peptide matches that map to P88385 and P27385. Evidence of an S/T-X-F↓X-D/E-like
motif was not observed in this stretch of amino acids. The semi-tryptic cleavage at the
C-terminus of the peptide indicates that the cleavage site that separates P88385 from
P27385 in Mhp385 is

761

L-N-V↓A-V-S766. This cleavage site does not adhere to the

previously established cleavage motif, suggesting that a different protease is responsible
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for this event. Consistent with this view, cleavage at this site is comparatively
inefficient because we identified the Mhp385 preprotein.

Figure 5.3 Expression of Mhp385 by M. hyopneumoniae cells. (A) Whole cell lysates
from M. hyopneumoniae strain 232 cells were separated on a 1D SDS-12%
polyacrylamide gel and stained with GelCode Blue or transferred onto PVDF
membrane. The membranes were incubated with pre-immune (PI) or immune (I)
antisera raised against each Mhp385 recombinant protein (F1385-F4385), followed by
sheep anti-rabbit serum. Identified proteins are indicated on the right by arrow heads
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and molecular mass markers are indicated on the left. (B) A 1D SDS-7%
polyacrylamide gel of whole cell lysates from M. hyopneumoniae strain 232 cells
stained or transferred onto PVDF membrane and reacted with anti-F1385 serum. The
arrows indicate proteins recognised by the antiserum, which were excised, digested with
trypsin and subjected to LC-MS/MS. (C) Section of a 2DGE gel (Bio-Safe Coomassie
stained) of whole cell lysates from M. hyopneumoniae strain 232 cells. A corresponding
gel was transferred onto PVDF and probed with anti-F4385 antiserum. Two prominent
protein spots were detected (circled), excised from the gel and subjected to trypsin
digestion followed by LC-MS/MS. (D) Protein sequence of Mhp385. Peptides identified
by LC-MS/MS of the 115 kDa band shown in panel B are underlined. Highlighted in
bold are the peptides identified by LC-MS/MS of the 88 kDa band in panel B. Peptides
identified by LC-MS/MS of both protein spots boxed in panel C are in bold and
italicised. Highlighted in bold and dash underlined is the Mhp385 semi-tryptic peptide
identified in a global analysis of the M. hyopneumoniae strain 232 proteome by 1D
SDS-PAGE followed by LC-MS/MS. The transmembrane domain is boxed.
5.2.4

Expression of Mhp384 in M. hyopneumoniae
Whole cell lysates from M. hyopneumoniae strain 232 cells probed with anti-

F1384 serum identified a 60 kDa protein (P60384), while anti-F3384 serum detected a 50
kDa protein (P50384) (Figure 5.4A). No evidence of the 109 kDa Mhp384 preprotein
was observed by probing blots with F1384-F3384 antisera (data not shown), indicating
that the single endoproteolytic cleavage event that generates P60384 and P50384 is
efficient. Since anti-F2384 serum detected both P60384 and P50384 the cleavage site of
Mhp384 is likely to occur within the sequence of this fragment. LC-MS/MS was
performed on trypsin digests of proteins found within gel slices containing P60384 and
P50384 (Figure 5.4B). Tryptic peptides from P60384 matched to the N-terminal sequence
of Mhp384, while peptides from P50384 matched to the C-terminal sequence of Mhp384
(Figure 5.4C and Table 9.6, Table 9.12 and Table 9.13).
Two semi-tryptic peptides, with sequences
530

530

NEEVKQQESQVK541 and

NEEVKQQESQVKDQAK545, were identified in a global analysis of the M.

hyopneumoniae strain 232 proteome by 1D SDS-PAGE followed by LC-MS/MS
(Figure 9.2 and Table 9.11). These semi-tryptic peptides define the N-terminus of
P50384 (Figure 5.4C). These data indicate that the cleavage site for Mhp384 spans the
sequence

527

I-L-F↓N-E-E532 with a phenylalanine residue (F) in the -1 position of the

cleavage site and a glutamic acid residue (E) in the position +2. This cleavage site is
similar to the cleavage motif S/T-X-F↓X-D/E suggested by Bogema et al. (2011).

122

Figure 5.4 Expression of Mhp384 by M. hyopneumoniae cells. (A) Whole cell lysates
from M. hyopneumoniae strain 232 cells were separated on a 1D SDS-12%
polyacrylamide gel and stained with GelCode Blue or transferred onto PVDF
membrane. Membranes were treated with pre-immune (PI) or immune (I) antisera raised
against each Mhp384 recombinant protein (F1384-F3384), followed by sheep anti-rabbit
serum. Arrows point to cleavage fragments of Mhp384. Molecular mass markers are
indicated on the left. (B) A 1D SDS-10% polyacrylamide gel of whole cell lysate of M.
hyopneumoniae strain 232 cells, GelCode Blue stained or transferred onto PVDF
membrane and reacted with anti-F1384 and anti-F3384 sera. The arrows indicate proteins
recognised by the antisera that were excised, digested with trypsin and subjected to LCMS/MS. (C) Amino acid sequence of Mhp384. Peptides identified by LC-MS/MS of
the 60 kDa band shown in panel B are in bold. Highlighted in bold and underlined are
the peptides identified by LC-MS/MS of the 50 kDa band in panel B. Highlighted in
bold and dash underlined is one of the two Mhp384 semi-tryptic peptides identified in a
global analysis of the M. hyopneumoniae strain 232 proteome by 1D SDS-PAGE
followed by LC-MS/MS. The transmembrane domain is boxed.
5.2.5

Mapping the Cleavage Site in the P97 Paralogue Mhp107
To further refine the cleavage sites in the P97 and P102 paralogue families, we

also looked for the presence of a semi-tryptic peptide within another P97 paralogue,
Mhp107. Previously we were unsuccessful in attempts to determine if the
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multifunctional adhesin Mhp107 undergoes endoproteolytic processing (Seymour et al.,
2011). Immunoblotting studies showed that Mhp107 and homologues in different
strains of M. hyopneumoniae migrate with a mass of approximately 100 kDa, although
the predicted molecular mass of Mhp107 is approximately 120 kDa (Seymour et al.,
2011). LC-MS/MS analysis of M. hyopneumoniae strain 232 proteins separated by 1D
SDS-PAGE that migrated within the mass range of approximately 25-30 kDa identified
tryptic peptides that match to the N-terminal 199 amino acids of Mhp107 (Figure 5.5
and Table 9.6 and Table 9.14). In this mass range a semi-tryptic peptide with the
sequence 184QINENILNIGNFTTNF199 matched to Mhp107 (Figure 9.3 and Table 9.11).
The semi-tryptic cleavage at the C-terminus of this peptide indicates that the cleavage
site is

197

T-N-F↓S-D-Q202. The cleavage site strongly resembles the cleavage motif

suggested by Bogema et al. (2011). Cleavage at this site would remove 199 amino acids
from the N-terminus of Mhp107 generating a mature C-terminal cleavage fragment with
a theoretical molecular mass of 96.4 kDa and a 23.4 kDa N-terminal cleavage fragment.
The C-terminal cleavage protein has a theoretical molecular mass similar to that of the
protein detected by Western blotting with anti-Mhp107 sera in Seymour et al. (2011).
The Mhp107 preprotein was not identified in the whole proteome analysis suggesting
that cleavage of Mhp107 is efficient.
5.2.6

Prediction of Regions of Disorder among the P97 and P102 Paralogue
Families
It was recently shown that the two TTKF↓QE cleavage sites in the P102

paralogue Mhp683 reside within long (greater than 40 amino acids) disordered regions
(Bogema et al., 2011). To determine if protein disorder plays a role in the
endoproteolytic cleavage of other P97 and P102 paralogues, we applied several protein
disorder prediction algorithms, as recommended by Ferron et al. (2006) to Mhp385,
Mhp384 and Mhp107, and to MHJ_0194 and MHJ_0195, respectively the P97 and
P102 homologues in M. hyopneumoniae strain J, whose cleavage sites were previously
identified (Djordjevic et al., 2004; Hsu et al., 1997). Since several disorder predicting
algorithms interpret coiled-coil regions as disordered (Ferron et al., 2006), coiled-coil
analyses were also performed.
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Figure 5.5 Identification of the endoproteolytic cleavage site in Mhp107. (A) Section of
a 1D polyacrylamide gel of whole cell lysates from M. hyopneumoniae strain 232 cells
stained with Flamingo fluorescent gel stain. Protein standard markers are shown on the
left. The gel slice containing proteins with molecular masses between 25 and 30 kDa
that was excised and subjected to trypsin digestion and LC-MS/MS analysis is
indicated. (B) Mhp107 amino acid sequence. Mhp107 tryptic peptides identified by LCMS/MS analysis of the 25-30 kDa proteins in the gel in panel A are highlighted in bold
and underlined. The Mhp107 semi-tryptic peptide identified is in bold and underlined
with a dashed line.
The endoproteolytic cleavage sites in Mhp384 and in MHJ_0195 occur within a
long region of disorder (greater than 50 amino acids long) (Figure 5.6B &E). However,
Mhp107 is predicted not to be disordered at the site of cleavage (Figure 5.6C). The
endoproteolytic cleavage site in Mhp385 occurs prior to the start of a short, five amino
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Figure 5.6 Distribution of the disorder score over the amino acid sequence of Mhp385
(A), Mhp384 (B), Mhp107 (C), MHJ_0194 (P97 homologue) (D) and MHJ_0195 (P102
homologue) (E). The disorder algorithm used is listed above each graph. Scores above
0.5 correspond to disordered regions, whereas those below 0.5 correspond to ordered
regions. The dashed line indicates the site of endoproteolytic cleavage. Predicted coiledcoil regions using the Paircoil2 algorithm (P-score less than 0.025) are shaded in grey.
acid long disordered region (Figure 5.6A). Although PONDR VSL1 and PONDR-FIT
predicted that the endoproteolytic cleavage site of MHJ_0194 occurs within a
disordered region (Figure 5.6D), both Paircoil2 (amino acid residues 173-203; P-score
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less than 0.025) and COILS2 (residues 175-203; probability greater than 0.9 using
weights and a 21-long window) identified a coiled-coil domain at the cleavage site,
suggesting that this region is not likely to be disordered.
5.2.7

Cellular Location of Mhp385 and Mhp384
Trypsin digestion of viable Mycoplasma cells has been widely used to

demonstrate the surface location of proteins (Burnett et al., 2006; Wilton et al., 2009;
Wilton et al., 1998). Electrophoretic profiles of whole cell lysates from M.
hyopneumoniae strain 232 cells, which were exposed to concentrations of trypsin
ranging from 0-300 µg/mL prior to 1D SDS-PAGE, showed a gradual loss of a number
of proteins across the entire mass range but particularly with proteins with masses
greater than 80 kDa (Figure 5.7A). Immunoblots of lysates from trypsin digested M.
hyopneumoniae cells showed that the Mhp385 preprotein (P115385) and the Mhp385 and
Mhp384 cleavage fragments (P88385, P27385, P60384 and P50384) were readily digested
by trypsin (Figure 5.7B-E). P115385 and the C-terminal cleavage fragments P27385 and
P50384 were more susceptible to trypsin than the N-terminal cleavage fragments P88385
and P60384. Antiserum against the ribosomal protein L7/L12 was used to control for cell
lysis (Burnett et al., 2006). L7/L12 protein was identified at trypsin concentrations up to
300 µg/mL indicating that the cells remained intact during the digestion procedure
(Figure 5.7F).
5.2.8

Mhp385 and Mhp384 Bind Porcine Cilia
To investigate whether Mhp385 and Mhp384 have a role in adherence, the

recombinant fragments were assessed for their ability to bind to purified swine tracheal
cilia coated on a microtitre plate. F1384, F2384, F3384, F1385, F2385, F3385 and positive
control F2P97, which includes the R1 cilium-binding domain and R2 repeat region from
P97 (Jenkins et al., 2006), reproducibly bound to cilia (P < 0.05) (Figure 5.8). F4385 did
not bind cilia.
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Figure 5.7 Trypsin sensitivity of Mhp385 and Mhp384 in M. hyopneumoniae cells.
Whole cell lysates from freshly cultured M. hyopneumoniae strain 232 cells treated with
a range of trypsin concentrations (µg/mL), as listed at the top of the gel, were subjected
to SDS-PAGE and stained with GelCode Blue (A) or transferred onto PVDF for
immunoblot analyses. (B-E) Immunoblots probed with antiserum raised against F1385
(1:500), F4385 (1:1000), F1384 (1:500), and F3384 (1:500), respectively. (F) Control
immunoblot probed with antiserum (1:5000) against cytosolic ribosomal protein L7/L12
(Burnett et al., 2006). Molecular mass markers are indicated on the left.
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Figure 5.8 Adherence of Mhp385 and Mhp384 recombinant proteins to swine cilia.
Mhp384 and Mhp385 recombinant protein fragments and the positive control F2P97
protein (Jenkins et al., 2006) were incubated with purified swine tracheal cilia coated on
a microtitre plate. Bound protein was detected using polyclonal antiserum raised against
the respective recombinant protein. Each bar represents the mean response above
background plus the upper standard error from triplicate wells from two independent
experiments (n = 6). Bars marked with an asterisk represent results that are significantly
different (P < 0.05) from background.
5.2.9

Mhp385 and Mhp384 Bind Heparin
P97 (Jenkins et al., 2006) and its paralogues Mhp493 (Wilton et al., 2009),

Mhp271 (Deutscher et al., 2010) and Mhp107 (Seymour et al., 2011), and the P102
paralogue Mhp683 (Bogema et al., 2011) bind heparin. Since GAGs sensitive to
heparinase are found along the surface of porcine respiratory cilia (Erlinger, 1995), our
prevailing hypothesis is that members of the P97 and P102 paralogue families bind cilia
during the early stages of colonization by targeting proteoglycans decorated with
highly-sulfated heparin-like GAGs. To determine if recombinant proteins spanning
Mhp385 and Mhp384 bind heparin, an analogue for the highly sulfated iduronic acid(1→4)-D-glucosamine disaccharide domains of heparan sulfate (Rabenstein, 2002), dot
blots and microtitre plate binding studies were performed using biotinylated porcine
heparin (Figure 5.9). F2385, F3385, F2384 and F3384 bound heparin in dot blot and the
microtitre plate binding assays (Figure 5.9A and B). F1384 displayed faint reactivity in
heparin-binding dot blot assays and low absorbance values in microtitre plate heparinbinding assays, indicating that it is at best a weak heparin-binding protein. F4385 showed
evidence of weak heparin-binding in the dot blot assays and low absorbance values in
the microtitre plate heparin-binding assays. In contrast, F1385 bound heparin in
microtitre plate binding assays but only faint reactivity was observed in heparin dot blot
assays. Since the absorbance values of F1384 and F4385 in the heparin microtitre plate
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assays were low, indicating weak heparin-binding potential, they were not investigated
further.
Heparin-binding to F1385, F2385, F3385, F2384 and F3384 was dose-dependent and
saturating (Figure 5.9C). Unlabelled heparin effectively inhibited biotinylated heparin
binding to F1385, F2385, F3385, F2384 and F3384, indicating that the interaction was
specific (Figure 5.9C). From the specific heparin-binding curves the KD for heparin to
each recombinant protein was calculated: F1385 19 ± 2.6 nM; F2385 2.7 ± 0.15 nM; F3385
16 ± 1.7 nM; F2384 26 ± 2.2 nM and F3384 8.9 ± 2.6 nM. To provide some indication of
the type of interaction occurring between the recombinants and biotinylated heparin,
competitive-binding assays were performed using unlabelled heparin, fucoidan,
chondroitin sulfates A and B and porcine intestinal mucin (Figure 5.9D-E). Consistent
with previous studies (Bogema et al., 2011; Deutscher et al., 2010), fucoidan, a highly
sulfated polysaccharide extracted from seaweed, was most efficient at inhibiting the
F2385, F2384 and F3384 interaction with heparin. At 600 µg/mL (30 times the
concentration of heparin) porcine intestinal mucin reduced the adherence of heparin to
F1385, F3385, F2384 and F3384 by at least 30%. Chondroitin sulfates A and B did not
inhibit adherence of F2385, F2384 and F3384 to heparin and chondroitin sulfate A was a
minor inhibitor of heparin binding to F1385 and F3385.
5.2.10 Plasminogen Binding Assays with Mhp385 and Mhp384
Earlier we demonstrated that Mhp384 and Mhp385 proteins are surface exposed
on M. hyopneumoniae cells. To investigate whether these proteins contribute to M.
hyopneumoniae interaction with plasminogen we employed SPR technology. For this
real-time protein-protein interaction analysis, purified porcine plasminogen was
immobilised onto a sensor chip and each of the recombinant fragments of Mhp385 and
Mhp384 were flowed over the immobilised plasminogen. None of the Mhp385 or
Mhp384 recombinant proteins showed any significant binding to the immobilised
plasminogen by SPR analysis (Figure 5.10). All binding responses were below 20 RU.
Two concentrations (100 nM and 200 nM) of F2384 were flowed over the immobilised
plasminogen and gave very similar responses, indicating that the low level of binding is
non-specific (Figure 5.10B). The positive control recombinant P42 (Seymour et al.,
2012) showed significant binding to the immobilised plasminogen (Figure 5.10).
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Figure 5.9 Recombinant protein fragments of Mhp385 and Mhp384 bind heparin. (A)
Dot blot of F1-F4385 and F1-F3384 recombinant proteins stained with amido black or
probed with biotinylated heparin or streptavidin peroxidase only. (B) Binding curves of
biotinylated heparin to F1-F4385 and F1-F3384 recombinant proteins immobilised on a
microtitre plate. (C) Specific biotinylated heparin binding curves to F1385, F2385, F3385,
F2384 and F3384 recombinant proteins. (D-H) Competitive-binding assays for F1385,
F2385, F3385, F2384 and F3384, respectively, with biotinylated heparin and various
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unlabelled sulfated polysaccharides: heparin (■), fucoidan (▲), porcine mucin type II
(●), chondroitin sulfate A (▼) and chondroitin sulfate B (♦). All data represent the mean
and standard error of triplicate readings from two independent experiments (n = 6),
except the competition assays a representative experiment of two independent
experiments is shown (n = 3).

Figure 5.10 Analysis of Mhp385 (A) and Mhp384 (B) recombinant fragments binding
to plasminogen by SPR. P42 was utilised as a positive control (Seymour et al., 2012).
Plasminogen was immobilised on a CM4 chip and each recombinant (200 nM) was
injected at a flow rate of 10 µL/min for 600 s. Both 100 nM and 200 nM of F2384 where
flowed over the immobilised plasminogen to demonstrate that the binding is nonspecific. The arrows indicate the end of protein injection, at which stage the dissociation
phase was monitored for 1000 s by allowing buffer to flow over the chip. The difference
between the experimental and control flow cell is shown in resonance units (RU). The
data show one of two duplicate experiments with similar results.
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5.3 Discussion
Adherence to host tissues is an early and essential step in pathogenesis and a
complex molecular interplay between bacterial adhesins and host receptor molecules.
Here we show that the P97 and P102 paralogues, Mhp385 and Mhp384, respectively,
are expressed during broth culture and undergo endoproteolytic cleavage generating
P88385 and P27385, and P60384 and P50384 on the surface of M. hyopneumoniae cell,
under the conditions used in this study. Based on the binding abilities of the
recombinant Mhp385 and Mhp384 fragments expressed in this study, P88385 and P50384
bind heparin and porcine cilia. The sequences of recombinant F1384 and half of F2384
make up P60384; therefore, the location of the heparin-binding site(s) within F2384 will
determine the affinity P60384 has for heparin. However, this cleavage fragment has at
least one cilium-binding site. P27385 was only shown to be a weak heparin-binder. The
affinity of the recombinant fragments F1385, F2385, F3385, F2384 and F3384 to heparin is
similar to that reported for other M. hyopneumoniae heparin-binding P97 and P102
paralogues and the M. gallisepticum protein MG1142 (Bogema et al., 2011; Deutscher
et al., 2010; Jenkins et al., 2007; Seymour et al., 2011; Wilton et al., 2009). The fact
that Mhp385 and Mhp384 bind to cilia and heparin, combined with the presence of
heparinase sensitive GAGs along the surface of porcine respiratory cilia (Erlinger,
1995), means that they are both likely to be important to the ability of M.
hyopneumoniae to colonise the porcine respiratory tract.
The P97 and P102 paralogue families are targets of endoproteolytic processing
events (Bogema et al., 2011; Burnett et al., 2006; Djordjevic et al., 2004; Hsu et al.,
1997; Seymour et al., 2010; Seymour et al., 2011; Seymour et al., 2012; Wilton et al.,
2009). Prior to this study a P97 or P102 paralogue at a mass consistent with its deduced
amino acid sequence had not been found by MS, indicating that, at least in vitro,
cleavage is efficient and critical for protein function. Recent studies comparing the
endoproteolytic cleavage sites in MHJ_0194 (P97 homologue), MHJ_0195 (P102
homologue), and the P97 and P102 paralogues Mhp493 (P216) and Mhp683 (P135),
respectively, showed that most endoproteolytic cleavage events occur at a phenylalanine
residue (-1 position) with an alcohol-containing residue in the -3 position and an acidic
(D/E) residue in the +2 position (Bogema et al., 2011). Cleavage at these S/T-X-F↓XD/E sites is invariably efficient. Here, we show that cleavage sites in Mhp384 and
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Mhp107 conform to the S/T-X-F↓X-D/E motif. LC-MS/MS revealed that both cleavage
sites have a phenylalanine residue at -1 position, an acidic residue in the +2 position,
and possess the sequences

527

ILF↓NEE532 and

197

TNF↓SDQ202, respectively. The

location of the endoproteolytic cleavage site in Mhp384 and MHJ_0195, like Mhp683
and Mhp493 (Bogema et al., 2011), was localised within a disordered region spanning
more than 40 amino acids. Our inability to find evidence of the Mhp384 preprotein by
MS or Western blotting indicates that cleavage is efficient. Our studies show that
primary amino acid sequence and the degree of protein disorder encompassing, or in
close proximity to the site of endoproteolysis appear to influence protease cleavage
behaviour. Disordered regions are flexible and, therefore, more accessible to proteases
(Uversky and Dunker, 2010). Notably, however, the cleavage site in Mhp107 does not
fall within a predicted region of disorder. The inefficient MHJ_0194 cleavage site that
removes the C-terminal 28 kDa R2-containing region of the adhesin occurs within a
coiled-coil region. As further cleavage sites are mapped in surface proteins of M.
hyopneumoniae we will examine the association between protein disorder and
endoproteolytic cleavage.
A P97 paralogue that migrates at a mass equivalent to its predicted mass (of 115
kDa) was identified here for the first time. Western blots of whole cell lysates from M.
hyopneumoniae strain 232 cells probed with F1385-F4385 antisera identified a 115 kDa
protein and LC-MS/MS analyses generated peptide coverage spanning the length of
P115385. These data confirm that a proportion of the Mhp385 preprotein remains intact
and that the cleavage event that generates P88385 and P27385 is inefficient. Trypsin
digestion studies show P115385 is accessible on the cell surface of M. hyopneumoniae.
The cleavage site in Mhp385 that generates P88385 and P27385 displays the sequence
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LNV↓AVS766, which bears no sequence resemblance to the S/T-X-F↓X-D/E cleavage

motif within Mhp384 and other paralogues of P97 and P102 (Bogema et al., 2011). This
suggests that Mhp385 is processed by a different protease. The cleavage site
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ATNT↓NTNTGFS869 in the C-terminal region of MHJ_0194 (Djordjevic et al., 2004)

also bears no sequence identity to the S/T-X-F↓X-D/E consensus motif or to the
Mhp385 cleavage site sequence. Therefore, cleavage at this site is likely to be
performed by a different protease again. This cleavage event in MHJ_0194 is likely to
be significant in a biological context because it results in the separation of the R1
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cilium-binding domain from the R2 repeat region and effectively destroys a heparinbinding site (Jenkins et al., 2006). Collectively, our data suggest that endoproteolytic
processing of the P97 and P102 paralogues involves at least three proteases.
Both Mhp385 and Mhp384 contain several more S/T-X-F↓X-D/E-like motifs.
Further research is required to ascertain if cleavage is occurring at these sites. The
cleavage products identified in the current study were the strongly reactive protein
bands, other than Mhp385 preprotein (P115385), identified by immunoblotting, whose
identities were confirmed by LC-MS/MS. Immunoblots of whole cell lysates of M.
hyopneumoniae probed with anti-F4385 serum display a faint ladder suggesting further
cleavage of Mhp385, cross reactivity with other R1-containing M. hyopneumoniae
proteins or a combination of both. Future studies examining enriched fractions of the M.
hyopneumoniae proteome will assist in the identification and characterization of further
cleavage fragments. It is also possible that these cleavage sites are not accessible to the
protease(s) due to protein folding or the presence (or absence) of post-translational
modifications surrounding cleavage motifs. It is clear from data presented here and with
other P97 and P102 paralogue family members (Bogema et al., 2011; Burnett et al.,
2006; Djordjevic et al., 2004; Hsu et al., 1997; Seymour et al., 2010; Seymour et al.,
2011; Seymour et al., 2012; Wilton et al., 2009) that processing is complex and strainspecific. Further research is needed to refine our understanding of surface adhesin
processing and the precise role it plays in pathogenesis.
F4385 does not bind cilia and only showed evidence of weak heparin-binding.
Apart from 20 amino acids missing at the N-terminus of the fragment, F4385 is identical
to P27385. Therefore, in this study, we identify only weak heparin-binding as a function
of P27385; however, the weak binding suggests that this is not the main function of this
cleavage fragment. The release of P27385 from the C-terminus of Mhp385 is likely to be
important because the molecule contains a short R1-like motif comprised of four
tandem pentapeptide repeats. The cilium adhesins Mhp183 (P97) and Mhp271 are the
only other molecules in the four sequenced strains of M. hyopneumoniae to contain a R1
repeat region. Although the R1 repeat region in Mhp385 does not contain a sufficient
number of tandem R1 repeats for cilium-binding, the P97 R1 region is an immunogenic
domain (Chen et al., 2001), and R1 repeat regions may also be a source of surface
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variation with the number of tandem repeats in P97 and Mhp271 varying between field
strains(de Castro et al., 2006; Deutscher et al., 2010; Stakenborg et al., 2006; Wilton et
al., 1998). The function of the R1-like domain in Mhp385 is currently unknown,
although it contains the minimum number of tandem pentapeptide repeats sufficient to
bind the mAb F2G5 (Minion et al., 2000). This repeat region also shares high similarity
with porcine collagen type VI (α3 chain), which implicates that molecular mimicry may
be utilised as a means of avoiding host immune system recognition. P27385 remains
associated with the surface of M. hyopneumoniae cells despite the absence of anchorage
motifs and transmembrane domains.
Members of the P97 and P102 paralogue families have been shown to be
multifunctional proteins (Bogema et al., 2011; Burnett et al., 2006; Deutscher et al.,
2010; Jenkins et al., 2006; Seymour et al., 2010; Seymour et al., 2011; Seymour et al.,
2012; Wilton et al., 2009). We add Mhp385 and Mhp384 to that list with their ability to
bind cilia and GAGs. Gene families are common among the mycoplasmas and many
encode surface exposed lipoproteins that are purported to play a role in immune evasion
(Citti et al., 2000; Markham et al., 1999; Rosengarten and Wise, 1990). Most
lipoprotein family members are transcriptionally silent, with a single lipoprotein family
member dominating the cell surface architecture (Glew et al., 1995). Phase and
antigenic size variation of M. hyopneumoniae lipoproteins have not been reported, and
we have not identified evidence for such a mechanism from our proteome analyses.
Only a few genes in the M. hyopneumoniae genome display tandem repeat sequences
(Minion et al., 2004; Vasconcelos et al., 2005). Clearly, M. hyopneumoniae does not
appear to employ the same evasion strategies as reported for many other Mycoplasma
species. The surface architecture of M. hyopneumoniae is potentially quite variable with
P97, P102 and their paralogues being the specific target of several proteases. Genes
encoding members of the P97 and P102 paralogue families are derived from gene
fusions with unrelated sequences (Minion et al., 2004), and the C-terminal regions of
most P97 and P102 paralogues are novel. Our cumulative data suggest that processing
of P97, P102 and their paralogues generates N-terminal endoproteolytic fragments that
retain a transmembrane domain and remain tethered to the membrane, and C-terminal
cleavage fragments, often novel in sequence, that retain a presence on the surface of M.
hyopneumoniae despite lacking known anchorage motifs. All members of the P97 and
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P102 paralogue families characterised to date are targets of endoproteolytic cleavage
generating fragments that play essential roles in binding cilia, ECM molecules and
circulatory host proteins. Consequently, processing may represent a novel mechanism to
generate surface diversity. Further studies are needed to gain an understanding of the
proteases involved in adhesin processing and the circumstances that govern the
efficiency of cleavage.
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6.

Concluding Comments
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M. hyopneumoniae infections cause significant economic losses to the swine
production industry. Current vaccines against M. hyopneumoniae are expensive to
produce and are ineffective in eliminating M. hyopneumoniae from infected pigs and
preventing M. hyopneumoniae colonisation. The development of improved vaccines
requires a comprehensive understanding of the surface architecture of M.
hyopneumoniae and knowledge of the molecules that play important roles in adherence,
invasion and immune evasion. In this thesis we investigated 1) the interaction of M.
hyopneumoniae with plasminogen as a mechanism to enable dissemination from the site
of infection; 2) the role of the R1 and R2 repeat regions, which play important roles in
the archetype cilium adhesin P97, in M. hyopneumoniae proteins Mhp271 and Mhp385;
3) the binding properties of members of the P97 and P102 paralogue families, Mhp271,
Mhp385 and Mhp384; and 4) the endoproteolytic processing of Mhp271, Mhp385 and
Mhp384 that will play an important role in the functions of these molecules.
M. hyopneumoniae can occupy tissue sites distal from the respiratory tract
including the liver, spleen and kidneys in swine. We hypothesised that plasminogen
may be utilised by M. hyopneumoniae to disseminate from the site of infection. For this
to occur, proteins displayed on the cell surface of M. hyopneumoniae must be capable of
recruiting and activating plasminogen to the active serine protease plasmin. To
determine if M. hyopneumoniae binds plasminogen, porcine plasminogen was purified
from serum and used to show that M. hyopneumoniae binds plasminogen in a lysinedependent manner. The M. hyopneumoniae-bound plasminogen, once activated by tPA
or uPA, degrades fibrinogen and, therefore, has the potential to degrade other ECM
components. Like many microbial pathogens that recruit host plasminogen during
infection, M. hyopneumoniae does not appear to generate its own plasminogen activator
but is reliant on activators provided by the host. Plasmin activity in the BALF of swine
increases during M. hyopneumoniae infection (Seymour et al., 2012), suggesting that M.
hyopneumoniae may recruit plasminogen in the swine respiratory tract, which is
subsequently converted to plasmin using host activators. Further investigation is
required to see how M. hyopneumoniae utilises plasminogen/plasmin in vivo.
All M. hyopneumoniae cilium adhesins characterised to date belong to the P97
and P102 paralogue families. P97 was the first cilium adhesin identified and its gene is
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transcribed in vivo with its gene-operon partner P102 (Adams et al., 2005). Anti-P102
antibodies have been detected on the surface of respiratory cilia infected with M.
hyopneumoniae (Adams et al., 2005), suggesting it plays a role in binding cilia, and
P102 was recently shown to promote binding to PK15 cell monolayers (Seymour et al.,
2012). P97 binds cilia via a minimum of eight tandem R1 pentapeptide repeats (Minion
et al., 2000) and this domain remains the only cilium-binding region that is well
characterised in M. hyopneumoniae. We investigated the function of the tandem R1
repeat regions found within the C-terminus of the P97 paralogues Mhp271 and Mhp385.
The R1 repeat regions in each of these molecules have less than the eight tandem R1
repeats required for cilium-binding. We show that the number of repeats in the long R1
region and R2 region in Mhp271 varies, while the short R1 regions in Mhp271 and
Mhp385 are not highly variable, between the strains of M. hyopneumoniae analysed in
this study. The recombinant fragment of the C-terminus of Mhp271, F2271,
encompassing the long R1 region and the R2 region, binds heparin and heparin reduces
the adherence of F2271 to cilia. The R1 and R2 repeat regions in P97 do not bind cilia
when expressed separately (Jenkins et al., 2006). Thus, either the sequence(s) involved
in F2271 binding cilia and heparin are shared, binding heparin induces a conformational
change in F2271 such that it loses cilium-binding capacity, or the presence of an R2
region can compensate when less than eight tandem R1 repeats are present to enable
cilium-binding via the heparinase sensitive GAGs on the surface of cilia. Since the R1
region does not vary with passage, the variation in number of R1 and perhaps R2
repeats observed between M. hyopneumoniae strains appears to be the result of host
pressure (de Castro et al., 2006; Stakenborg et al., 2006; Wilton et al., 1998). Further
study is required to understand what triggers the variation within the R1 and R2 regions
while the rest of each of the proteins are conserved between strains.
Aside from a role in cilium-binding, we show that the R1 and R2 repeats regions
may be involved in binding fibronectin. We show that F2271 binds fibronectin in a dosedependent and saturating manner. It was recently found that a recombinant protein
containing the P97 R2 region binds fibronectin (Seymour, 2011); therefore, the R2
region may be responsible for F2271 binding to fibronectin. Fibronectin could be utilised
by M. hyopneumoniae to form molecular bridges between itself and its host cell
receptor integrin α5β1 to promote cell invasion. F2271 also possesses a C-terminal lysine,
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for which plasminogen often has a high affinity, though it was found to be an inefficient
plasminogen binder in SPR binding studies. No primary function was assigned to the Cterminal recombinant fragment of Mhp385 containing the R1 repeat region and a Cterminal lysine residue (F4385). The R1 and R2 repeat regions may, however, also be
involved in molecular mimicry as a result of their high similarity to porcine proteins.
The R1 and R2 tandem repeats share similarity to the repeat regions in porcine collagen
type VI (α3 isoform) and in porcine KIAA1398 protein, respectively.
Both the cilia-blocking mAbs F2G5 and F1B6, which recognise 2.5 tandem R1repeats (Minion et al., 2000; Zhang et al., 1995), and antiserum raised against the R1
repeat region in P97 (Djordjevic et al., 2004) detect a ladder of proteins in Western
blots against M. hyopneumoniae whole cell lysates. P97 is endoproteolytically cleaved
and a number of cleavage fragments have been characterised by MS; however,
processing of P97 is complex and strain-specific and further proteolytic events are yet to
be identified (Djordjevic et al., 2004). We show that Mhp271 and Mhp385 are
endoproteolytically cleaved, under the conditions used in this study. Tryptic peptides
unique to Mhp271 were detected by MS/MS from two slices of a 1D SDSpolyacrylamide gel of TX-114 aqueous phase extract of M. hyopneumoniae cells. Based
on the locations that these peptides were found on gel slices and the presence of the
same cleavage motif as in the N-terminal of P97 in a position two amino acids different,
we hypothesise that Mhp271 is cleaved at the same N-terminal cleavage site as P97.
Cross-reactivity due to significant sequence similarity between Mhp271 and P97
precluded an analysis of how Mhp271 contributes to the ladder of proteins generated by
mAb F1B6.
Mhp385 is only likely to contribute two bands to the ladder of proteins
mentioned - the preprotein (P115385) and the 27 kDa C-terminal cleavage fragment
(P27385). We showed that the Mhp385 preprotein (P115385) is cleaved once at a novel
cleavage site to form P88385 and P27385. Most paralogues undergo cleavage at S/T-XF↓X-D/E sites and cleavage at sites that conform strictly to this motif is typically
efficient (Bogema et al., 2011). The different cleavage motif in Mhp385 and the
identification of the Mhp385 preprotein indicate that Mhp385 is inefficiently cleaved by
a different protease. This is the first time a P97 paralogue (or a P102 paralogue) has
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been identified as a full length molecule (preprotein). The heparin- and cilium-binding
sites of Mhp385 lie within P88385. No primary function could be assigned to P27385
apart from the presence of the R1 repeats. The other known occurrence of inefficient
cleavage in M. hyopneumoniae occurs within the C-terminus of P97 between the R1 and
R2 repeat regions where the cleavage site does not conform to the S/T-X-F↓X-D/E
motif.
We also characterised the P102 paralogue Mhp384, whose gene is cotranscribed with mhp385 during M. hyopneumoniae infection. Mhp384 is efficiently
endoproteolytically cleaved within an S/T-X-F↓X-D/E-like site to form P60384 and
P50384, under the conditions used in this study. The cleavage site is located within a
large region (greater than 50 amino acids) of disorder. We also identified that the
cleavage site of the previously characterised P97 paralogue Mhp107 is at an S/T-XF↓X-D/E-like motif; however, the cleavage site is not within a region of disorder.
Therefore, further work is required to examine the role protein disorder plays in altering
the efficiency of endoproteolytic cleavage. Further work is also required to determine
whether other the S/T-X-F↓X-D/E-like motifs within both Mhp384 and Mhp385 are
also sites of endoproteolytic cleavage. The cleavage of Mhp384 will not destroy its
cilium-binding ability with each cleavage fragment containing at least one ciliumbinding domain. P50384 contains at least one heparin-binding domain. The location of
the heparin-binding domain within the recombinant fragment F2384 will determine
whether P60384 has heparin-binding ability.
Most members of the P97 and P102 paralogue families are endoproteolytically
cleaved. All cleavage fragments can be detected on the cell surface, though the
mechanism(s) of how they remain associated with the cell surface are unknown.
Efficient endoproteolytic cleavage suggests that cleavage is important for protein
function, while inefficient cleavage might serve to provide a surface architecture that is
antigenically and functionally versatile. Our results extend the knowledge of the surface
protein topography of M. hyopneumoniae and how surface proteins are modified posttranslationally, and identify Mhp271, Mhp385 and Mhp384 as potential adhesins of M.
hyopneumoniae. Although the vaccine potential of P97 and P102 paralogues described
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in this study was not determined, these proteins represent worthy candidates for
assessment in future vaccination trials.
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Appendix I Composition of Buffers and Solutions

Commonly Used Buffer Solutions
PBS (pH 7.2 or pH 7.5)
NaCl
KCl
Na2HPO4
KH2 PO4

8 g/L
0.2 g/L
1.15 g/L
0.30 g/L

PBST
Tween 20 in PBS

0.05% (v/v)

PBS-T
Tween 20 in PBS

0.1% (v/v)

Growth and Nutrient Media
LB Broth
tryptone
yeast extract
NaCl

10 g/L
5 g/L
5 g/L

LB Agar
tryptone
yeast extract
NaCl
agar

10 g/L
5 g/L
5 g/L
15 g/L

SOC Medium
tryptone
yeast extract
NaCl
KCl
MgCl2
MgSO4
glucose

2.0% (w/v)
0.5% (w/v)
10 mM
2.5 mM
10 mM
10 mM
20 mM

Glycerol Stock Solution
glycerol

50% (w/v)

Hanks Buffered Salt Solution for Modified Friis Medium
Hanks A
NaCl
80 g/500 mL
KCl
4 g/500 mL
1 g/500 mL
MgSO4
MgCl2
1 g/500 mL
CaCl2
1.4 g/500mL
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Hanks B
Na2HPO4
KH2PO4

1.5 g/500 mL
0.6 g/500 mL

0.5% Phenol Red (pH to 7.0)
phenol red
1 M sodium hydroxide

0.5 g/100 mL
1.1 mL/100 mL

Yeast Extract
Saccharomyces cerevisiae (Baker's yeast) type II
Modified Friis Medium (pH 7.4)
hanks A
hanks B
brain heart infusion
PPLO without CV
0.5% phenol red
Milli-Q water
bacitracin
ampicillin/methicillin
yeast extract
horse serum
pig serum

167 g/L

15.2 mL
15.2 mL
4.9 g
5.25 g
2.6 mL
827 mL
0.144 g/5.7 mL
0.144 g/5.7 mL
34 mL
50 mL
50 mL

Agarose Gel Electrophoresis Reagents
5X TBE Buffer (Stock Solution)
Tris
boric acid
0.5 M EDTA (pH 8.0)

54 g/L
27.5 g/L
20 mL/L

0.5X TBE Running Buffer (Working Solution)
5X TBE buffer
100 mL/L
Milli-Q water
900 mL/L
Loading Dye
bromophenol blue
ficoll

0.25% (w/v)
15% (w/v)

DNA Sequencing
5X Sequencing Buffer
Tris-HCl
MgCl2

400 mM (pH 9)
10 mM

EDTA-Blue Dextran Solution
EDTA (pH 8.0)
blue dextran

25 mM
50 mg/mL
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DNA Sequencing Loading Dye
formamide
EDTA-blue dextran solution

250 µL
50 µL

Recombinant Protein Purification
Buffer B (pH 8.0)
urea
NaH2PO4
Tris

8M
0.1 M
0.01 M

Buffer C (pH 6.3)
urea
NaH2PO4
Tris

8M
0.1 M
0.01 M

Buffer D (pH 5.9)
urea
NaH2PO4
Tris

8M
0.1 M
0.01 M

Buffer E (pH 4.5)
urea
NaH2PO4
Tris

8M
0.1 M
0.01 M

Native Lysis Buffer
lysozyme
Tris-HCl (pH 8.0)

10 mg/mL
25 mM

Glutathione Elution Buffer (pH 8.0)
Tris-HCl
reduced glutathione

50 mM
10 mM

Plasminogen Purification Reagents
High Salt Wash Buffer (pH 7.5)
Na2HPO4
NaCl
EDTA
PMSF

0.05 M
5M
5 mM
1 mM

εACA Elution Buffer (pH 7.5)
εACA in PBS

200 mM
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Protein Quantification
Bradford Reagent
Coomassie G-250
ethanol (100%)
orthophosphoric acid (85%)

100 mg/L
50 mL/L
100 mL/L

SDS-PAGE Solutions
10X SDS-PAGE Running Buffer / Laemmli Buffer
Tris
250 mM
glycine
1.92 M
SDS
1% (w/v)
SDS-PAGE Sample Buffer (4X)
1 M Tris (pH 6.8)
SDS
β-mercaptoethanol
glycerol
bromophenol blue

60 mM
1 g/100 mL
1 g/100 mL
10 g/100 mL
0.01 g/100 mL

Laemmli 7% Resolving Gel (4 gels)
Milli-Q water
30% acrylamide-bis solution (29:1)
1.5 M Tris (pH 8.8)
10% SDS
APS
TEMED

20.3 mL
9.31 mL
10.0 mL
400 µL
45 mg
16 µL

Laemmli 10% Resolving Gel (4 gels)
Milli-Q water
30% acrylamide-bis solution (29:1)
1.5 M Tris (pH 8.8)
10% SDS
APS
TEMED

15.9 mL
13.3 mL
10.0 mL
400 µL
45 mg
16 µL

Laemmli 12% Resolving Gel (4 gels)
Milli-Q water
30% acrylamide-bis solution (29:1)
1.5 M Tris (pH 8.8)
10% SDS
APS
TEMED

13.2 mL
16.0 mL
10.0 mL
400 µL
45 mg
16 µL
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Laemmli 15% Resolving Gel (4 gels)
Milli-Q water
30% acrylamide-bis solution (29:1)
1.5 M Tris (pH 8.8)
10% (w/v) SDS
APS
TEMED

9.2 mL
20.0 mL
10.0 mL
400 µL
45 mg
16 µL

Laemmli 4% Stacking Gel (4 gels)
Milli-Q water
30% acrylamide-bis solution (29:1)
1 M Tris (pH 6.8)
10% (w/v) SDS
APS
TEMED

10.83 mL
1.95 mL
1.95 mL
150 µL
10 mg
11 µL

2D SDS-PAGE Reagents
TX-114 Buffer
TX-114
Tris-HCl (pH 8.0)
NaCl
EDTA

1% (v/v)
10 mM
150 mM
1 mM

Equilibration Buffer
urea
SDS
Tris-HCl (pH 8.5)
bromophenol blue

6M
2% (w/v)
250 mM
0.0025% (w/v)

SSS
urea
DTT
CHAPS
Bio-Lyte 3/10 ampholyte (Bio-Rad)
Tris

9.6 g/20 mL
0.308 g/20 mL
0.8 g/20 mL
0.4 mL/20 mL
0.097 g/20 mL

MSS
urea
thiourea
DTT
CHAPS
sulfobetaine
Bio-Lyte 3/10 ampholyte (Bio-Rad)
Tris

6 g/20 mL
3.04 g/20 mL
0.2 g/20 mL
0.4 g/20 mL
0.4 g/20 mL
0.4 mL/20 mL
0.1 g/20 mL

Bromophenol Blue Solution
bromophenol blue

0.1 g/10 mL
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Agarose Gel Overlay Solution
agarose
1X SDS-PAGE running buffer
bromophenol blue solution

0.5 g
100 mL
0.1 mL

Protein Staining Reagents
Fixing Solution
methanol
acetic acid
formalin
Milli-Q water

50 mL
12 mL
38 µL
38 mL

Silver Nitrate Solution
silver nitrate
Milli-Q water
formalin

0.2 g
100 mL
75 µL

Colloidal Coomassie
ammonium sulfate
phosphoric acid (85%)
Coomassie G-250
methanol

17% (w/v)
3.6% (v/v)
0.1% (w/v)
34% (v/v)

Colloidal Coomassie Destain
acetic acid

1% (v/v)

Amido Black Protein Stain
amido black
acetic acid

0.2 g/200 mL
14 mL/200 mL

Amido Black Destain
acetic acid

14 mL/200 mL

Mass Spectrometry
Solubilisation Buffer
urea
thiourea
Tris
C7bZ0

7M
2M
40 mM
1% (w/v)

MS Buffer A
acetonitrile
formic acid

2% (v/v)
0.2% (v/v)
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MS Buffer B
acetonitrile
formic acid

98% (v/v)
0.2% (v/v)

Urea Buffer (pH 9)
urea
NH4HCO3

8M
100 mM

SCX Buffer A
KH2PO4
acetonitrile

20 mM (pH 3)
20 % (v/v)

SCX Buffer B
KH2PO4
acetonitrile
KCl

20 mM (pH 3)
20% (v/v)
0.5 M

Immunoblot and Ligand Blot Analysis
10X Western Transfer Buffer
Tris
glycine
SDS

250 mM
1.92 M
0.4% (w/v)

1X Western Transfer Buffer
10X Western transfer buffer
methanol
Milli-Q water

100 mL/L
200 mL/L
700 mL/L

TBS (pH 7.4)
Tris
NaCl

10 mM
150 mM

TBST (pH 7.4)
Tween 20 in TBS

0.05% (v/v)

Developing Solution
DAB
100 mM Tris (pH 7.6)
0.03% H2O2

25 mg
50 mL
7.5 µL

Microtitre Plate Binding Analysis
Carbonate Coating Buffer (pH 9.5-9.7)
NaHCO3
Na2CO3

1.47 g/500 mL
0.8 g/500 mL
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ABTS Solution (per 96 well microtitre plate)
0.1 M citric acid
4.41 mL
0.2 M Na2HPO4
3.09 mL
Milli-Q water
7.5 mL
ABTS
8.25 mg
H2O2
4.5 µL
p-Nitrophenyl Phosphate Substrate Buffer (pH 9.3)
4-nitrophenyl phosphate disodium salt hexahydrate
NaCO3
MgCl2

1 mg/mL
50 mM
1 mM

Surface Plasmon Resonance
HBS-EP+
HEPES
NaCl
EDTA
surfactant P20

10 mM
150 mM NaCl
3 mM
0.05% (v/v)
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Appendix II Supplementary Data

Table 9.1 Fragment ions for the peptides belonging to Mhp271 identified by LCMS/MS analysis of gel slice B in Figure 4.3D. This gel slice includes the 95 to 115 kDa
proteins of a TX-114 aqueous phase extract from M. hyopneumoniae strain 232 cells.
Mascot table of fragment ions and Mascot annotated MS/MS spectra are shown for each
peptide unique to Mhp271 that was identified. Mascot matched ions are shown in red.
Missed ions found by manual inspection of the raw spectra are in pink.
A) Peptide: VLDFQEDLNQAR; mass: 724.361118 (2+); Mascot ions score: 37.
#

b

b++

1

100.0757

50.5415

2

213.1598 107.0835

3

328.1867 164.5970

310.1761 155.5917

D

4

475.2551 238.1312

457.2445 229.1259

F

5

603.3137 302.1605

586.2871 293.6472

585.3031 293.1552

Q

6

732.3563 366.6818

715.3297 358.1685

714.3457 357.6765

E

7

847.3832 424.1953

830.3567 415.6820

829.3727 415.1900

D

8

960.4673 480.7373

943.4407 472.2240

942.4567 471.7320

L

b*

b*++

b0

b0++

Seq.
V
L

9 1074.5102 537.7587 1057.4837 529.2455 1056.4997 528.7535

N

10 1202.5688 601.7880 1185.5422 593.2748 1184.5582 592.7828

Q

11 1273.6059 637.3066 1256.5794 628.7933 1255.5953 628.3013

A

12

R

Seq.

y

y++

y*

y*++

y0

y0++

#

V

12

L

1348.6492 674.8282 1331.6226 666.3149 1330.6386 665.8229 11

D

1235.5651 618.2862 1218.5386 609.7729 1217.5545 609.2809 10

F

1120.5382 560.7727 1103.5116 552.2594 1102.5276 551.7674

9

Q

973.4697 487.2385

956.4432 478.7252

955.4592 478.2332

8

E

845.4112 423.2092

828.3846 414.6959

827.4006 414.2039

7

D

716.3686 358.6879

699.3420 350.1747

698.3580 349.6826

6

L

601.3416 301.1745

584.3151 292.6612

5

N

488.2576 244.6324

471.2310 236.1191

4

Q

374.2146 187.6110

357.1881 179.0977

3

A

246.1561 123.5817

229.1295 115.0684

2

R

175.1190

158.0924

1

88.0631

79.5498

169

B) Peptide: LTEYIQELGTK; mass: 647.845991 (2+); Mascot ions score: 36.
#

b

b++

1

114.0913

57.5493

2

215.1390 108.0731

197.1285

99.0679

T

3

344.1816 172.5944

326.1710 163.5892

E

4

507.2449 254.1261

489.2344 245.1208

Y

5

620.3290 310.6681

602.3184 301.6629

I

6

748.3876 374.6974

731.3610 366.1842

730.3770 365.6921

Q

7

877.4302 439.2187

860.4036 430.7055

859.4196 430.2134

E

8

990.5142 495.7608

973.4877 487.2475

972.5037 486.7555

L

b*

b*++

b0

b0++

Seq.
L

9 1047.5357 524.2715 1030.5092 515.7582 1029.5251 515.2662

G

10 1148.5834 574.7953 1131.5568 566.2821 1130.5728 565.7900

T

11

K

Seq.

y

y++

y*

y*++

y0

y0++

#

L

11

T

1181.6048 591.3061 1164.5783 582.7928 1163.5943 582.3008 10

E

1080.5572 540.7822 1063.5306 532.2689 1062.5466 531.7769

9

Y

951.5146 476.2609

934.4880 467.7477

933.5040 467.2556

8

I

788.4512 394.7293

771.4247 386.2160

770.4407 385.7240

7

Q

675.3672 338.1872

658.3406 329.6740

657.3566 329.1819

6

E

547.3086 274.1579

530.2821 265.6447

529.2980 265.1527

5

L

418.2660 209.6366

401.2395 201.1234

400.2554 200.6314

4

G

305.1819 153.0946

288.1554 144.5813

287.1714 144.0893

3

T

248.1605 124.5839

231.1339 116.0706

230.1499 115.5786

2

K

147.1128

130.0863

74.0600

65.5468

1
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C) Peptide: TSTNLPENIIAR; mass: 664.857306 (2+); Mascot ions score: 46.
#

b

b++

b0++

Seq.

1

102.0550

51.5311

2

189.0870

95.0471

84.0444

42.5258

T

171.0764

86.0418

S

3

290.1347 145.5710

272.1241 136.5657

T

4

404.1776 202.5924

5

517.2617 259.1345

387.1510 194.0792

386.1670 193.5872

N

500.2351 250.6212

499.2511 250.1292

L

6

614.3144 307.6608

7

743.3570 372.1821

597.2879 299.1476

596.3039 298.6556

P

726.3305 363.6689

725.3464 363.1769

E

8
9

857.3999 429.2036

840.3734 420.6903

839.3894 420.1983

N

970.4840 485.7456

953.4575 477.2324

952.4734 476.7404

I

10 1083.5681 542.2877 1066.5415 533.7744 1065.5575 533.2824

I

11 1154.6052 577.8062 1137.5786 569.2930 1136.5946 568.8009

A

12

R

Seq.

y

y++

b*

y*

b*++

y*++

b0

y0

y0++

#

T

12

S

1227.6692 614.3382 1210.6426 605.8250 1209.6586 605.3329 11

T

1140.6371 570.8222 1123.6106 562.3089 1122.6266 561.8169 10

N

1039.5895 520.2984 1022.5629 511.7851 1021.5789 511.2931

9

L

925.5465 463.2769

908.5200 454.7636

907.5360 454.2716

8

P

812.4625 406.7349

795.4359 398.2216

794.4519 397.7296

7

E

715.4097 358.2085

698.3832 349.6952

697.3991 349.2032

6

N

586.3671 293.6872

569.3406 285.1739

5

I

472.3242 236.6657

455.2976 228.1525

4

I

359.2401 180.1237

342.2136 171.6104

3

A

246.1561 123.5817

229.1295 115.0684

2

R

175.1190

158.0924

1

88.0631

79.5498
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D) Peptide: LTGFDQGLNNQLPK; mass: 772.899167 (2+); Mascot ions score: 55.
b

b++

b0

b0++

Seq.

1

114.0913

57.5493

2

215.1390 108.0731

197.1285

99.0679

T

3

272.1605 136.5839

254.1499 127.5786

G

4

419.2289 210.1181

401.2183 201.1128

F

5

534.2558 267.6316

516.2453 258.6263

D

#

b*

b*++

L

6

662.3144 331.6608

645.2879 323.1476

644.3039 322.6556

Q

7

719.3359 360.1716

702.3093 351.6583

701.3253 351.1663

G

8

832.4199 416.7136

815.3934 408.2003

814.4094 407.7083

L

9

946.4629 473.7351

929.4363 465.2218

928.4523 464.7298

N

10 1060.5058 530.7565 1043.4793 522.2433 1042.4952 521.7513

N

11 1188.5644 594.7858 1171.5378 586.2726 1170.5538 585.7805

Q

12 1301.6484 651.3279 1284.6219 642.8146 1283.6379 642.3226

L

13 1398.7012 699.8542 1381.6747 691.3410 1380.6906 690.8490

P

14

K

Seq.

y

y++

y*

y*++

y0

y0++

#

L

14

T

1431.7227 716.3650 1414.6961 707.8517 1413.7121 707.3597 13

G

1330.6750 665.8411 1313.6484 657.3279 1312.6644 656.8359 12

F

1273.6535 637.3304 1256.6270 628.8171 1255.6430 628.3251 11

D

1126.5851 563.7962 1109.5586 555.2829 1108.5745 554.7909 10

Q

1011.5582 506.2827

994.5316 497.7694

9

G

883.4996 442.2534

866.4730 433.7402

8

L

826.4781 413.7427

809.4516 405.2294

7

N

713.3941 357.2007

696.3675 348.6874

6

N

599.3511 300.1792

582.3246 291.6659

5

Q

485.3082 243.1577

468.2817 234.6445

4

L

357.2496 179.1285

340.2231 170.6152

3

P

244.1656 122.5864

227.1390 114.0731

2

K

147.1128

130.0863

1

74.0600

65.5468
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Table 9.2 Fragment ions for the peptide Mhp271AAVSEAGIAEILSR identified by
LC-MS/MS of gel slice C (Figure 4.3D) containing 75 to 95 kDa proteins of a TX-114
aqueous phase extract from M. hyopneumoniae strain 232 cells. Mascot table of
fragment ions and Mascot annotated MS/MS spectra are shown. Mascot matched ions
are shown in red. This peptide had a mass of 693.876453 (2+) and Mascot ions score of
97.
#

b

b++

b0

b0++

Seq.

y

y++

y*

y*++

y0

y0++

#

1

72.0444

36.5258

A

14

2

143.0815

72.0444

A

1315.7216 658.3644 1298.6951 649.8512 1297.7110 649.3592 13

3

242.1499 121.5786

V

1244.6845 622.8459 1227.6579 614.3326 1226.6739 613.8406 12

4

329.1819 165.0946

311.1714 156.0893

S

1145.6161 573.3117 1128.5895 564.7984 1127.6055 564.3064 11

5

458.2245 229.6159

440.2140 220.6106

E

1058.5841 529.7957 1041.5575 521.2824 1040.5735 520.7904 10

6

529.2617 265.1345

511.2511 256.1292

A

929.5415 465.2744

912.5149 456.7611

911.5309 456.2691

9

7

586.2831 293.6452

568.2726 284.6399

G

858.5043 429.7558

841.4778 421.2425

840.4938 420.7505

8

8

699.3672 350.1872

681.3566 341.1819

I

801.4829 401.2451

784.4563 392.7318

783.4723 392.2398

7

9

770.4043 385.7058

752.3937 376.7005

A

688.3988 344.7030

671.3723 336.1898

670.3882 335.6978

6

10

899.4469 450.2271

881.4363 441.2218

E

617.3617 309.1845

600.3352 300.6712

599.3511 300.1792

5

11 1012.5310 506.7691

994.5204 497.7638

I

488.3191 244.6632

471.2926 236.1499

470.3085 235.6579

4

12 1125.6150 563.3111 1107.6045 554.3059

L

375.2350 188.1212

358.2085 179.6079

357.2245 179.1159

3

13 1212.6470 606.8272 1194.6365 597.8219

S

262.1510 131.5791

245.1244 123.0659

244.1404 122.5738

2

14

R

175.1190

158.0924

88.0631

79.5498

1

173

Table 9.3 List of peptides unique to P97 identified in LC-MS/MS analysis of gel slices
B and C (Figure 4.3D). Gel slice B includes the 95 to 115 kDa proteins, while gel slice
C includes the 75 to 95 kDa proteins, of a TX-114 aqueous phase extract from M.
hyopneumoniae strain 232 cells separated by 1D SDS-PAGE.
Peptide
Slice B

Score

K.VEVEALFK.G
R.NPEDLDIK.L
K.SIVLIPYR.L
K.SVLNSWTGK.I
K.AEISNLLNK.K
K.KWGLETNR.A
K.SGFFPGDKR.S
K.NLLEGTDFK.T
K.LANYFPVLK.N
K.KENIYDFGK.Y
K.AEISNLLNKK.E
K.KKDPYNQIK.E
K.DIFAEADKLK.F
K.YSLIENSAFK.T
K.TEYLPFFEK.G
K.DKSIVLIPYR.L
K.LNQQIENLSTK.I
K.NEAQIFEALKK.Y
K.KYSLIENSAFK.T
K.FFADDLYPDTK.D
K.AAQFNNFAPWAK.L
K.SDIYEQTVAFAK.Q
K.LTILETLYDLAK.K
K.EDYFPMAFSYK.L
K.EDYFPMAFSYK.L
R.AIDFQYDLNTAR.N
K.EIHQLSFNILAR.N
K.IDLPNINQQIFK.T
K.LEYTDENKLSLK.T
K.IGSNSVLNQPQTTK.E
K.LDDNLQYSFEAIK.K
K.GQNLSAYEFLADIK.S
K.DKFFADDLYPDTK.D
K.TVLNLQYQFQEVK.V
K.TEVELIEDNIAGDAK.L
K.SDGFYGVLLLPQSVK.T
K.DKLTILETLYDLAK.K
K.LDDNLQYSFEAIKK.G
K.TTILDKNLLEGTDFK.T
K.LPNNLGNIFEFSFAK.D
K.NGHQVASYFQDLLTK.D
K.TELEGKNEAQIFEALK.K
K.LDYGNILNPYNTQLAK.V
R.EILASPDEVQPVINILR.L
K.TELEGKNEAQIFEALKK.Y

38
30
32
46
38
46
43
42
52
71
60
47
41
56
44
44
43
56
19
55
66
45
57
33
46
65
56
35
61
104
59
76
89
101
88
69
100
46
79
87
34
38
49
80
82
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R.LNSPNLEYSLDAASASLDK.K
K.FFADDLYPDTKDNILVK.E
K.ELDKTVLNLQYQFQEVK.V
R.LNSPNLEYSLDAASASLDKK.D
K.DNSSYFLNFEDFVNNLTLK.N
K.DSSTNQYVSIQNQIPSLFLK.A
K.NQEIYQALDGNYAYEFGAFK.S
K.AEGAPSQQSPTTELTNYLPDLGK.K
K.AEGAPSQQSPTTELTNYLPDLGKK.I
K.KAEGAPSQQSPTTELTNYLPDLGK.K
K.KAEGAPSQQSPTTELTNYLPDLGKK.I

102
28
69
93
59
69
70
39
29
68
49

Slice C
K.SIVLIPYR.L
K.ENIYDFGK.Y
K.SVLNSWTGK.I
K.SGFFPGDKR.S
K.LANYFPVLK.N

31
40
36
34
41

K.AEISNLLNKK.E
K.DIFAEADKLK.F
K.YSLIENSAFK.T
K.TEYLPFFEK.G
K.NEAQIFEALKK.Y

45
42
41
48
53

K.FFADDLYPDTK.D
K.AAQFNNFAPWAK.L
K.LTILETLYDLAK.K
K.EDYFPMAFSYK.L
K.EDYFPMAFSYK.L
R.AIDFQYDLNTAR.N
K.EIHQLSFNILAR.N
K.IGSNSVLNQPQTTK.E
K.LDDNLQYSFEAIK.K
K.GQNLSAYEFLADIK.S
K.DKFFADDLYPDTK.D
K.TVLNLQYQFQEVK.V
K.TEVELIEDNIAGDAK.L
K.SDGFYGVLLLPQSVK.T
K.DKLTILETLYDLAK.K
K.LDDNLQYSFEAIKK.G
K.LPNNLGNIFEFSFAK.D
K.LDYGNILNPYNTQLAK.V
R.EILASPDEVQPVINILR.L
K.TELEGKNEAQIFEALKK.Y
R.LNSPNLEYSLDAASASLDK.K
K.ELDKTVLNLQYQFQEVK.V
R.LNSPNLEYSLDAASASLDKK.D
K.DNSSYFLNFEDFVNNLTLK.N
K.DSSTNQYVSIQNQIPSLFLK.A
K.NQEIYQALDGNYAYEFGAFK.S
K.AEGAPSQQSPTTELTNYLPDLGK.K
K.AEGAPSQQSPTTELTNYLPDLGKK.I

75
56
42
33
42
46
42
89
69
57
80
48
40
48
88
21
82
55
89
24
104
46
23
80
44
102
50
38
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Table 9.4 Fragment ions for the peptides identified as belonging to MHJ_0105 from 2D
LC-MS/MS of a trypsin digested M. hyopneumoniae strain J proteome. Mascot table of
fragment ions and Mascot annotated MS/MS spectra are shown. Mascot matched ions
are shown in red. Missed ions found by manual inspection of the raw spectra are in
pink.
A) Peptide: FDFGKLDSIFSGK; mass: 487.632711 (3+); Mascot ions score: 27.
b

b++

1

148.0757

74.5415

2

263.1026 132.0550

245.0921 123.0497

D

3

410.1710 205.5892

392.1605 196.5839

F

#

b*

b*++

b0

b0++

Seq.
F

4

467.1925 234.0999

449.1819 225.0946

G

5

595.2875 298.1474

578.2609 289.6341

577.2769 289.1421

K

6

708.3715 354.6894

691.3450 346.1761

690.3610 345.6841

L

7

823.3985 412.2029

806.3719 403.6896

805.3879 403.1976

D

8

910.4305 455.7189

893.4040 447.2056

892.4199 446.7136

S

9 1023.5146 512.2609 1006.4880 503.7476 1005.5040 503.2556

I

10 1170.5830 585.7951 1153.5564 577.2819 1152.5724 576.7898

F

11 1257.6150 629.3111 1240.5885 620.7979 1239.6045 620.3059

S

12 1314.6365 657.8219 1297.6099 649.3086 1296.6259 648.8166

G

13

K

Seq.

y

y++

y*

y*++

y0

y0++

#

F

13

D

1313.6736 657.3404 1296.6470 648.8272 1295.6630 648.3352 12

F

1198.6467 599.8270 1181.6201 591.3137 1180.6361 590.8217 11

G

1051.5782 526.2928 1034.5517 517.7795 1033.5677 517.2875 10

K

994.5568 497.7820

977.5302 489.2687

976.5462 488.7767

9

L

866.4618 433.7345

849.4353 425.2213

848.4512 424.7293

8

D

753.3777 377.1925

736.3512 368.6792

735.3672 368.1872

7

S

638.3508 319.6790

621.3243 311.1658

620.3402 310.6738

6

I

551.3188 276.1630

534.2922 267.6498

533.3082 267.1577

5

F

438.2347 219.6210

421.2082 211.1077

420.2241 210.6157

4

S

291.1663 146.0868

274.1397 137.5735

273.1557 137.0815

3

G

204.1343 102.5708

187.1077

94.0575

2

K

147.1128

130.0863

65.5468

1

74.0600
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B) Peptide: IKFDFGKLDSIFSGK; mass: 568.032057 (3+); Mascot ions score: 38.
b

b++

1

114.0913

57.5493

2

242.1863 121.5968

225.1598 113.0835

K

3

389.2547 195.1310

372.2282 186.6177

F

4

504.2817 252.6445

487.2551 244.1312

486.2711 243.6392

D

5

651.3501 326.1787

634.3235 317.6654

633.3395 317.1734

F

6

708.3715 354.6894

691.3450 346.1761

690.3610 345.6841

G

7

836.4665 418.7369

819.4400 410.2236

818.4559 409.7316

K

8

949.5506 475.2789

932.5240 466.7656

#

b*

b*++

b0

b0++

Seq.
I

931.5400 466.2736

L

9 1064.5775 532.7924 1047.5510 524.2791 1046.5669 523.7871

D

10 1151.6095 576.3084 1134.5830 567.7951 1133.5990 567.3031

S

11 1264.6936 632.8504 1247.6671 624.3372 1246.6830 623.8452

I

12 1411.7620 706.3846 1394.7355 697.8714 1393.7514 697.3794

F

13 1498.7940 749.9007 1481.7675 741.3874 1480.7835 740.8954

S

14 1555.8155 778.4114 1538.7890 769.8981 1537.8049 769.4061

G

15

K

Seq.

y

y++

y*

y*++

y0

y0++

#

I

15

K

1588.8370 794.9221 1571.8104 786.4088 1570.8264 785.9168 14

F

1460.7420 730.8746 1443.7155 722.3614 1442.7314 721.8694 13

D

1313.6736 657.3404 1296.6470 648.8272 1295.6630 648.3352 12

F

1198.6467 599.8270 1181.6201 591.3137 1180.6361 590.8217 11

G

1051.5782 526.2928 1034.5517 517.7795 1033.5677 517.2875 10

K

994.5568 497.7820

977.5302 489.2687

976.5462 488.7767

9

L

866.4618 433.7345

849.4353 425.2213

848.4512 424.7293

8

D

753.3777 377.1925

736.3512 368.6792

735.3672 368.1872

7

S

638.3508 319.6790

621.3243 311.1658

620.3402 310.6738

6

I

551.3188 276.1630

534.2922 267.6498

533.3082 267.1577

5

F

438.2347 219.6210

421.2082 211.1077

420.2241 210.6157

4

S

291.1663 146.0868

274.1397 137.5735

273.1557 137.0815

3

G

204.1343 102.5708

187.1077

94.0575

2

K

147.1128

130.0863

65.5468

1

74.0600
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C) Peptide: KLAIYFPSLDNLITK; mass: 579.360491 (3+); Mascot ions score: 33.
#

b

b++

1

129.1022

65.0548

56.5415

K

2

242.1863 121.5968

225.1598 113.0835

L

3

313.2234 157.1153

296.1969 148.6021

A

4

426.3075 213.6574

409.2809 205.1441

I

5

589.3708 295.1890

572.3443 286.6758

Y

6

736.4392 368.7233

719.4127 360.2100

F

7

833.4920 417.2496

816.4654 408.7364

8

920.5240 460.7656

903.4975 452.2524

b*
112.0757

b*++

b0

b0++

Seq.

P
902.5135 451.7604

S

9 1033.6081 517.3077 1016.5815 508.7944 1015.5975 508.3024

L

10 1148.6350 574.8211 1131.6085 566.3079 1130.6245 565.8159

D

11 1262.6780 631.8426 1245.6514 623.3293 1244.6674 622.8373

N

12 1375.7620 688.3846 1358.7355 679.8714 1357.7514 679.3794

L

13 1488.8461 744.9267 1471.8195 736.4134 1470.8355 735.9214

I

14 1589.8938 795.4505 1572.8672 786.9372 1571.8832 786.4452

T

15

K

Seq.

y

y++

y*

y*++

y0

y0++

#

K

15

L

1607.9043 804.4558 1590.8778 795.9425 1589.8938 795.4505 14

A

1494.8203 747.9138 1477.7937 739.4005 1476.8097 738.9085 13

I

1423.7831 712.3952 1406.7566 703.8819 1405.7726 703.3899 12

Y

1310.6991 655.8532 1293.6725 647.3399 1292.6885 646.8479 11

F

1147.6358 574.3215 1130.6092 565.8082 1129.6252 565.3162 10

P

1000.5673 500.7873

983.5408 492.2740

982.5568 491.7820

9

S

903.5146 452.2609

886.4880 443.7476

885.5040 443.2556

8

L

816.4825 408.7449

799.4560 400.2316

798.4720 399.7396

7

D

703.3985 352.2029

686.3719 343.6896

685.3879 343.1976

6

N

588.3715 294.6894

571.3450 286.1761

570.3610 285.6841

5

L

474.3286 237.6679

457.3021 229.1547

456.3180 228.6627

4

I

361.2445 181.1259

344.2180 172.6126

343.2340 172.1206

3

T

248.1605 124.5839

231.1339 116.0706

230.1499 115.5786

2

K

147.1128

130.0863

74.0600

65.5468

1
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D) Peptide: KLLEGEDFENFGDLLK; mass: 623.043763 (3+); Mascot ions score: 67.
#

b++

b

b*

b*++

1

129.1022

2

242.1863 121.5968

3

355.2704 178.1388

338.2438 169.6255

4

484.3130 242.6601

467.2864 234.1468

5

541.3344 271.1709

6

670.3770 335.6921

7
8

65.0548

b0

b0++

Seq.

56.5415

K

225.1598 113.0835

L

112.0757

L
466.3024 233.6548

E

524.3079 262.6576

523.3239 262.1656

G

653.3505 327.1789

652.3665 326.6869

E

785.4040 393.2056

768.3774 384.6923

767.3934 384.2003

D

932.4724 466.7398

915.4458 458.2266

914.4618 457.7345

F

9 1061.5150 531.2611 1044.4884 522.7478 1043.5044 522.2558

E

10 1175.5579 588.2826 1158.5313 579.7693 1157.5473 579.2773

N

11 1322.6263 661.8168 1305.5998 653.3035 1304.6157 652.8115

F

12 1379.6478 690.3275 1362.6212 681.8142 1361.6372 681.3222

G

13 1494.6747 747.8410 1477.6482 739.3277 1476.6642 738.8357

D

14 1607.7588 804.3830 1590.7322 795.8698 1589.7482 795.3777

L

15 1720.8428 860.9251 1703.8163 852.4118 1702.8323 851.9198

L

16

K

Seq.

y

y++

y*

y*++

y0

y0++

#

K

16

L

1738.8534 869.9303 1721.8269 861.4171 1720.8428 860.9251 15

L

1625.7693 813.3883 1608.7428 804.8750 1607.7588 804.3830 14

E

1512.6853 756.8463 1495.6587 748.3330 1494.6747 747.8410 13

G

1383.6427 692.3250 1366.6161 683.8117 1365.6321 683.3197 12

E

1326.6212 663.8142 1309.5947 655.3010 1308.6107 654.8090 11

D

1197.5786 599.2930 1180.5521 590.7797 1179.5681 590.2877 10

F

1082.5517 541.7795 1065.5251 533.2662 1064.5411 532.7742

9

E

935.4833 468.2453

918.4567 459.7320

917.4727 459.2400

8

N

806.4407 403.7240

789.4141 395.2107

788.4301 394.7187

7

F

692.3978 346.7025

675.3712 338.1892

674.3872 337.6972

6

G

545.3293 273.1683

528.3028 264.6550

527.3188 264.1630

5

D

488.3079 244.6576

471.2813 236.1443

470.2973 235.6523

4

L

373.2809 187.1441

356.2544 178.6308

3

L

260.1969 130.6021

243.1703 122.0888

2

K

147.1128

130.0863

1

74.0600

65.5468
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E) Peptide: LNESSENKLPGNSGHIFEFSLRR; mass: 658.633615 (4+); Mascot ions
score: 21.
#

b++

b

b*

b*++

b0

b0++

Seq.

1

114.0913

57.5493

2

228.1343

114.5708

211.1077

106.0575

L

3

357.1769

179.0921

340.1503

170.5788

339.1663

170.0868

E

4

444.2089

222.6081

427.1823

214.0948

426.1983

213.6028

S

5

531.2409

266.1241

514.2144

257.6108

513.2304

257.1188

S

6

660.2835

330.6454

643.2570

322.1321

642.2729

321.6401

E

7

774.3264

387.6669

757.2999

379.1536

756.3159

378.6616

N

8

902.4214

451.7143

885.3948

443.2011

884.4108

442.7091

K

9 1015.5055 508.2564

998.4789

499.7431

997.4949

499.2511

L

10 1112.5582 556.7828 1095.5317 548.2695 1094.5477 547.7775

P

N

11 1169.5797 585.2935 1152.5531 576.7802 1151.5691 576.2882

G

12 1283.6226 642.3149 1266.5961 633.8017 1265.6121 633.3097

N

13 1370.6546 685.8310 1353.6281 677.3177 1352.6441 676.8257

S

14 1427.6761 714.3417 1410.6496 705.8284 1409.6655 705.3364

G

15 1564.7350 782.8711 1547.7085 774.3579 1546.7245 773.8659

H

16 1677.8191 839.4132 1660.7925 830.8999 1659.8085 830.4079

I

17 1824.8875 912.9474 1807.8610 904.4341 1806.8769 903.9421

F

18 1953.9301 977.4687 1936.9035 968.9554 1935.9195 968.4634

E

19 2100.9985 1051.0029 2083.9720 1042.4896 2082.9879 1041.9976

F

20 2188.0305 1094.5189 2171.0040 1086.0056 2170.0200 1085.5136

S

21 2301.1146 1151.0609 2284.0880 1142.5477 2283.1040 1142.0557

L

22 2457.2157 1229.1115 2440.1892 1220.5982 2439.2051 1220.1062

R

23

R

Seq.

y

y++

y*

y*++

y0

y0++

#

L

23

N

2518.2433 1259.6253 2501.2168 1251.1120 2500.2328 1250.6200 22

E

2404.2004 1202.6038 2387.1738 1194.0906 2386.1898 1193.5986 21

S

2275.1578 1138.0825 2258.1313 1129.5693 2257.1472 1129.0773 20

S

2188.1258 1094.5665 2171.0992 1086.0533 2170.1152 1085.5612 19

E

2101.0937 1051.0505 2084.0672 1042.5372 2083.0832 1042.0452 18

N

1972.0512 986.5292 1955.0246 978.0159 1954.0406 977.5239 17

K

1858.0082 929.5078 1840.9817 920.9945 1839.9977 920.5025 16

L

1729.9133 865.4603 1712.8867 856.9470 1711.9027 856.4550 15

P

1616.8292 808.9182 1599.8026 800.4050 1598.8186 799.9130 14

G

1519.7764 760.3919 1502.7499 751.8786 1501.7659 751.3866 13
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N

1462.7550 731.8811 1445.7284 723.3678 1444.7444 722.8758 12

S

1348.7120 674.8597 1331.6855 666.3464 1330.7015 665.8544 11

G

1261.6800 631.3436 1244.6535 622.8304 1243.6695 622.3384 10

H

1204.6586 602.8329 1187.6320 594.3196 1186.6480 593.8276

9

I

1067.5996 534.3035 1050.5731 525.7902 1049.5891 525.2982

8

F

954.5156

477.7614

937.4890

469.2482

936.5050

468.7561

7

E

807.4472

404.2272

790.4206

395.7139

789.4366

395.2219

6

F

678.4046

339.7059

661.3780

331.1926

660.3940

330.7006

5

S

531.3362

266.1717

514.3096

257.6584

513.3256

257.1664

4

L

444.3041

222.6557

427.2776

214.1424

3

R

331.2201

166.1137

314.1935

157.6004

2

R

175.1190

88.0631

158.0924

79.5498

1

Table 9.5 Fragment ions for peptide LDESAFSSLTFPK of MHJ_0105 from trypsin
digestion of surface exposed proteins from M. hyopneumoniae strain J identified by 2D
LC-MS/MS. Mascot table of fragment ions and Mascot annotated MS/MS spectra are
shown. Mascot matched ions are shown in red. This peptide had a mass of 721.408363
(2+) and Mascot ions score of 93.
#

b

++

b

0

b

0++

b

Seq.

1

114.0913 57.5493

2

229.1183 115.0628

211.1077 106.0575

D

L

3

358.1609 179.5841

340.1503 170.5788

E

4

445.1929 223.1001

427.1823 214.0948

S

5

516.2300 258.6186

498.2195 249.6134

A

6

663.2984 332.1529

645.2879 323.1476

F

7

750.3305 375.6689

732.3199 366.6636

S

8

837.3625 419.1849

819.3519 410.1796

S

9

950.4466 475.7269

932.4360 466.7216

L

10 1051.4942 526.2508 1033.4837 517.2455

T

11 1198.5626 599.7850 1180.5521 590.7797

F

12 1295.6154 648.3113 1277.6048 639.3061

P

13

K
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Seq.

y

y

++

y*

++

y*

y

0

y

0++

#

L

13

D

1328.6369 664.8221 1311.6103 656.3088 1310.6263 655.8168 12

E

1213.6099 607.3086 1196.5834 598.7953 1195.5994 598.3033 11

S

1084.5673 542.7873 1067.5408 534.2740 1066.5568 533.7820 10

A

997.5353 499.2713

980.5088 490.7580

979.5247 490.2660

9

F

926.4982 463.7527

909.4716 455.2395

908.4876 454.7475

8

S

779.4298 390.2185

762.4032 381.7053

761.4192 381.2132

7

S

692.3978 346.7025

675.3712 338.1892

674.3872 337.6972

6

L

605.3657 303.1865

588.3392 294.6732

587.3552 294.1812

5

T

492.2817 246.6445

475.2551 238.1312

474.2711 237.6392

4

F

391.2340 196.1206

374.2074 187.6074

3

P

244.1656 122.5864

227.1390 114.0731

2

K

147.1128

130.0863

1

74.0600

65.5468

Table 9.6 Mascot database search results for Mhp385, Mhp384 or Mhp107 proteins
identified by LC-MS/MS analysis of gel slices or protein spots excised from 1D or 2D
polyacrylamide gels containing whole cell lysates from M. hyopneumoniae strain 232
cells.
Protein of Protein
Interest
Molecular
Mass
(kDa)

UniProt
Mascot Total
Distinct Entire
Accession Score
Peptides Peptides Protein
Number
Matched
Sequence
Coverage
(%)

Cleavage
Product
Sequence
Coverage
(%)

115
88
27 (left)
27 (right)
60
50
25-30

Q600R9
Q600R9
Q600R9
Q600R9
Q600S0
Q600S0
Q601U4

N/A
23
27
19
46
22
24

Mhp385
Mhp385
Mhp385
Mhp385
Mhp384
Mhp384
Mhp107

1339
768
381
350
1103
413
187

24
21
8
7
26
10
4

22
17
6
5
22
8
4

27
17
6
4
25
9
4
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Table 9.7 List of peptides identified as belonging to the 115 kDa Mhp385 preprotein
from LC-MS/MS of a trypsin digested SDS-PAGE gel slice as described in Materials
and Methods.
Peptide Sequence+

Modifications

Precursor
Ion m/z

Precursor
Ion
Charge

Ions
Score*

K.TGIDYSQFFDFYQK.N
K.NNTSLPINFATDYGWNR.Y
R.LVYQLPDDKK.A
K.LTFYAAFSPNFAK.K
K.ITEFSEDDYYPQINFEK.N
R.NAENQIVAEK.N
K.NFSQTIEHLNR.L
K.SEILALLNANKFDK.L
K.NILENGDYYGYEFNEDR.L
K.LLVHNSQLPNVEEFAK.L
K.LLVHNSQLPNVEEFAK.L
K.MSEGIINLWNK.S
K.TNQEVSTFLSLLAK.R
R.DFVEHIR.E
K.IGSVDQNGNLIQVIYQTK.K
K.IGSVDQNGNLIQVIYQTK.K
K.KETLDLVVNENNK.L
K.ETLDLVVNENNK.L
K.LNEIATNFPSADQIIFLK.K
K.KEDYTQLVDSIK.Q
K.EDYTQLVDSIK.Q
K.NLESSKPEAAK.V
K.DQPQIHSSKPVR.V
R.VIIIESSESLFALK.-

Deamidated (N)
Deamidated (N)
Oxidation (M)
Deamidated (N)
-

879.9131
991.9791
609.8524
738.8974
1069.4725
558.2896
679.8467
788.4443
1056.4500
919.5005
920.0002
660.8264
775.9227
458.2539
995.5613
996.0275
758.4075
694.3677
1017.5710
719.9008
655.8115
587.3336
696.3903
774.9576

2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+

72
55
50
51
63
57
66
65
36
(23)
44
85
94
31
(71)
89
74
51
62
100
60
47
58
69

+

modified amino acids are underlined
* lower ions score of duplicate matches are shown in parentheses
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Table 9.8 List of peptides identified as belonging to the 88 kDa Mhp385 N-terminal
cleavage from LC-MS/MS of a trypsin digested SDS-PAGE gel slice as described in
Materials and Methods.
Peptide Sequence+

Modifications

-.MENTNLHYK.K
R.LQVQNQAK.L
K.QLFNADNTK.K
K.TGIDYSQFFDFYQK.N
K.LTFYAAFSPNFAK.K
K.KIAADLNK.S
K.ITEFSEDDYYPQINFEK.N
K.ITEFSEDDYYPQINFEK.N
R.NAENQIVAEK.N
K.NFSQTIEHLNR.L
K.NFSQTIEHLNR.L
K.SEILALLNANK.F
K.SEILALLNANKFDK.L
K.SEILALLNANKFDK.L
K.LLVHNSQLPNVEEFAK.L
K.LLVHNSQLPNVEEFAK.L
K.TNQEVSTFLSLLAK.R
K.TNQEVSTFLSLLAK.R
K.TESAFNTR.D
R.DFVEHIR.E
K.DQGLLAESLGQNLDYK.I

Oxidation (M)
Deamidated (N)
Deamidated (N)
Deamidated (N)
Deamidated (N)
Deamidated (N)
-

Precursor
Ion m/z
583.2785
464.7719
525.7656
879.9131
738.8665
436.7765
1069.4911
1069.9743
558.3030
679.8615
680.3505
593.3387
788.4762
788.9550
919.5005
919.9829
775.9227
776.4293
463.2420
458.2660
882.4598

Precursor
Ion Charge
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+
2+

Ions
Score*
50
38
39
65
39
41
63
(35)
39
66
(39)
65
61
(51)
38
(22)
(72)
76
38
29
50

+

modified amino acids are underlined
* lower ions score of duplicate matches are shown in parentheses

Table 9.9 List of peptides identified as belonging to the Mhp385 C-terminal cleavage
fragment from LC-MS/MS of a trypsin digested protein spot (left hand side anti-F4385
serum reactive spot) cut from a 2D polyacrylamide gel as described in Materials and
Methods.
Peptide Sequence+

Modifications

Precursor
Ion m/z

K.IGSVDQNGNLIQVIYQTK.K
K.IGSVDQNGNLIQVIYQTK.K
K.KETLDLVVNENNK.L
K.ETLDLVVNENNK.L
K.ETLDLVVNENNK.L
K.LNEIATNFPSADQIIFLK.K
K.KEDYTQLVDSIK.Q
K.EDYTQLVDSIK.Q

Deamidated (N)
-

995.5431
996.0092
758.3957
694.3875
694.4025
1017.5521
719.8747
655.8170

Precursor
Ion
Charge
2+
2+
2+
2+
2+
2+
2+
2+

Ions
Score*
(68)
76
82
21
(16)
65
95
52

+

modified amino acids are underlined
* lower ions score of duplicate matches are shown in parentheses
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Table 9.10 List of peptides identified as belonging to the Mhp385 C-terminal cleavage
fragment from LC-MS/MS of a trypsin digested protein spot (right hand side anti-F4385
serum reactive spot) cut from a 2D polyacrylamide gel as described in Materials and
Methods.
Peptide Sequence+

Modifications

Precursor
Ion m/z

K.IGSVDQNGNLIQVIYQTK.K
K.IGSVDQNGNLIQVIYQTK.K
K.KETLDLVVNENNK.L
K.ETLDLVVNENNK.L
K.ETLDLVVNENNK.L
K.KEDYTQLVDSIK.Q
K.EDYTQLVDSIK.Q

Deamidated (N)
-

995.5251
996.0271
758.3957
694.3575
694.4025
719.8595
655.8315

Precursor
Ion
Charge
2+
2+
2+
2+
2+
2+
2+

Ions
Score*
(70)
95
88
40
(32)
81
54

+

modified amino acids are underlined
* lower ions score of duplicate matches are shown in parentheses

Table 9.11 Mascot identification results of semi-tryptic peptides identified by LCMS/MS that indicate the cleavage site of Mhp385, Mhp384 and Mhp107.
UniProt
Protein
Accession
Number

Precursor Precursor Error Semi-tryptic Peptide^
Ion m/z
Ion
(ppm)
Charge

Ions
Score

Q600R9
Q600S0
Q600S0
Q601U4

701.3772
723.3505
944.4466
926.4605

40
46
44
57

Mhp385
Mhp384
Mhp384
Mhp107

+2
+2
+2
+2

-11
-20
-29
-5

IQFELEPISLNV
NEEVKQQESQVK
NEEVKQQESQVKDQAK
QINENILNIGNFTTNF

^ no modifications were observed
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Table 9.12 List of peptides identified as belonging to the 60 kDa Mhp384 N-terminal
cleavage fragment from LC-MS/MS of a trypsin digested SDS-PAGE gel slice as
described in Materials and Methods.
Peptide Sequence+

Modifications

Precursor
Ion m/z

K.YNLELNSYNIDLGK.A
R.TNFNSAEFDK.L
R.TNFNSAEFDKLVANLK.V
R.LNAFDALNFHFDK.S
K.SYSFDLADAVDLSSLSQK.Y
K.NIGLNVTNTSK.T
K.SFQFLPENFTGQISLR.N
F.SLNSEPIFILPENFEIKPDLK.D
K.LVFASINDEKNELVLNMVLYD
K.T
K.NYEFNSEISK.Y
K.NNLDIAQLFSLPSD.P
K.NNLDIAQLFSLPSDPK.S
K.NNLDIAQLFSLPSDPK.S
K.SVPNTTFFADIK.G
V.PNTTFFADIK.G
K.LEGTFLVNDQVPAGLNLTQDK.
H
K.LEGTFLVNDQVPAGLNLTQDK.
H
V.PAGLNLTQDK.H
R.NALELFDAR.T
K.LEVKNDLPVTVFASTINTK.I

Oxidation (M)

828.4116
586.7580
905.9774
776.3848
973.4943
580.8275
942.5088
815.1210
861.8080

Deamidated (N)
-

K.NDLPVTVFASTINTK.I
K.NDLPVTVFASTINTK.I
K.IAHLLNKPLELK.G
K.KMSPLFDFLNFSTSK.N
K.MSPLFDFLNFSTSK.N
K.MSPLFDFLNFSTSK.N

Precursor
Ion
Charge
2+
2+
2+
2+
2+
2+
2+
2+
2+

Ions
Score*

615.7907
773.9012
886.4678
886.9754
670.3572
577.3000
1136.609
0
758.4105

2+
2+
2+
2+
2+
2+
2+

35
18
66
(51)
44
37
50

3+

(13)

528.7950
524.7785
1045.604
1
810.4235
Deamidated (N) 810.9412
694.9546
Oxidation (M)
889.4476
Oxidation (M)
825.4217
Deamidated (N), 825.9114
Oxidation (M)

2+
2+
2+

54
53
40

2+
2+
2+
2+
2+
2+

65
(41)
47
54
87
(54)

Deamidated (N)
Deamidated (N)

94
56
59
71
97
32
40
17
40

+

modified amino acids are underlined, and semi-tryptic peptides are italicised. These
semi-tryptic peptides are most likely formed due to chemical preparation (Alves et al.,
2008).
* lower ions score of duplicate matches are shown in parentheses
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Table 9.13 List of peptides identified as belonging to the 50 kDa Mhp384 C-terminal
cleavage fragment from LC-MS/MS of a trypsin digested SDS-PAGE gel slice as
described in Materials and Methods.
Peptide Sequence+

Modifications

Precursor
Ion m/z

Precursor
Ion
Charge

Ions
Score*

K.TIQAENGGTYLSK.L
K.TIQAENGGTYLSK.L
K.YQNKPVIASISALNNPNLK.F
K.IGADFEKVEQNNK.N
K.SHDFLNAPAATMVLVATVES
ENTEK.Y
K.LFSSDYQNGK.K
K.LFSSDYQNGKK.E
K.TKIESQFQNLDLAK.N
K.TKIESQFQNLDLAK.N
K.IESQFQNLDLAK.N

Deamidated (N)
Deamidated (N)
Oxidation (M)

691.4093
691.8725
695.4040
746.8913
897.4637

2+
2+
2+
2+
3+

(37)
59
37
37
85

Deamidated (N)
Deamidated (N)
Deamidated (N)
Deamidated (N)

580.2799
644.3411
817.9623
818.4336
703.8651

2+
2+
2+
2+
2+

38
30
93
(59)
52

+

modified amino acids are underlined
* lower ions score of duplicate matches are shown in parentheses

Table 9.14 List of peptides identified as belonging to the Mhp107 N-terminal cleavage
fragment cleavage fragment from LC-MS/MS of a trypsin digested SDS-PAGE gel slice
as described in Materials and Methods.
Peptide Sequence+

Modifications

K.ISFVSFKPEQISK.N
K.LFSGDQLKK.E
K.ADFNFVLQK.M
R.QINENILNIGNFTTNF.S

-

Precursor Ion Precursor Ion Ions
m/z
Charge
Score
755.3914
2+
49
518.2986
2+
37
541.2885
2+
54
926.4605
2+
57

+

Italicised is the semi-tryptic peptide of which its LC-MS/MS spectrum is annotated in
Figure 9.3
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Figure 9.1 Annotated LC-MS/MS spectrum of the Mhp385 semi-tryptic peptide
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Figure 9.2 Annotated LC-MS/MS spectrum of the Mhp384 semi-tryptic peptides
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Figure 9.3 Annotated LC-MS/MS spectrum of the Mhp107 semi-tryptic peptide
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